Step by Step Minimally Invasive Glaucoma Surgery
Step by Step Minimally Invasive Glaucoma Surgery Editors Ashok Garg MS, PhD, FIAO (Bel) FRSM, ADM, FAIMS, FICA International and National Gold Medalist Medical Director Garg Eye Institute and Research Centre 235-Model Town, Dabra Chowk Hisar-125005 (India)
Shlomo Melamed MD, PhD Profesor of Ophthalmology Sackler Medical School Tel-Aviv University Head and Chairman Sam Rothberg Glaucoma Centre Tel-Hashomer, Israel
Jerome Jean – Phillippe Bovet MD Consultant Ophthalmic Surgeon FMH Clinique de L’oeil 15, Avenyue Du Bois-de-law Chapelle CH-1213, Onex Switzerland
Bojan Pajic MD Chief of Glaucoma Department Chief Corneal and Refractive Surgery Department, Vision Care Klinik Pallas, Louis Giroud Str. 20 4600 Olten, Switzerland
Roberto G Carassa MD Associate Professor of Ophthalmology Director, Glaucoma Service Deptt. of Ophthalmology and Visual Sciences, University Hospital S. Raffaele, Milano, Italy
Tanuj Dada MD Additional Professor of Clinical Ophthalmology RP Centre for Ophthalmic Sciences AIIMS, Ansari Nagar New Delhi-110029, India
Foreword
Robert Jay Weinstock
JAYPEE BROTHERS MEDICAL PUBLISHERS (P) LTD New Delhi
Published by Jitendar P Vij
Jaypee Brothers Medical Publishers (P) Ltd EMCA House, 23/23B Ansari Road, Daryaganj, New Delhi 110 002, India Phones: +91-11-23272143, +91-11-23272703, +91-11-23282021, +91-11-23245672 Fax: +91-11-23276490, +91-11-23245683 e-mail:
[email protected] Visit our website: www.jaypeebrothers.com Branches • 2/B, Akruti Society, Jodhpur Gam Road Satellite Ahmedabad 380015 Phone: +91-079-30988717 • 202 Batavia Chambers, 8 Kumara Krupa Road, Kumara Park East Bangalore 560 001, Phones: +91-80-22285971, +91-80-22382956, +91-80-30614073 Tele Fax : +91-80-22281761 e-mail:
[email protected] • 282 IIIrd Floor, Khaleel Shirazi Estate, Fountain Plaza, Pantheon Road Chennai 600 008, Phones: +91-44-28262665, +91-44-28269897 Fax: +91-44-28262331 e-mail:
[email protected] • 4-2-1067/1-3, Ist Floor, Balaji Building, Ramkote Cross Road Hyderabad 500 095, Phones: +91-40-55610020, +91-40-24758498 Fax: +91-40-24758499 e-mail:
[email protected] • 1A Indian Mirror Street, Wellington Square, Kolkata 700 013 Phones: +91-33-22456075, +91-33-22451926 Fax: +91-33-22456075 e-mail:
[email protected] • 106 Amit Industrial Estate, 61 Dr SS Rao Road, Near MGM Hospital Parel, Mumbai 400 012 Phones: +91-22-24124863, +91-22-24104532, +91-22-30926896 Fax: +91-22-24160828 e-mail:
[email protected] • “KAMALPUSHPA” 38, Reshimbag, Opp. Mohota Science College, Umred Road, Nagpur 440 009 (MS) Phones: +91-712-3945220, + 91-712-2704275 e-mail: jpmednagpur @rediffmail.com
Step by Step Minimally Invasive Glaucoma Surgery © 2006, Editors All rights reserved. No part of this publication and interactive DVD ROM should be reproduced, stored in a retrieval system, or transmitted in any form or by any means: electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the editors and the publisher. This book has been published in good faith that the material provided by contributors is original. Every effort is made to ensure accuracy of material, but the publisher, printer and editors will not be held responsible for any inadvertent error(s). In case of any dispute, all legal matters are to be settled under Delhi jurisdiction only. First Edition: 2006 ISBN 81-8061-738-6 Typeset at JPBMP typesetting unit Printed at Paras Press
Dedications • My Respected Param Pujya Guru Sant Gurmeet Ram Rahim Singh Ji for his blessings & motivation. • My Respected Parents, teachers, my wife Dr. Aruna Garg, son Abhishek and daughter Anshul for their constant support and patience during all these days of hard work. • My dear friend Dr. Amar Agarwal, a leading International Ophthalmologist from India for his continued support and guidance. Dr. Ashok Garg • To my loving wife Shuvit.
Dr. Shlomo Melamed
• Yveric, Luc and Fanny Laure. • Silvio Korol, who was not only a teacher but also an intellectual guide and a friend. Dr. Jerome Bovet • To my son Valentin Aleksandar.
Dr. Bojan Pajic
• To my collaborators Dr. Marina Fiori and Dr. Paolo Bettin, for their constant help and support in my clinical work and research. Dr. Roberto G Carassa • The Revered Sufi Saint Hazoor Maharaj Gurmeet Ram Rahim Singh Ji, Dera Sacha Sauda Ashram, Sirsa, Haryana, India. Dr. Tanuj Dada
CONTRIBUTORS Ahmed Galal MD, Ph D
Vissum/Instituto Oftalmologico De Alicante Alicante Spain Amar Agarwal
Bojan Pajic MD Chief, Cornea and Refractive Surgery Deptt., Vision Care Klinik Pallas Louis Giroud Str. 20 4600 Olten, Switzerland Cyres K Mehta
MS, FSVH, FAGE MS, FRCS, FRC Ophth. Director & Consultant
Director Dr. Agarwal’s Eye Hospital 19, Cathedral Road Chennai-600086 India André Mermoud MD Prof. of Ophthalmology Jules Gonin Eye Hospital CH-1004 Lausanne Switzerland Ashok Garg MS, Ph D, FRSM
Medical Director Garg Eye Institute & Research Centre 235-Model Town Dabra Chowk Hisar-125005 (India)
Mehta International Eye Institute Seaside, 147, Colaba Road Mumbai-400005, India Daljit Singh MS, DSC 57, Joshi Colony Amritsar-143001, India Ehud I Assia MD Deptt. of Ophthalmology Meir Hospital Sapir Medical Centre Tsharnihovski St. 44281, Kafar, Saba Israel Guillérmo Avalos-Urzua MD Terranova No. 676-101 Col. Providencia Guadalajara, Jal Mexico CP-44630
viii
Step by Step Minimally Invasive Glaucoma Surgery
Harsh Kumar MD Chief Glaucoma Service Centre for Sight Safdarjung Enclave New Delhi, India J Agarwal MS Director Dr. Agarwal’s Eye Hospital Pvt. Ltd. 19, Cathedral Road Chennai-600086, India Jens Funk MD Prof. of Ophthalmology AugenklinikUniversitatsklinikum Killianstr. 5 79106 Freiburg Germany Jerome Bovet MD Consultant Ophthalmic Surgeon, FMH Clinique de I’oeil 15, Avenue du Bois-de-laChapelle CH-1213 Onex Switzerland Jorge L Alió MD, PhD Director Instituto Oftalmologico De Alicante Avda. Denia 111, 03015 Alicante Spain
Jose L Rodriguez - Prats MD Instituto Oftalmologico De Alicante Avda. Denia 111, 03015 Alicante Spain JT Lin PhD 4532, Old Carriage Trail OVIEDO Florida 32765 USA Kamaljeet Singh MS Associate Professor Ophthalmology 4A/7, Panna Lal Road Allahabad, India Kaweh Mansouri MD Jules Gonin Eye Hospital Lausanne, Switzerland Keiki R Mehta MS, DO, FIOS
Chairman & Medical Director Mehta International Eye Institute 147, Shahid Bhagat Singh Road Colaba Road Mumbai-400005, India Khristo Takhchidi MD Director General, S.N. Fyodorov Eye Microsurgery Complex Moscow, Russia
Contributors
ix
Mordechai Goldenfeld MD The Sam Rothberg Glaucoma Centre Goldschleger Eye Institute Sheba Medical Centre Tel-Hashomer Israel
Roberto G Carassa MD Director Glaucoma Service Deptt. of Ophthalmology and Visual Sciences University Hospital S. Raffaele via Olgettina 60 20132 Milano, Italy
Mona Pache MD AugenklinikUniversitatsklinikum Killianstr. 5 79106 Freiburg Germany
Shlomo Melamed MD Prof. of Ophthalmology Sackler Medical School Tel Aviv University Head and Chairman Sam Rothberg Glaucoma Centre Goldschleger Eye Institute Sheba Medical Centre Tel-Hashomer, Israel
Nikolai Ereskin MD Consultant, S.N. Fyodorov Eye Microsurgery Complex, Moscow, Russia Pascal Rozot MD Clinique Monticelli Marseilles France
Subrata Mandal MD Dr. RP Centre for Ophthalmic Sciences, AIIMS New Delhi, India Sunita Agarwal MS, DO, PSVH
Ranjit H Maniar MS 17, Vithal Court, 6th Floor 151, August Kranti Marg Mumbai-400036, India Richard J Fugo MD, PhD 100, West Fornance Street The Fugo Building Norristown, PA-19401 USA
Dr. Agarwal’s Eye Hospital 19, Cathedral Road Chennai-600086, India 15, Eagle Street, Langford Town, Bangalore, India Sylvian Roy MD Jules Gonin Eye Hospital CH 1004, Lausanne Switzerland
x
Step by Step Minimally Invasive Glaucoma Surgery
Tanuj Dada MD Associate Professor Dr. R.P. Centre for Ophthalmic Sciences AIIMS, Ansari Nagar New Delhi-110029, India T Agarwal FORCE, DO, FICS
Director Dr. Agarwal’s Eye Hospital 19, Cathedral Road Chennai-600086, India
Vivek Kadambi MD, DOMS Director Kadambi Laser Vision Clinic & Research Foundation Pvt. Ltd. 157, Defence Colony 4th Main Road, Indira Nagar Bangalore-560038 India
FOREWORD One of the most wonderful and stimulating aspects of modern ophthalmology is the continued spirit of ingenuity in advancing the treatment of ophthalmic disease. This is manifested by continuous research in both medical and surgical techniques in the quest to improve our patient’s vision and prevent and treat eye disease. The ophthalmic subspecialty of glaucoma continues to be one of the most interesting and dynamic areas of ophthalmology with numerous improvements in not only the pharmacologic treatment of glaucoma but also the surgical arena. Traditionally glaucoma has been managed with medications until the disease has progressed to a significantly advanced state requiring more than pharmacologic therapy. However, recent trends indicate that surgeons throughout the world are transitioning to a more aggressive mind set with quicker movement towards interventional glaucoma procedures and techniques that reduce intraocular pressure and treat the disease surgically. Dr. Ashok Garg and his colleagues have compiled a brilliant book with concentration on the most novel and successful glaucoma procedures and surgeries available today. The authors, who hail from a diverse international population, have managed to come together and present a
xii
Step by Step Minimally Invasive Glaucoma Surgery
thorough analysis of the latest technological modalities for treating glaucoma. Through advancements in communication and technology over the past decade these surgeons have been able to share their experiences and technologies leading to the rapid advancement of minimally invasive glaucoma surgery. It is rare to find a text with such a complete and thorough analysis of all the different possible treatment technologies available today. I commend the editors for their diligence in assembling such a diverse and comprehensive text of glaucoma therapy and surgery. Their tireless efforts has enabled surgeons, worldwide, to assemble and share their knowledge and skills in one of the most advanced treatises on glaucoma to date. This book serves not only as an excellent core book on treatment modalities for glaucoma but also serves to introduce and educate all glaucoma specialists to up and coming progressive technologies that they will be using for years to come. I am sure you will enjoy this book as much as I have and in this new era of minimally invasive glaucoma surgery you will come away with a tremendous amount of knowledge and hope for the future of our glaucoma patients. Dr. Robert Jay Weinstock MD The Eye Institute of West Florida 148 13th Street SW Largo, Florida 33770 , USA Tel. (727) 585-6644
PREFACE Glaucoma is a complex multifactorial slowly progressive neurodegenerative disorder associated with raised intraocular pressure leading to death of retinal ganglion cells and degeneration of their connected optic nerve fibers and subsequent visual loss. The aim of Modern Glaucoma Treatment is to preserve visual function with minimal side effects. Effective management of Glaucoma requires a reduction of intraocular pressure to a level appropriate for the stage of disease. There is tremendous improvement in Medical Management of Glaucoma with newer drugs but burden of daily treatment, cost factor, possible side effects and inconvenience and poor compliance leads to progression of disease inspite of early diagnosis and prompt treatment. There are lot of surgical procedures available for Glaucoma management but they have their own postoperative complications which are sometimes difficult to treat leading to the frustration of the patient. In last 5 years tremendous advances have been made specially in minimally invasive glaucoma surgery with minimal postoperative complications and better visual results. This step by step book has been written specially to acquaint ophthalmologist with latest minimally invasive glaucoma surgical techniques. Seventeen chapters of this book are written by International known Glaucoma specialists covering MIGS specially Excimer Laser Trabeculotomy, Sclerothalamotomy, Trans-scleral Diode Laser Cyclophotocoagulation, Milling Trabeculoplasty, VDSCI, Customized Laser Assisted Filtration Surgery (CLAFS), SLT, Pneumatic Trabeculoplasty, Femtosecond Lasers and Neuroprotective Therapeutic approach. These
xiv
Step by Step Minimally Invasive Glaucoma Surgery
are all high techniques with excellent visual results available in this single Internatioonal book. An added attraction of this book is interactive CD showing all latest MIGS techniques. We are highly grateful to Shri Jitendar P Vij (Chairman and Managing Director), Mr. Tarun Duneja, General Manager (Publishing) and all staff members of our publisher M/s Jaypee Brothers Medical Publishers (Pvt) Ltd. who took active interest in this project and prepared this handy high quality book in a short time. We are quite certain this step by step MIGS book shall be a useful companion to every ophthalmologist who do Glaucoma work. Editors
CONTENTS 1. Minimally Invasive Glaucoma Surgery (MIGS) – A New Approach ........................................................ 1 Ashok Garg (India) 2. YAG Laser Iridotomy ................................................ 9 Kamaljeet Singh (India) 3. Laser Sclerotomy ....................................................... 23 J Agarwal, T Agarwal, Sunita Agarwal, Ashok Garg (India) 4. Laser Trabeculoplasty .............................................. 33 Kamaljeet Singh (India) 5. Laser Treatment in Glaucomas .............................. 43 Andre Mermoud, Sylvian Roy (Switzerland) 6. Miscellaneous Laser Applications ........................ 81 Harsh Kumar, Tanuj Dada (India) 7. Trabecular Meshwork Ablation as an Alternative to Invasive Glaucoma Surgery ........ 97 Mona Pache, Jens Funk (Germany) 8. Sclerothalamotomy ab Interno a Minimally Invasive Glaucoma Surgery ................................. 113 Bojan Pajic (Switzerland) 9. Laser Surgical Treatment of Glaucoma by Excimer Laser with 193 nm Wavelength ........... 135 Khristo Takhchidi, Nikolai Ereskin (Russia)
xvi
Step by Step Minimally Invasive Glaucoma Surgery
10. Topical Anesthetic and the Subconjunctival Bubble in Glaucoma and Combined Operations ................................... 147 Jérôme Bovet (Switzerland) 11. Cyclophotocoagulation ......................................... 161 Tanuj Dada, Subrata Mandal (India) 12. Milling Trabeculoplasty: A New Technique for Non-penetrating Glaucoma Surgery ........... 197 Jose L Rodriguez-Prats, Jorge L Alió, Ahmed Galal (Spain) 13. Deep Sclerectomy with T-flux Implant with “Outside In” Drainage ...........................................225 Ranjit Maniar (India) 14. Viscocanalostomy ................................................... 247 Roberto G Carassa (Italy) 15. Pneumatic Trabeculoplasty – A Noninvasive Glaucoma Treatment ............................................. 261 Guillérmo Avalos-Urzua (Mexico) 16. Selective Laser Trabeculoplasty ..........................271 Mordechai Goldenfeld, Shlomo Melamed (Israel) 17. Customized Laser Assisted Filtration Surgery (CLAFS) Using a Solid-State UV Laser ..............281 JT Lin (USA), Vivek Kadambi (India) 18. Non-penetrating Filtration Surgery with the CO2 Laser .................................................297 Ehud I Assia (Israel) 19. Open Angle Filter Surgery for Glaucoma: Deep Sclerocanalostomy (DSC) – A New Technique ................................................... 309 Jerome Bovet (Switzerland)
Contents
xvii
20. Bimanual Microphaco and Deep Sclerocanalostomy (BMP and DSC) – A New Technique ................................................... 327 Jerome Bovet (Switzerland) 21. Very Deep Sclerectomy — or How to Increase Uveoscleral Outflow .............................. 345 Kaweh Mansouri, André Mermoud (Switzerland) 22. G-Probe as Primary Glaucoma Procedure in Cases of Coexisting POAG and Cataract ..... 357 Cyres K Mehta, Keiki R Mehta (India) 23. Combined Phacoemulsification and Deep Sclerectomy with T-Flux® ...................................... 373 Pascal Rozot (France) 24. Glaucoma Surgery Techniques with the Fugo Blade® .............................................................................. 387 Daljit Singh (India), Richard J Fugo (USA) Index ........................................................................... 425
2
Step by Step Minimally Invasive Glaucoma Surgery
INTRODUCTION Glaucoma is a complex disorder to treat. Increased intraocular pressure (IOP) accompanied with optic nerve damage requires a life long mandatory treatment to maintain IOP level at acceptable level with visual acuity preservance. Medical management of glaucoma is usually first line of defence which has its own side effects and complications on prolonged use. Second line of treatment is conventional glaucoma surgery – Trabeculectomy which has its own postoperative complications specially bleb leakage. In last one decade intensive research work has been done in glaucoma surgery. When conventional methods fail patients can be well served by innovative new surgical techniques specially non-penetrating glaucoma surgery also known as minimally invasive glaucoma surgery. These new techniques clear the way for restored fluid passage through the eye. These infrastructure improvements are essentially extraocular techniques which has improved visual success rate with minimum postoperative complications. CLASSIFICATION Minimally invasive glaucoma surgery (MIGS) are broadly classified in following groups : a. Surgical-based MIGS or NPGS. b. Laser-based MIGS or NPGS. c. Scleral expansion bands. Here, I am giving broad outlines as the details are described in different chapters of this book.
Minimally Invasive Glaucoma Surgery — A New Approach
3
Surgical Based MIGS Surgical based MIGS have made tremendous strides in last one decade. It includes viscocanalostomy, deep sclerectomy, milling trabeculoplasty, sclerothalamotomy ab interno and deep sclero-canalostomy (DSC). Viscocanalostomy Viscocanalostomy introduced by Dr. Robert Stegmann (South Africa) in early nineties increases the aqueous outflow through different mechanism of action. It creates a bypass by which aqueous humor can reach Schlemm’s canal skipping the trabecular meshwork which is the site of the increased outflow resistance in OAG. Viscocanalostomy has several potential advantages over conventional trabeculectomy the major being the absence of external filtration thus independent of conjunctival and episcleral scarring. Postoperative management is comparatively easy with minimal complications. However, this technique is technically strong and requires a long learning curve. Deep Sclerectomy Deep sclerectomy is another non-penetrating glaucoma surgery which has offered excellent results. This techniques has been advocated with the implantation of a collagen drainage device. Dr. Andre Mermoud (Switzerland) has shown the excellent results of deep sclerectomy alone and very deep sclerectomy with collagen implant (VDSCI) which is relatively a new technique. It has been clinically documented that deep sclerectomy significantly lowers the complication rates of glaucoma surgery.
4
Step by Step Minimally Invasive Glaucoma Surgery
Milling Trabeculoplasty Milling trabeculoplasty developed by Dr. Jorge L. Alio (Spain) is considered a variation of deep sclerectomy with more refining. This technique provides the opportunity to perform a non-penetrating glaucoma surgery with greater attention for the dissection of the deep scleral flap or the deroofing of the Schlemm’s canal with the additional advantage that is being much faster. Certainly milling trabeculoplasty is an evolving technique for sclapel free NPGS. It is a promising technique specially for surgical management of POAG. Sclerothalamotomy (STT) Sclerothalamotomy ab interno is a new NPGS technique developed by Dr. Bojan Pajic (Switzerland). STT ab interno circumvents the trabecular meshwork resistance by creating a drainage canal in the sclera but the site of perforation is reached from inside and four sclerectomy sites are created using a special high frequency diathermy probe. STT is certainly a promising technique which ensures an efficacy and longevity of filtration. Deep Sclerocanalostomy (DSC) Deep sclerocanalostomy technique has been shown by Dr. Jerome Bovet (Switzerland). This combined new technique of NPGS is all connected with dissection or injection of the Schlemm canal. DSC allows a synthesis of the three main surgical techniques for non-penetrative Filter surgery. This reduces the risks of each while increasing the long-term chances of such in term of IOP control.
Minimally Invasive Glaucoma Surgery — A New Approach
5
Laser-Based MIGS Besides the conventional laser techniques in glaucoma management, a number of new techniques are on the horizon with better IOP control and visual acuity management. Research ophthalmologists have shown new techniques with the use of Excimer Laser, Infrared Laser, CO2, Laser and Selective Laser Trabeculoplasty (SLT). Excimer Laser Trabeculotomy Excimer laser trabeculotomy ab interno (ELT) developed by Jens Funk (Germany) is a minimally invasive procedure that uses an excimer laser to ablate pores in the trabecular meshwork of patients with open angle glaucoma. As this procedure uses photoablation, no thermal effect is generated thus helps in thermal necrosis and scar formation potentially allowing a persistent effect over the years. ELT is certainly effective as monotherapy. Prof. Khristo Takhchidi (Russia) has designed a special excimer laser unit with 193 nm wavelength for glaucoma surgery. This new technique of NPGS that uses the excimer laser can reduce the risk of perforating the trabeculodescemetic membrane. With this technique the ablation is precise and homogenous. Titanium Sapphire Laser Trabeculoplasty Dr. Gabriel Simon (Spain) has evolved a new technique of titanium Sapphire Laser Trabeculoplasty (TiSaLT) using infra red laser. In this techniques laser energy targets and is absorbed by pigment inciting shock waves through the tissue ablating the tissue and unclogging blocked passage ways. This procedure causes minimal thermal damage and can be repeated.
6
Step by Step Minimally Invasive Glaucoma Surgery
Non-penetrating Glaucoma Surgery with the CO2 Laser Dr. Ehud Assia (Israel) has shown a new technique of nonpenetrating glaucoma surgery with the CO2 laser. The clinical studies have shown that CO2 laser can effectively ablate the dry tissue without tissue perforation. In this procedure deep ablation down to the trabecular meshwork and Descemet’s membrane leaving a microthin wall 30u-50u thick with no perforation. This promising procedure enables accurate dissection of the scleral wall and unroofing of the Schlemm’s canal without penetration into the anterior chamber. Selective Laser Trabeculoplasty Selective laser trabeculoplasty (SLT) is another promising MIGS technique Dr. Mark. A Latina (USA) has pioneered this technique. In this procedure we can selectively treat the trabecular meshwork. With an Nd : YAG laser without creating a thermal burn. This procedure has been developed as an alternative to argon laser trabeculoplasty (ALT). In SLT ophthalmic surgeon selectively target pigmented trabecular meshwork cells instead of complete photocoagulation of the trabecular meshwork which is not necessary. SLT is certainly a better procedure with minimal side effects with good efficacy at lowering of IOP over a longer period. Scleral Expansion Bridge (SEB) Scleral expansion bridge (SEB) best known for their use in presbyopia has been recently shown to be useful in glaucoma management. The cornerstone behind use of SEBs is the Schachar theory of accommodation. This procedure is in early stages of development with essential
Minimally Invasive Glaucoma Surgery — A New Approach
7
principle of increasing the effective working distance of the lens by expanding the sclera which shall reverse presbyopia and increase the tension of the longitudinal muscle improve aqueous outflow and thus reduces intraocular tension. The scleral expansion band offers a new potentially reversible, safe surgical alternative to the management of ocular hypertension and primary open angle glaucoma. By these state of Art MIGS techniques, in near future we can indeed personalize an operation for every given glaucoma patient with maximal visual acuity preservance, effective IOP control and minimum complications. Certainly glaucoma customization holds great future.
10
Step by Step Minimally Invasive Glaucoma Surgery
INTRODUCTION Meyer Schwickerath reported for the first time the use of Xenon arc photocoagulator in cracking a hole in the iris.1 But the heat produced by xenon led to corneal and lenticular damage.1,2 Ruby laser was tried for some time without much success.3 The first successful laser iridotomy by argon laser was reported in 1970s.4-7 In 1980 the laser iridotomy replaced the surgical iridotomy. Later Nd:YAG laser was found more successful for this procedure.8-10 It is now most commonly applied laser for iridotomy. INDICATIONS • Acute/subacute angle closure glaucoma with symptoms • Chronic congestive glaucoma with anterior synechiae • Occludable angles with positive provocative tests • Occludable angle with signs of previous attack/ critically narrrow angle • Fellow eye • Iris bombe • Subluxated or luxated lens with intact vitreous face • Phacomorphic glaucoma with pupillary block mechanism • Aphakic/pseudophakic pupillary block • Nanophthalmos • Incomplete surgical iridectomy • Mixed mechanism glaucoma if filtering surgery is not required • Aqueous miss direction syndrome • Phakic IOLs • Plateau iris syndrome • Pigmentary glaucoma • To deepen narrow angle before laser trabeculoplasty
YAG Laser Iridotomy
11
CONTRAINDICATIONS • • • • •
Opaque or cloudy cornea Widely dilated pupil Flat anterior chamber with iridocorneal touch Active inflammation Rubeosis irides
ABRAHAM CONTACT LENS Abraham contact lens is most commonly used lens for performing this procedure.11 It has a 66 planoconvex button bounded in the front surface of the lens. When laser beam falls on this lens its size is reduced to half of the original size on the iris and doubles the original size on cornea. This increases the power density on the iris and decreases power density to one-fourth on cornea. This helps immensely during the argon laser iridotomy. Same lens is very useful for YAG laser iridotomy also. A high magnification up to 40X should be used on slit-lamp for performing this procedure (Fig. 2.1). Contact lens helps in the following ways: 1. The lids remain separated. 2. Chances of corneal epithelial burns are reduced as the lens absorbs heat energy by acting as a heat sink. 3. The eye movements can be controlled by the lens. PREOPERATIVE PREPARATION Pilocarpine eye drops are instilled preoperatively. It stretches the iris, which thins the iris stroma and also facilitates in the penetration of laser beam because cutting a well-stretched thin paper is easier than cutting a loose paper.
12
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 2.1: Slit lamp
If the patient has already had an attack of acute congestive glaucoma, first medical treatment is carried out (Box 2.1). This will reduce the corneal edema. In addition, the pupil can be easily constricted by pilocarpine. The steroid drops should also be instilled if iritis is present for a couple of days before proceeding for laser iridotomy. If acute attack does not abort, one can proceed with iridotomy. So, preoperatively pilocarpine eye drops are instilled one hour prior to constrict the pupil to maximum. Apraclonidine 1 percent is instilled one hour prior to the procedure to prevent postoperative pressure spike.12 Topical proparacaine 0.5 percent is instilled just before the procedure to anesthetize the conjunctiva and cornea. THE SELECTION OF IRIDOTOMY SITE It is usually superonasal between the peripheral and middle third of iris. The reasons for this are (a) the superior
YAG Laser Iridotomy
13
Box 2.1 We follow the New York Eye and Ear Infirmary approach1 to acute angle closure glaucoma, which is as follow: 1. Careful history of symptoms relating to intermittent angle closure attacks, attacks in the other eye, use of prescription or nonprescription drugs which may precipitate attacks, and type of activity precipitating the attack. 2. Examination of the affected eye and other eye with attention to central and peripheral anterior chamber depth as well as shape of the peripheral iris. 3. Administration of oral isosorbide, acetazolamide as aqueous suppressants, and even intravenous mannitol at our place. 4. The patient lies supine to permit the lens to fall posteriorly with vitreous dehydration. 5. The eye is reassessed after 1 hour. IOP is usually decreased, but the angle usually remains appostionally closed. One drop of 2 or 4 percent pilocarpine is given and patient is reexamined 30 minutes later. 6. If IOP is reduced and the angle is open, the patient may be treated medically with topical low dose pilocarpine, aqueous suppressants and steroids, until the eye quiets and laser iridotomy may be performed. 7. If IOP is unchanged or elevated and angle remains closed. Lens related angle closure should be suspected, further pilocarpine is withheld and the attack broken by argon laser peripheral iridoplasty. Peripheral iridoplasty does not eliminate pupillary block and is not a substitute for laser iridotomy, which must be performed as soon as the eye is quiet. However, even in eyes with extensive synechial closure, IOP is lowered sufficiently for a few days for the inflammation to resolve. Peripheral iridoplasty is much safer than attempting surgical iridectomy on an inflammed eye with elevated IOP. The risks of intraoperative surgery are avoided and even if malignant glaucoma is present the angle remains open long enough for inflammation to clear. Peripheral iridoplasty is highly effective in ameliorating attacks of angle closure glaucoma in Asian eyes. 1. Kramer P, Ritch R. The treatment of angle closure glaucoma revisited (editorial). Ann Ophthalmol 1984;16:1101-03.
14
Step by Step Minimally Invasive Glaucoma Surgery
site remains covered by the lid (b) the nasal side remains away from the macula preventing foveal burn (c) the junction of middle and peripheral third helps in easy penetration. (d) crypt is selected because here the iris is thinnest and easy to penetrate (e) the iris should be examined for any strands. If present, they should be avoided, as they are difficult to penetrate. (f) the lower site is chosen in silicon filled eye because the silicon oil floats and can go to upper site and block the iridotomy. LASERS USED Several lasers can be used. But the commonly used lasers are Nd: YAG and argon. We will describe here the YAG laser iridotomy. Nd: YAG Laser Iridotomy This is most frequently applied method for laser iridotomy. There are several advantages of using YAG laser. This produces extremely high energy, which acts by mechanical disruption. When compared to argon laser, it does not require pigment for absorption for its thermal effect. The spot size is usually fixed to one size (50-75 um) in lasers from different companies. The pulse duration is also fixed for each instrument. The energy levels can be varied. Depending on the color of iris the required energy levels for penetration can be between 5-15 mJ. More energy is required for brown iris. The pulses can be between 1 to 3, which depends largely on the choice of surgeon. YAG laser penetrates simultaneously the iris stroma and pigment epithelium. The only problem with YAG laser iridotomy is bleeding from iris capillaries, which should be avoided if visible.
YAG Laser Iridotomy
15
After selecting the site and applying the Abraham’s lens the laser shot is placed at the iris surface after properly focusing the laser beam. Usually one shot is sufficient for blue iris, but at times more than may be required. In brown iris more shots may be needed and the required energy levels may be also be high. The created opening should not be less than 150-200 um,13 otherwise there are chances of its closure. If some difficulty is experienced in enlarging the hole another site may be chosen. Two sites, even if small, are less likely to close (Fig. 2.1). Argon and YAG Laser Combined My technique is first using low intensity large size 200 um argon laser burns to create a crator and then utilizing single pulse low intensity shot of Argon laser also coagulates the capillaries thus reducing the chances of iris bleed.14 POST-LASER TREATMENT • Steroid drops are given to prevent mild iritis. • Pilocarpine eye drops are advised to keep the pupil constricted so that the opening remains patent. COMPLICATIONS 1. Common complications — Transient IOP rise — Iridocyclitis 2. Others — Closure of iridotomy — Hyphema — Corneal damage cataract formation 3. Rare complications — Retinal burns — Malignant glaucoma
16
Step by Step Minimally Invasive Glaucoma Surgery
— Monoocular blurring — Endothelial cell loss — Posterior synechia Common Complications Transient Rise of IOP This is commonest complication. The rise of IOP occurs due to decrease in aqueous outflow facility, although aqueous outflow facility gets reduced.15 Other studies suggest that it could be because of release of prostaglandins16-18 and prostaglandin like substances into the aqueous,19 which occurs due to breakdown in the blood aqueous barrier. The blood plasma and fibrin are also released, which may also block the iridotomy site or angle leading to IOP rise. For preventing this rise 1 percent apraclonidine eye drops should be instilled one hour prior to laser iridotomy and also immediately after the procedure. Iridocyclitis As a reaction to YAG laser insult a mild iritis can occur.20 This can easily be managed by giving steroid drops for 3-5 days. However, rarely severe iridocyclitis,21 cystoid macular edema22 and even endophthalmitis23 have been reported. Other Communications Hyphema If the laser beam hits iris capillaries, the blood may be seen leaking from them.8,9 This bleeding can be easily managed by applying pressure with the help of contact lens. If
YAG Laser Iridotomy
17
previous to the YAG laser, Argon laser is utilized the chances of bleeding are reduced as it coagulates the capillaries. Closure of Iridotomy The size of iridotomy should be about 150-200 um,13 because small iridotomy may close due to pigment granules and debris release from the iris by YAG laser disruption. For keeping the iridotomy patent pilocarpine should be instilled postoperatively. If it seems to the clinician that confirmation of patency is required, a provocative mydriatic test should be done after stopping pilocarpine drops. Although most of the time a slit-lamp evaluation done under high magnification confirms the patency, wherein anterior capsule’s visibility suffices. Long-term patency rates of YAG laser iridotomy are very good in dark Asian irides in line with other studies in white and AfroCaribbean eyes.24-26 Cataract Formation The incidence of cataract formation is much less with YAG laser than with argon laser iridotomy. It is said that they are non-progressive. Laser peripheral iridotomy disrupts the natural flow of aqueous in the eye and results in significant increase in lens-iris contact.27 Theoretically, this may predispose to a more rapid development of cataract since less aqueous is in contact with the lens epithelium. Several studies have attempted to look at this issue, but follow-up has been short, no lens grading system was used, and no acceptable control groups were studied.28-29 Focal lenticular opacities seen after argon laser peripheral iridotomy are said not to progress, but once again, followup has been short in published reports.
18
Step by Step Minimally Invasive Glaucoma Surgery
Rare Complications Retinal Burns Retinal burns may occur due to YAG laser iridotomy since the laser beam may hit the retina. If the precautions mentioned previously are not taken it may also hit the fovea and cause sudden diminution of vision. The best way of avoiding this complication is by choosing the superonasal site. Some authorities believe that using the Abraham lens also prevents damage to fovea. Malignant Glaucoma This is also rarely described complication and has been reported in one eye and both eyes too. Endothelial Cell Loss One study documented a higher rate of endothelial cell loss after argon laser peripheral iridotomy than after YAG laser peripheral iridotomy.24 Posterior Synechia Another potential complication of laser peripheral iridotomy is the development of posterior synechiae following laser iridotomy.25 Posterior synechiae can both limit vision in dim environments and make later cataract surgery more challenging. Failure of Iridotomy Several studies demonstrate a relation between the extent of angle closure by PAS and failure of iridotomy to control IOP and progression of glaucoma. 30-32 Iridectomy or
YAG Laser Iridotomy
19
iridotomy is less effective in eyes with glaucomatous visual field loss and further surgical or medical treatment is often required to control IOP.33,34 REFERENCES 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.
Meyer-Schwickerath G. Erfahrungen mit der lichokoagulation der Netzhaut und der iris. Doc Ophthalmol 1956;10:91. Hogan MF, Schwartz A. Experimental photocoagulation of the iris of guinea pigs. Am J Ophthalmol 1960;49:629. Perkins AS. Laser iridotomy for secondary glaucoma. Trans Ophthalmol UK 1971;91:777. Khuri CH. Argon laser iridectomies. Am J Ophthalmol 1973;76:490. Anderson DR, Forster RK, Lewis M. Laser iridotomy for aphakic pupillary block. Arch Ophthlol 1975;93:343. Yassur Y, Melamed S, Cohen S, Ben-Sira I. Laser iridotomy in closed angle glaucoma. Arch Opthalmol 1979;97:1920. Pollack IP. Use of argon lasr to produce iridotomies. Ophthalmic Surg 1980;11:506. Latina MA, Puliafito CA, Steinert RR, Epstein DL. Experimental iridotomy with a Q-switched Nd: YAG laser. Arch Ophthalmol 1984;102:1211. Klapper RM. Q-switched Nd: YAG laser iridotomy. Ophthalmology 1984;91:1017. Vernon SA, Cheng H. Freeze frame analysis on high-speed cinematography of Nd: YAG laser explosions in ocular tissues. Br J Ophthalmol 1986;70:321. Abraham RK. Procedure for outpatient argon laser iridectomies for angle closure glaucoma. Int Ophthalmol Clin 1976;16:1. Krupin T, Stank T, Feitl ME. Apraclonidine pretreatment decreases the acute intraocular pressure rise after laser trabeculoplasty or iridotomy. J Glau 1992;1:79. Fleck BW. How large must an iridotomy be? Br J Ophthalmol 1990;74:583.
20 14.
15. 16.
17. 18. 19. 20.
21. 22. 23. 24. 25.
Step by Step Minimally Invasive Glaucoma Surgery
Del-Priore LV, Robin AL, Pollack IP. Neodymium: YAG and argon laser iridotomy. Long-term follow-up in a prospective, randomized clinical trial. Ophthalmology 1988;95:1207-11. Wetzel W. Ocular aqueous humour dynamics after photodisruptive laser surgery. Ophthalmics Surg 1994;25: 298. Sugiyama K, Kitazawa Y, Kawai K, Enya T. Biphasic intraocular pressure response to Q-switched Nd: YAG laser irradiation of the iris and the apparent mediatory role of prostaglandins. Exp Eye Res 1990;51:531. Gailitis R, Peyman G A, Pulido J, et al. Prostaglandin release following Nd: YAG iridotomy in rabbits. Ophthalmic Surg 1986;17:467. Joo CK, Kim JH. Prostaglandin E in rabbit aqueous humour after Nd: YAG laser photodisruption of iris and the effect of topical indomethacin pretreatment. 1992;33: 1685. Weinreb RN, Weaver D, Mitchell MD. Prostanoids in rabbit aqueous humour: effect of the laser photocoagulation of the iris. Invest Ophthalmol Vis Sci 1985;26:1087. Schrems W, van Dorp HP, Wendel M, Krieglstein GK. The effect of YAG laser iridotomy on the blood aqueous barrier in the rabbit. Graefes Arch Clin Exp Ophthalmol 1984;221: 179. Cohen JS, Biblar L, Tucker D. Hypopyon following laser iridotomy. Ophthalmic Surg 1984;15:604. Margo CE, Lessner A, Goldey SH, Sherwood M. Lensinduced endophthalmitis after Nd: YAG laser iridotomy. Am J Ophthalmol 1992;113:97. Choplin NT, Bene CH. Cystoid macular oedema following laser iridotomy. Ann Ophthalmol 1983;15:172. Schwartz LW, Moster MR, Spaeth GL, et al. NeodymiumYAG laser iridectomies in glaucoma associated with closed or occludable angles. Am J Ophthalmol 1986;102:41-44. Canning CR, Capon MRC, Sherrard ES, et al. Neodymium: YAG laser iridotomies short-term comparison with
YAG Laser Iridotomy
26.
27. 28. 29. 30. 31. 32. 33. 34.
21
capsulotomies and long-term follow-up. Graefes Arch Clin Exp Ophthalmol 1988;226:49-54. Del-Priore LV, Robin AL, Pollack IP. Neodymium: YAG and argon laser iridotomy. Long-term follow-up in a prospective, randomized clinical trial. Ophthalmology 1988;95:1207-11. Caronia RM, Liebmann JM, Stegman Z, et al. Increase in iris-lens contact after laser iridotomy for pupillary block angle closure. Am J Ophthalmol 1998;122:53-57. Robin AL, Pollack IP. A comparison of neodymium: YAG and argon laser iridotomies. Ophthalmology 1984;91:101116. Quigley HA. Long-term follow-up of laser iridotomy. Ophthalmology 1981;88:218-24. Salmon JF. Long-term intraocular pressure control after Nd: YAG laser iridotomy in chronic angle-closure glaucoma. J Glaucoma 1993;2:291-96. Yamamoto T, Shirato S, Kitazawa Y. Treatment of primary angle-closure glaucoma by argon laser iridotomy: a longterm follow-up. Jpn J Ophthalmol 1985;29:1-12. Kim YY, Jung HR. Dilated miotic-resistant pupil and laser iridotomy in primary angle-closure glaucoma. Ophthalmologica 1997;211:205-08. Gelber EC, Anderson DR. Surgical decisions in chronic angle-closure glaucoma. Arch Ophthalmol 1976;94:148184. Richardson P, Cooper RL. Laser iridotomy. Aust NZ J Ophthalmol 1987;15:119-23.
24
Step by Step Minimally Invasive Glaucoma Surgery
INTRODUCTION Lasers have been in use for the treatment of glaucoma for the last few decades. A bloodless sutureless technique of using the Nd:Yag laser has been started by the authors (SA) to treat glaucoma. This is called laser sclerotomy. If the patient has a cataract then one can do the cataract removal with the Laser Phakonit technique followed by either a Rollable or Foldable IOL implantation. HISTORY The author first performed this technique on a diabetic patient who was already undergoing hemodialysis as a result of renal failure. His renal failure made the use of acetazolamide an absolute contraindication. Using the ND:Yag laser of the Paradigm machine which is also used for cataract surgeries by the author, the author performed the laser sclerotomy. In this, the idea was to create a hole via the clear corneal incision in the trabecular meshwork. The hole passes through and through to exit the sclera forming a filtering channel into the subconjunctival space. ND:YAG LASER It is a solid state laser having an ionizing effect causing photodisruption, thermal effect causing photovaporization, photocoagulation and photocarbonization. The laser fiberoptic (Fig. 3.1) has a Helium Neon aiming beam with the diameter of the optic end being 380 μ. This fiberoptic is encased within a silicon sleeve. The ‘male socket’ connects the fiberoptic to the laser machine. The laser machine the author advocates is the Paradigm Photon machine which works at 3 Watts.
Laser Sclerotomy
25
Fig. 3.1: Nd:YAG laser fiberoptic (1) laser fiberoptic (2) male socket (3) diameter of ocular end of laser fiberoptic is 380 (4) helium neon aiming beam
LASER SCLEROTOMY WITH ND:YAG – INSTRUMENTATION • 0.9 mm diamond blade: Custom made diamond blade similar to the one used in laser Phakonit. • Viscoelastic: Hydroxy methyl cellulose used for maintenance of anterior chamber with protection of corneal endothelium. • Nd:Yag laser fiberoptic. • Paradigm laser machine. SURGICAL TECHNIQUE Paracentesis The anterior chamber is filled initially with viscoelastics to facilitate a smooth incision (Fig. 3.2). Hydroxymethyl propyl cellulose (viscon) is the preferred viscoelastic. The site of paracentesis is preferably 45 degrees away from the main incision so that a repository may be used later on for control of the eye ball during the procedure.
26
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 3.2: Paracentesis with viscoelastic injection
Clear Corneal Incision A keratome/diamond blade of 0.9 mm size (Fig. 3.3) is used to make a clear corneal incision superiorly depending on the site planned for sclerotomy. The entry point may be directly opposite the planned site of sclerotomy or juxtaposed to the planned site of sclerotomy. Depending on the surgeon’s preferences the director of the blade may be adjusted accordingly with the initial entry point parallel to the limbus and the tunnel incision varying according to the planned site of sclerotomy. Recently the author has opted for a variation in the conventional corneal tunnel with the initial entry point parallel but about 2 mm away from the limbus and the tunnel directed towards the limbus. The sclerotomy is then performed in the same area. Laser Sclerotomy After the corneal incision is made the anterior chamber is filled with more viscoelastic (Fig. 3.4) and then the laser
Laser Sclerotomy
27
Fig. 3.3: 0.9 mm diamond blade for clear corneal incision
Fig. 3.4: Anterior chamber filled with viscoelastic
fiberoptic (Fig. 3.5) is introduced through the clear corneal incision. A short burst of laser is given directly opposite the intended site of sclerotomy (Fig. 3.6). The procedure is
28
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 3.5: Laser fiberoptic introduced through main incision and repositor is used to support the laser fiberoptic
Fig. 3.6: Laser ablation through the trabecular meshwork
Laser Sclerotomy
29
performed without the need of an operative goniolens using just the aiming beam as a guide. When the aiming beam is seen about 1.5 mm (Fig. 3.7) from the limbus a short burst of laser brings the laser fiberoptic out of the scleral bed and under the conjunctiva. Following this the fiberoptic is removed and the anterior chamber washed with BSS to remove traces of viscoelastic. BSS is injected near the sclerotomy site and sub-conjunctival bleb formation (Fig. 3.8) is looked for to assess the patency of the sclerotomy. Peripheral Iridectomy Depending on whether a PBI was done before or not a peripheral iridotomy (Fig. 3.9) may be done near the area of sclerotomy using the laser itself but preferably only in pseudophakic or aphakic patients lest the crystalline lens gets damaged inadvertently.
Fig. 3.7: Laser ablation carried through the sclera 1.5 mm from corneal limbus
30
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 3.8: BSS is injected into the anterior chamber to form bleb
Fig. 3.9: Peripheral iridectomy is made in the area of sclerotomy using ND:Yag laser or iris scissors
Laser Sclerotomy
31
Closure of Incision The clear corneal incision is closed by stromal hydration (Fig. 3.10). Laser Phakonit and IOL Implantation If the patient has a cataract then one can perform the cataract extraction with the Laser Phakonit technique followed by an IOL implantation. This concludes a triple procedure which is less traumatic than performing a triple procedure with trabeculectomy. Phakic Laser Sclerotomy Laser sclerotomy has been performed safely in phakic individuals. Care has to be exercised when the laser is used, to prevent inadvertent damage of the crystalline lens with
Fig. 3.10: Anterior chamber is reformed and incision sealed with stromal hydration
32
Step by Step Minimally Invasive Glaucoma Surgery
the laser energy. Iris pigmentation of the lens is the only complication seen in 20 percent of the phakic patients treated. Laser Sclerotomy in Pseudophakia and Aphakia About 55 percent of the patients who underwent laser sclerotomy were already operated for cataract. Results varied according to the degree of pre-operative IOP and the type of glaucoma. A case of keratoplasty with pseudophakos was treated with this procedure. When impending ciliary staphyloma formation conventional trabeculectomy could not be performed. Also long-term use of anti-glaucoma medication has resulted in subconjunctival fibrosis. The laser sclerostomy in this case was useful.
34
Step by Step Minimally Invasive Glaucoma Surgery
INTRODUCTION Zwing and Flocks in 1961 introduced for the first time the concept of using selectively Xenon Arc photocoagulation in the filtration angle of animals and reported lowering of intraocular pressure (IOP). Several workers tried this by different techniques of creating holes in trabecular meshwork (TM), but failed as the holes closed due to fibrous scarring. It goes to the credit of Wise and Witter in 1979, who described the successful protocol of laser trabeculoplasty. ARGON LASER TRABECULOPLASTY Indications • Chronic open-angle glaucoma as initial treatment and as a supplement to maximum tolerable medical therapy • Exfoliation syndrome • Pigmentary glaucoma • Open-angle glaucoma in aphakia and pseudophakia • Previous history of single operation failed trabeculoplasty. The best laser for trabeculoplasty is Green laser. A gonio prism having antireflective coating on the front surface is best for visualizing the angle. Goldmann three mirror or single mirror lens can be used, but both of these require rotation of lens for viewing the 360° of angle. A Thorpe four-mirror gonioscopy lens can also be used. In this lens all the mirrors are inclined at 62°. The best lens, however is Ritch trabeculoplasty laser lens. It has two mirrors inclined at 59° for viewing the inferior quadrants and the other two at 64° for viewing the superior angle. It also has 17 D plano-convex button lens over the mirrors. This provides ×1.4 magnification and also reduces the 50 um
Laser Trabeculoplasty
35
spot to 35 um. Therefore we get a 35 um burn on the trabeculum. This produces a burn, which is slightly more than 35 um. Whereas, a 50 um spot produces a burn of 70 um or more, which causes more damage to TM and surrounding structures. The Technique Before beginning actual treatment with argon laser, the instrument should be made parfocal with the surgeon’s eyes. This can be accomplished by placing a paper as target at the same distance where patient’s eye is usually placed. The surgeon then focuses each eye separately on the paper. The aiming beam should make a round circle without any distortion. This makes the instrument parfocal with the surgeon’s eyes. The slit-lamp should be used with ×25 magnification. Too high a magnification can reduce the field whereas, too less magnification will provide with a reduced detail. Preoperatively, Apraclonidine eye drops are instilled to reduce the chances of post-laser spike of IOP. Paracaine eye drops instilled immediately before the procedure is sufficient to give adequate anesthesia for placing Gonio lens in the eyes. The laser settings are 50 um spot, 0.1 sec, energy of 400600 mw. In heavily pigmented trabeculum more energy may be required. The aim is to get a depigmentation spot or a gas bubble at the focussed site. The laser beam is applied in between the pigmented and nonpigmented trabeculum. A posterior placement will burn iris and is likely to produce anterior synechia. Whereas, an anterior placement of the aiming beam can lead to corneal burn. We prefer to apply 50 laser shots on the inferior 180° and then watch the IOP for about three
36
Step by Step Minimally Invasive Glaucoma Surgery
months for its control. If the IOP is not well controlled, the superior portion is lasered as second stage procedure (Fig. 4.1). How Does ALT help? Argon laser improves the outflow of aqueous by photocoagulation of the trabecular meshwork (TM). A number of theories have been proposed to explain this effect of ALT on aqueous outflow. The most widely accepted are the mechanical and cellular theories. According to the mechanical theory, ALT causes coagulative damage to the trabecular meshwork, which results in collagen shrinkage and subsequent scarring of the TM. This tightens the meshwork in the area of each burn and reopens the adjacent, untreated intertrabecular spaces.2-4 The cellular theory proposes that in response to coagulative necrosis induced by the laser, there is migration
Fig. 4.1: Argon laser trabeculoplasty: 1, 2, 3 are correct reaction 1: Blenching 2: Small bubble, 3: Large bubble with pigment fallout, 4: Posterior placement of reaction leading to anterior synechia formation
Laser Trabeculoplasty
37
of macrophages, which phagocytose debris and thus clear the TM. Complications Transient Rise of IOP This is the most commonly encountered complication after laser trabeculoplasty. In majority of the patients a mild rise of IOP occurs, which may remain high for a period for 24 hours only. The pressure starts rising with in 2 hours of trabeculoplasty. Therefore IOP should be rechecked within hours of the procedure. The next day usually the pressure comes down. Special care should be observed for those patients, who have advanced glaucoma. Apraclonidine 1 percent eye drops 1 hour prior and immediately after the procedure is instilled to prevent this complication. Transient Mild Iritis This is also a commonly seen complication in early postoperative period, especially in exfoliation syndrome and pigmentary glaucoma. Postoperatively, steroid eye drops prednisolone or fluoromethalone are given 6 hourly for at least 5-7 days. Other Complications • Corneal burn causing change in the size of corneal endothelial cells • Formation of anterior synechia. Results The 5 years success rate with ALT is reported to be 50 percent, with a decrease of 6 to 10 percent per year. The
38
Step by Step Minimally Invasive Glaucoma Surgery
reduction in IOP is between 6 and 9 mmHg. The pressure reduction starts occurring after first day and continues for a period of one month. After this, usually the pressure reduction does not occur. The reduction caused by ALT may be sufficient for some eyes. But in others, it can only help in reducing the number eye drops that the patient is instilling in his eyes. Factors Influencing the Response of ALT 1. Higher the pretreatment IOP more is the response. But if initial pressure has been more than 30 mmHg the response may not be very good. 2. Type of glaucoma. Good Responders • Chronic open-angle glaucoma • Exfoliation syndrome • Pigmentary glaucoma. Fair Responders • Open-angle glaucoma in aphakia and pseudophakia • Previous history of single operation failed trabeculoplasty. Poor Responders • Previous history of multiple surgery • Glaucoma associated with uveitis angle recession glaucoma • Congenital or juvenile glaucoma • Angle recession glaucoma.
Laser Trabeculoplasty
39
Repeat Trabeculoplasty If 360° ALT has already been done and the desired reduction is not obtained a repeat trabeculoplasty may not be of any use. But if reduction has been achieved once, and the effect has reduced over a period of time, a repeat trabeculoplasty may be beneficial in some patients. Comparison of Selective Laser Trabeculoplasty and ALT Selective laser trabeculoplasty (SLT) is an alternative laser treatment introduced by Latina et al in 1995. SLT utilizes a Q switched, frequency doubled NdYAG laser ( = 532 nm) that selectively targets the pigmented TM cells without adversely affecting the TM in vitro, rendering the TM architecture more preserved. There have been a number of studies that compared the efficacy of ALT and SLT based on post-treatment IOP reduction, and all reported that SLT is as effective as ALT in terms of IOP lowering. In general, both modalities lower IOP an average of 5 mm of mercury 6 months post-treatment. Furthermore, compared to ALT, SLT did not cause ablation craters at the border of pigmented and non-pigmented cells in the TM, and the cellular changes induced by SLT did not extend beyond the Schlemm’s canal as it would after ALT. In addition, SLT appears not to cause the membrane formed by migrating endothelial cells in the necrotic TM seen after ALT treatment. SLT allows the use of 80 to 100 times lower levels of energy and less laser spots on the TM, causing less damage to the TM. Based on the above observations and results, SLT appears to be less destructive and may be more repeatable clinically than ALT.
40
Step by Step Minimally Invasive Glaucoma Surgery
BIBLIOGRAPHY 1.
2. 3.
4.
5. 6.
7.
8.
9.
Agarwal HC, Sihota R, Das C, Dada T. Role of argon laser trabeculoplasty as primary and secondary therapy in openangle glaucoma in Indian patients. British J Ophthalmol 2002;86:733-36. Alexander R, Grierson I. Morphological effects of argon laser trabeculoplasty upon the glaucomatous human meshwork. Eye 1989;3:719-26. Cvenkel B, Hvala A, Drnovsek-Olup B, et al. Acute ultrastructural changes of the trabecular meshwork after selective laser trabeculoplasty and low power argon laser trabeculoplasty. Lasers Surg Med 2003;33:204-08. Damji KF, Shah KC, Rock WJ, et al. Selective laser trabeculoplasty vs argon laser trabeculoplasty: A prospective randomized clinical trial. Br J Ophthalmol 1999;83: 218-22. Feldman RM, Katz LJ, Spaeth GL, et al. Long-term efficacy of repeat argon laser trabeculoplasty. Ophthalmology 1991;98:1061-65. Hollo G. Argon and low energy, pulsed Nd:YAG laser trabeculoplasty. A prospective, comparative clinical and morphological study. Acta Ophthalmol Scand 1996;74:12631. Koller T , Sturmer J, Reme C, et al. Membrane formation in the chamber angel after failure of argon laser trabeculoplasty: Analysis of risk factors. Br J Ophthalmol 2000;84:48-53. Kramer T, Noecker R. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology 2001;108:773-79. Martinez-de-la-Casa J, Garcia-Feijoo J, Castillo A, et al. Selective vs argon laser trabeculoplasty: Hypotensive efficacy, anterior chamber inflammation, and postoperative pain. Eye 2004;18:498-502.
Laser Trabeculoplasty
10. 11.
12.
13.
14. 15. 16. 17. 18.
19. 20.
41
Melamed S, Pei J, Epstein D. Short-term effect of argon laser trabeculoplasty in monkeys. Arch Ophthalmol 1985;103: 1546-52. Mermound A, Herbort CP, Schnyder CC, et al. Comparison of the effects of trabeculoplasty using the Nd:YAG laser and argon laser. Klin Monatsbl Augenheilkd 1992;200:40406. Odberg T, Sandvik L. The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open-angle glaucoma. Acta Ophthalmol Scand 1999;77:176-81. Popiela G, Muzyka M, Szelepin L, et al. [Use of YAG-selecta laser and argon laser in the treatment of glaucoma] (abstract only; article in Polish). Klin Oczna 2000;102:12933. Reiss GR, Wilensky JT, Higginbotham EJ. Laser trabeculoplasty. Surv Ophthalmol 1991;35:407-28. Ritch R, Liebmann J, Robin A, et al. Argon laser trabeculoplasty in pigmentary glaucoma. Ophthalmology 1993;100:909-13. Shingleton BJ, Richter CU, Dharma SK, et al. Long-term efficacy of argon laser trabeculoplasty. A 10-year followup study. Ophthalmology 1993;100:1324-29. The Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT), II: Results of argon laser trabeculoplasty vs topical medicines. Ophthalmology 1990;97:1403-13. Weinreb RN, Tsai CS. Laser trabeculoplasty. In: Ritch R, Shields MB, Krupin T, (Eds): The glaucomas: Glaucoma therapy, 2nd ed. Missouri: Mosby-Year Book, 1996;III: 157579. Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. Arch Ophthalmol 1979;97:319-22. Zweng HC, Flocks M. Experimental photocoagulation of the anterior chamber angle: A priliminary report. Am J Ophthalmol 1961;52:163.
44
Step by Step Minimally Invasive Glaucoma Surgery
LASER PRINCIPLE AND INTRODUCTION The word laser was first used in the 60s when light was generated by stimulated emission of radiation. The word LASER is an abbreviation for Light Amplification by Stimulated Emission of Radiation.9 The physical and wavelength characteristics of the laser light were so specific that they gained rapid interest in the field of medical treatment. Laser light is monochromatic and spatially and temporally coherent. This results in a laser beam that is highly directional with little divergence, thus enabling focusing of the beam into a very small spot of high power per unit area. Monochromaticity means that the laser beam is composed of almost a single wavelength, which has great consequences in the surgical eye treatment. This allows light to be effectively absorbed by the pigments contained in the ocular tissues, e.g. the melanin, hemoglobin or the xanthophyll pigments.4 The molecules in biologic tissues are not transparent to wavelength shorter than 300 nm or greater than 100 nm. Between this range, the molecules absorb selectively the light depending on the spectral absorption characteristic of the pigments in the tissues. Laser effects in tissues can be summarized into three groups: photochemical, thermal and ionization effects. The photochemical effect results in photon absorbtion by molecules inducing chemical reactions. A thermal effect is present when photon absorbtion by electrons increases the molecular vibrations to a temperature peak that results in denaturation of proteins in biologic tissues. When the temperature reaches 60°C, the weak van der Waals forces that maintain the molecular bonds are broken and denaturation of the several intracellular proteins occurs.1 If laser energy is strong enough to tear electrons from the outer orbit, the atoms or molecules become ionized and relax this metastable state
Laser Treatment in Glaucomas
45
by producing mechanical (pressure) waves (photodisruption effect).7 The efficiency of laser beam onto biological tissues depend on the absorption spectra of cellular pigments.5 Melanin best absorbs wavelengths between 400 and 100 nm. Hemoglobin, naturally presents a red appearance that strongly reduces its absorption characteristics in the long wavelengths above 650 nm. Xanthophyll absorbs very well in the short wavelengths below 500 nm. The laser delivery systems used in laser glaucoma treatments are divided into two groups: non-contact and contact laser source.8 The non-contact delivery system produces a beam that is focused onto the area to be treated via a slit-lamp biomicroscope. It may be useful to place a contact lens to stabilize the eye and the lids, to reduce the optical aberrations of the anterior surface of the cornea and to gain access to structures that are otherwise invisible without a contact lens. The contact delivery system consists of laser source and optical guidance device such as fiberoptic and delivery tip that directly apply onto the tissue to be treated.10,11 The energy distribution of the laser beam can be set on two different modes.7 The fundamental mode gives a sharp focus spot with maximum energy at the focus point and minimum energy anterior or posterior to that point. The mode locking produces a series of brief spikes of photon, with a peak of energy that is much higher than the average energy of equivalent photon bursts that are delivered in a continuous flow. It is also possible to modulate the production of the laser light before delivery by placing an electronic shutter that keeps the excited molecules to a high energy level before relaxation. When the shutter opens, an extremely brief pulse (20 ns) of high energy is produced (Q-switch mode).7
46
Step by Step Minimally Invasive Glaucoma Surgery
Several wavelengths are used in ophthalmic laser photocoagulators. Krypton lasers produce red light (647 and 676 nm). Argon lasers produce green light (514.5 nm) and green and blue light (514.5 and 488 nm). Both are used in photocoagulation,14 whereas Nd:YAG lasers deliver infrared light (1064 nm) which is used with Q-switch mode in photodisruption. Diode lasers deliver red (640 nm) and infrared light (800-820 nm) that can be guided through a fiberoptic device for contact photocoagulation. A new type of laser has recently been developed to enhance the photodissociative effect of the YAG laser in intraocular surgery. It is made by combination of a classic YAG laser on which an erbium component has been added to produce fragmentation effects. The wavelength of 2940 nm is longer than Nd:YAG, thus water absorbs most of the energy with an important water absorption photothermal effect.6 The transfer of heat to the adjacent tissue is therefore reduced. The beam is directed through a fiberglass tip with a ceramic end. The first attempts have been made in cataract surgery to replace the ultrasonic emulsification currently used.13 But technical problems regarding the safety of this method in respect to the posterior capsule have not yet been completely solved. New attempts have been made in glaucoma therapy to increase the aqueous outflow by disrupting the trabecular meshwork and inner wall of Schlemm’s canal by an ab-interno approach. A quartz fiber contact endoprobe (320 micron core-diameter, 385 micron coating-diameter) applying single neighboring laser pulses (5-7 mJ) to the trabecular meshwork. The procedure was gonioscopically visualized. Although IOP lowering effect of erbium:YAG laser trabecular ablation did not prove as effective as in filtering procedures. LTA might be a valuable alternative in glaucoma surgery especially in order to avoid conjunctival scarring and postoperative hypotony.3-5 It is
Laser Treatment in Glaucomas
47
not known whether this new technique can be widely used in the field of glaucoma laser surgery to add new prospectives or replace existing and efficient laser technique and procedure that will be explained in more details in the subsequent chapters. The physical properties of the laser beam are such that safety aspects should always be considered when using or being in close proximity to laser devices. Every laser delivery system protects the operator from direct damages when using the laser by shutting off the beam with a filter. But this is not the case for personnel being nearby and staring at the laser system, for the filter will not prevent hazardous direct or reflected beam from reaching the retina of the observers.12 LASER IRIDOTOMY Laser iridotomy is a laser surgical procedure by which a small aperture through the iris is created to treat several forms of angle-closure glaucomas and more recently pigmentary glaucoma.25,31 It was introduced in the 80’s with the development of laser surgeries.21 The indication for laser iridotomy is given in the case of acute angle-closure glaucoma when the acute attack has been medically controlled, and the cornea is clear enough to allow sufficient penetration of the laser beam into the anterior chamber without excessive scattering.5,26 In the case of chronic angleclosure glaucoma, or eyes with peripheral anterior synechia, laser iridotomy may reduce the intraocular pressure (IOP) and allow the angle structures to resume a wider space, by deepening the anterior chamber.24 Pupillary block may be relief thus allowing a better control of the IOP. In aphakic or pseudophakic eyes, pupillary block from pockets of aqueous behind the iris plane could be relieved by adequate
48
Step by Step Minimally Invasive Glaucoma Surgery
laser iridotomy.1,6,30 In eyes with intumescent cataracts, or in the fellow eye of an acute angle-closure glaucoma eye, prophylactic laser iridotomy can be performed in order to avoid an attack of angle-closure glaucoma.30 In eyes with narrow angle, good visualization of the angle structures may be rendered difficult by the geometric disposition of the iris over the angle. This situation could prevent the performance of laser trabeculoplasty in such eyes. To avoid this complication, laser iridotomy can be performed to open a too narrow angle. In the plateau iris syndrome, anteriorly located ciliary processes support the peripheral iris. Variation in the angle values between dark and light are solely related to changes in iris thickness. Pilocarpine produces iris thinning and is an effective method of opening the angle.18 General disturbance of the geometry of the eye, like in the case of nanophthalmos, have greater risks for developing angle-closure glaucoma. A prophylactic laser iridotomy could reduce the incidence of such complications. In pigment dispersion syndrome, the iris often presents a marked concavity, forming an inverted pupillary block. Accommodation increases iris concavity in some patients with pigment dispersion syndrome. The most likely explanation is an accommodation-induced relative increase in anterior chamber pressure, secondary to anterior movement of the lens surface. Iridotomy prevents change in the iris profile with accommodation.19 In this case too, performance of laser iridotomy would reduce the pressure differential between the anterior and posterior plane of the iris, by creating a channel through the iris.2,4,7,12,22 In the field of refractive surgery, the placement of an intraocular contact lenses (ICL) in the posterior chamber in front of the anterior capsule of the lens reduces the angle and increases the risk for angle-closure glaucoma. Laser iridotomy performed before refractive surgery prevents the likelihood
Laser Treatment in Glaucomas
49
of such complications.22 Conversely, in the presence of strong hypermetropic eyes, the current IOL may not have sufficient refractive power for the intended emmetropization. Two intraocular lenses (piggyback) have been placed simultaneously in the capsular bag, thus also reducing the depth of the chamber. In that case too, a laser iridotomy will prevent an attack of angle-closure glaucoma.14 Laser iridotomy is contraindicated in any situation where the angle-closure is not mechanicaly reversible by deepening the anterior chamber, for instance, a flat anterior chamber, synechial closure of the angle by uveitis, neovascular glaucoma or by iridocorneal endothelial syndrome (ICE). In this situation they are absolute contraindications for laser iridotomy. Any corneal edema or opacities will strongly reduce the quality of the transmission of the laser, and are relative contraindications for the performance of the treatment. A gonioscopic contact lens, like the Goldmann is placed on the cornea of the patient after topical anesthesia. It sometimes happens that the iris is not contracted enough to present a smooth surface and thin stroma. Only a few shallow crypts are visible. The use of pilocarpine will contract the sphincter iridae and enlarge the angle of view before treatment. In some cases, the IOP rises a few hours after laser iridotomy.3,27 To prevent the peak of pressure, an alpha agonist such as apraclonidine can be given preand perioperatively.28 The location of the iridotomy should be either the 11 or 1 O’clock positions, so that the upper lid will cover the aperture made by the laser and prevent monocular diplopia (Fig. 5.1).11,16 A crypt should be selected if possible to facilitate the creation of the crater. As laser light is absorbed by ocular pigments, very light iridies are more difficult to perforate than darker. Conversely, very dark pigmented iris have generally thicker stroma and are
50
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 5.1: Iris aspect after Nd:YAG laser iridotomy located at 12 O’clock position. Note the depigmentation of the anterior surface of the stroma around the aperture
also difficult to penetrate.13 Laser energy used will then depend on color and density of irides pigments. Current power level for argon type laser ranges from 500 upto 1500 mW for a duration of 0.1 sec. Spot size is set at 50 μm. Nd:YAG laser energy level is set between 2.0 and 8.0 mJ with single burst mode. Small bubbles form around the spot site and, in case of dark brown pigmented iris, some pigments will be released into the anterior chamber. This can severely reduce visibility of the treated area and preclude the completion of the treatment. In such case, a break between laser applications should be made. When passing through the posterior plane of the iris, clouds of pigments burst in the iridotomy crater may appear. As soon as the iris stroma has been totally penetrated, a flow of aqueous humor “leaks” through the aperture and the iris
Laser Treatment in Glaucomas
51
stroma moves slightly backwards. Retroillumination through the pupil will reveal a red reflex via the iridotomy. Care should be exercised not to be overconfident in the patency of the iridotomy, as red reflex is not enough to ensure complete burn of iris stroma. Some very thin transparent membranes could still be present, preventing aqueous from freely flowing through the iridotomy. Gonioscopy should always be performed in doubtful cases. Ultrasound biomicroscopy will show an increase in the iridocorneal angle after completion of a successful iridotomy (Fig. 5.2). Corneal edema and epithelial erosion can occur when performing laser iridotomies. Such complications generally resolve in a few days. Endothelial cell can be affected by Nd:YAG laser, caused by the shock waves produced during the treatment. Endothelial cells count have shown that proper application of laser burn with Nd:YAG laser does
Fig. 5.2: Ultrasound biomicroscopy of the anterior chamber angle after patent iridotomy through the iris stroma, the angle is wider
52
Step by Step Minimally Invasive Glaucoma Surgery
not significantly increase the endothelial cells lost.15,17,23 Nevertheless, caution should be exercised not to focus the laser beam onto the Descemet’s membrane. The iris stroma is strongly vascularized by arteries from the major iris circle, and injury to arterioles cause instant bleeding in the anterior chamber. When this complication occurs, a gentle pressure with the contact glass will temporarily increase the IOP and promote hemostasis. Dramatic hyphema have been reported after such laser procedures.29 Argon laser, or Nd:YAG laser set on multi-mode iridotomy, generally prevent such complications, as the thermal effect of the laser burns coagulates the vessels and avoids bleeding when hitting a vascular branch.13 The stroma and iris pigment epithelium dispersion phenomena observed during completion of laser iridotomies increase the amount of particles in the anterior chamber. Inflammation and anterior uveitis are generally present after the procedure. To prevent extension and persistence of this inflammation, topical steroids are given and tapered in a few days. Posterior synechiae may develop as a result of prolonged inflammation.10 As mentioned before, the IOP rises in the next few hours after laser therapy. Close monitoring of the IOP is mandatory and adequate medication given in case of persistent elevated values. Some case of damages to the lens have been reported as the result of excessive laser application to the capsule behind the iris plane.32,33 Care should therefore be exercised when applying laser energy on an patent iridotomy. LASER TRABECULOPLASTY When laser burns are applied on the trabecular meshwork, persistent IOP reduction is followed. 30,31 The pathophysiology of the laser burns on the trabecular
Laser Treatment in Glaucomas
53
meshwork was hypothesized as follows: Thermal effect of the burns induces collagen shrinkage and scarring of the meshwork. This leads to mechanical traction on the adjacent intertrabecular space that becomes open, thus increasing the outflow facility.5,27 Argon blue-green laser (488 nm) was the laser of choice for this procedure. This has been named argon laser trabeculoplasty (ALT). It can be used in several forms of open-angle glaucoma. A Nd:YAG laser trabeculoplasty (YLT) has also been used as an alternative to the ALT. In case of hypopigmented trabeculum meshwork, YLT is a safe and effective alternative technique to perform laser trabeculoplasty, which is especially useful in poorly pigmented angles where ALT is known to be less effective.14 A non-contact laser delivery system coupled with a slitlamp, is used for the ALT procedure. To gain access to the entire angle structure, a contact lens with a gonioscopic mirror (CGI from LASAG, Bern, Switzerland) is placed on the cornea of the patient after topical anesthesia. In some cases, when the angle is too narrow to allow a good visibility of the trabecular meshwork, use of pilocarpine may enlarge the angle to enable the treatment. Laser spot parameters are set commonly with 50 μm spot size, 0.1 sec. of duration and 800 mW of power. The correct effect of the laser burns should be a blanching of the trabecular meshwork. When too much power is applied, a bubble will form and intense blanching and scarring will result. The power should then be reduced just enough to get blanching with minimal bubble creation. The amount of power required to get this result may vary with the degree of pigmentation of the trabecular meshwork.20 It is important to readjust the power setting throughout the laser session to get homogeneous treatment all over the treated quadrants. The laser beam spot must be kept on focus over
54
Step by Step Minimally Invasive Glaucoma Surgery
the entire portion of the treated zone. The spots should be placed evenly over the anterior half portion of the trabecular meshwork (Fig. 5.3). Attention should be paid not to burn adjacent structures of the meshwork such as the ciliary body, the iris processes or the cornea. Correct placement of the spot minimize the possibility of early postoperative IOP rise25 and peripheral anterior synechiae formations.23 Should hemorrhage occur during the laser treatment, it could be kept under control by gently applying a slight pressure to the globe through the contact lens. This relatively rare event might be the result of an inadvertent burn of a peripheral iris vessel from the ciliary circle. Caution should also be exercised not to damage the structure of the cornea. The corneal epithelium may be inadvertently removed when placing or moving the contact lens. The resulting corneal abrasion will heal within hours often without treatment. Corneal endothelium lesions are of greater importance and may lead to permanent corneal lesions. Corneal edema results from insult to the corneal endothelium and may persist for several months, severely impairing the visual outcome of the patient. Pre-existent
Fig. 5.3: Artist’s view of gonioscopic aspect of laser burns after argon and Nd:YAG laser trabeculoplasty, and complication of peripheral anterior synechiae (Courtesy Dr A Mermoud)
Laser Treatment in Glaucomas
55
endothelial pathology such as Fuch’s endothelial dystrophy or cornea guttata have greater risks to induce complications of the corneal endothelium.28 Care should be given not to treat too many areas of the trabecular meshwork. An experimental glaucoma model in rhesus monkey has been created by giving a large number of long duration laser burns.8 Postoperative IOP rise peak may also depend on the number of burns.25 Generally, 50 to 70 burns over 180° are enough to create a sustained consistent IOP drop overtime.13,26 It should be kept in mind that the long-term overall outcome of ALT is about 50 percent after 5 years.18,19 Most of the patients will probably require other types of treatment, for instance a filtration surgery. In order not to compromise the result of further filtrating surgery, it is advisable not to treat the upper quadrant, and to leave the trabecular meshwork untouched. It is not uncommon to encounter some pressure spike after argon ALT. To prevent or avoid the extension of such pressure rise, α-2 agonist may be given before and/or just immediately after the laser treatment.17 Apraclonidine or brimonidine are the therapy of choice.1,2,4 Even with an adequate postoperative therapy, the IOP sometimes remains elevated several weeks after the ALT. It should be emphasized that the ALT produces or enhance inflammation in the anterior chamber and over the trabecular meshwork.15 Inflammatory cells and inflammation products collect into the trabecular meshwork and dramatically reduce the outflow facility, resulting in persistent IOP elevation. This inflammatory reaction is thought to be the result of transient breakdown of the bloodaqueous barrier and is correlated with the type of glaucoma. Pigmentary and pseudoexfoliative glaucoma show the greatest inflammatory reaction after ALT compared with chronic open-angle glaucoma.
56
Step by Step Minimally Invasive Glaucoma Surgery
Beside the inflammatory reaction, the ALT can also induce other reactions or changes in the anterior chamber. Laser burns placed too posteriorly result in creation of peripheral anterior synechiae.19 This complication does not happen when burns are placed in the anterior trabecular meshwork. It is still unclear whether peripheral anterior synechiae play a role in the long-term outcome of ALT or not.12 The long-term results of the ALT is relatively modest. A mean success rate of 45 percent 5 years after ALT has been reported in several studies.3,6,18,19 Despite this rate, the ALT might be indicated in patients where classical filtrating surgeries cannot be performed for general health state reasons, for ophthalmological reasons, or because of nonmotivated patients.7,9,11,29 Primary ALT gives a longlasting and favorable effect in chronic open-angle glaucoma where 2/3 of the eyes were still managed without additional medication for 8 years. The success in pseudoexfoliation glaucoma was even higher the first 3 years, and stayed above 50 percent for 10 years.3,16,22 In young patients below 50 years, the overall results without additional medication is even higher.10 Some variations in the efficiency of the ALT may be seen between individuals having different intensity in the pigmentation of the trabecular meshwork. The caucasian patients have generally less pigmented meshwork in comparison to the black African patients, and the former may respond poorly to the ALT.21,24 LASER PERIPHERAL IRIDOPLASTY Not every angle-closure glaucoma may be relieved by laser iridotomy. Structural modifications of the anterior chamber angle, like appositional angle closure in the plateau-iris syndrome, peripheral anterior synechiae or attacks of
Laser Treatment in Glaucomas
57
severe acute angle-closure glaucoma with corneal edema, anterior chamber flattening and inflammation, will prevent laser iridotomy to be effective.4,5 In case of narrow anterior chamber angle induced by lens intumescence or anterior chamber crowding as the result of short anteroposterior axis eyes (hypermetropia or nanophthalmos), the trabecular meshwork might be also difficult to see through the gonioscopic mirror. In such situations, alternative laser procedures on the iris could be performed to open the angle.5,7,10 Localized heat application onto biological tissues induces protein coagulation and shrinkage around the burn spot. This produces contractions of the tissue fibers and can be used as mechanical retractors. The argon laser peripheral iridoplasty consists of using the thermal effect of argon laser burns of large spot size, long duration and low power applied at the iris periphery to promote contractions of the iris stroma that will retract the iris root and open the angle.8,6,10,11 The treatment is performed with a contact lens under topical anesthesia. In order to have maximum efficiency, the iris surface should be as smooth as possible. To stretch the iris stroma, pilocarpine 4 percent is given one hour before initiating the procedure. Alpha-agonist is also recommended to avoid postoperative rise of the IOP. The laser is set at 500 μm, 0.5 sec and 400 mW of power, depending on the irides coloration. Excess power results in bubble formation and pigment dispersion. In that case, power should be reduced. Enough power should be applied to produce a noticeable stromal contraction. Lighter irides require more power than darker, as pigments are less dense in the former and absorb less power at a time. Location of the burns must be at the most peripheral part of the iris to produce better results. Should the burns
58
Step by Step Minimally Invasive Glaucoma Surgery
be placed less peripherally, the contraction would not be acting directly against the iris root and the resulting effect would be much less effective. For instance, placement of burns in the mid-periphery would lead to failure of this procedure. The effect of laser burns on tissues is almost immediate and iris stroma shrinkage is followed by local opening of the anterior angle and local deepening of the anterior chamber. The spots are placed around the circumference of the iris over 360 degrees with two to three spot diameters inbetween. Postoperative treatment consists of an alpha-agonist like apraclonidine given once just after the laser session and topical steroids 3 times a day for a week. Caution should be given to the IOP rise in the early hours and adequate medication be administered accordingly. Complications are relatively seldom and consist in mild iritis lasting no longer than a few days. Corneal burns and endothelial decompensation might occur as the laser beam strikes the iris plane with a narrow angle in the case of plateau iris and shallow anterior chamber. Contrary to laser iridotomy, the iris is not cut through the entire stromal portion and the lens or retina will not suffer from damages linked to laser application. 2,3,9 A case of malignant glaucoma has been reported.1 CYCLOCOAGULATION WITH YAG AND DIODE LASER The intraocular pressure can be lowered not only by enhancing the outflow through the trabeculum meshwork, but also by reducing the production of aqueous humor from the ciliary body.1,18,21 During the era when laser techniques were not currently used, cyclodestruction was made by applying either an intense and focal heat onto the ciliary body, a procedure called cyclodiathermy, or by freezing
Laser Treatment in Glaucomas
59
the ciliary processes with the help of a cryoprobe applied close to the limbus.3,19 The laser technique used to destroy the ciliary body belongs to the group of cyclophotocoagulation, a way of reducing the activity of the ciliary body by the means of light as a vector of energy. Nd:YAG laser and diode laser are both used to achieve this goal. The laser delivery system can be of contact or non-contact type, if the laser beam has to be directed through a fiberoptic end probe or applied through the air to the globe via the optic devices of a slit lamp. The latter has the advantage that the end part of the delivery system does not carry the risk of transmitting infectious diseases and does not need to be sterilized, while the former can be more compact and easier to use on a patient in a bed. The energy delivery mode can be set on a pulse mode, whereas during short time intervals a predetermined burst of energy is emitted, or the beam is continuously emitted from the laser source during a preset time. The Nd:YAG laser produces a laser beam of 1064 nm, that is well below the lowest visible wavelengths. The pulse-wave mode creates a mechanical photodisruption that is concentrated in the pigment epithelium of the ciliary body. The continuous wave mode gives a very high level of energy that is mostly absorbed thermally over the ciliary body and partially absorbed in the sclera.16 The effects of Nd:YAG laser application onto the ciliary body result in destruction of tissue, inflammation fibrosis and coagulation necrosis. At the end stage, the production of aqueous humor is markedly reduced, thus lowering the IOP.12,20 The patient is given a retrobulbar injection of anesthetic to reduce the pain induced by the laser treatment and to avoid unexpected eye movements during the procedure. With a non-contact delivery system, the patient is seated
60
Step by Step Minimally Invasive Glaucoma Surgery
in front of a slit-lamp. The laser beam is set with the maximum offset value to separate the aiming beam from the Nd:YAG beam. The energy is set between 5 and 10 J/ pulse, the duration of the continuous mode is 20 ms. The beam is pointed between 1 and 2 mm from the limbus and burns are made around evenly spaced. The number of burns varies between 20 and 40. When using a contact delivery system, the probe is placed at less than 1 mm from the limbus and the energy level limited to 5 J. The diode laser produces a laser beam of 810 nm which is slightly lower than the lowest visible wavelength.15,22 There is only one mode, the continuous-wave mode. Two delivery systems can equally be used, the contact and noncontact, in the same way the Nd:YAG laser is being used (Fig. 5.4). The effects on the ciliary body are mostly due to the thermal action of the laser beam absorbed by the melanin pigments of the ciliary epithelium. Coagulation necrosis and tissue shrinkage are the main changes observed after diode laser cyclophotocoagulation.8 The patient is prepared according to the same protocol used for the Nd:YAG treatment. The power level for non-contact
Fig. 5.4: Diode cyclophotocoagulation probe for contact cyclocoagulation
Laser Treatment in Glaucomas
61
diode treatment is set between 1000 and 2000 mW, the duration is 2 sec, and the spot size varies between 150 and 500 μm.9 In the contact mode, the duration is slightly longer, giving a power level of 2000 mW.17 The laser beam or the diode probe are placed 1 mm behind the limbus and 20 to 40 burns are made over the entire 360 degrees of the limbus (Fig. 5.5).7,10,13 A new technique for controlling refractory glaucoma has been developed that acts directly from inside the eye instead of acting through the sclera. One reason for failure of trans-scleral cyclophotocoagulation, particularly in congenital glaucoma, may be the displacement of the ciliary processes. This displacement does not permit the indirect treatment to reach the appropriate area. Because endoscopic laser cyclophotocoagulation allows direct visualization of the processes, treatment can be accurately
Fig. 5.5: Inflammation is noticeable after Nd:YAG cyclophotocoagulation, with mixed perilimbal conjunctival injection. The laser burns are clearly visible around the limbus as white scars evenly spaced
62
Step by Step Minimally Invasive Glaucoma Surgery
applied to the very individual ciliary processes.6,14 Endoscopic cyclophotocoagulation treatment encompassed 180 to 360 degrees of the ciliary body circumference and is performed through a limbal incision. An 810 nm pulsed continuous-wave diode laser capable of 1.2 W output is being used. Generally, 800 mW are being used for less than 1 second, for a total of 0.8 J per treatment. Early results suggest that endoscopic cyclophotocoagulation is a safe and effective therapeutic modality for refractory glaucomas.11 The postoperative care of patients undergoing cyclophotocoagulation consists of patching the eye for one day with topical steroids to control the postoperative inflammatory stage (Fig. 5.5). The steroids are gently tapered and antiglaucoma medication adjusted according to the postoperative examinations. The conjunctiva is frequently burned and uveitis is present after every laser treatment but subsides with steroids application. The pain might be moderate to severe, generally lasting no longer than a few days. The most severe complication implies prolonged hypotony and phthisis bulbi, a feared event that had already occurred in several cases after cyclocryocoagulation.5 These complications tend to be less frequent when using the diode laser cyclophotocoagulation.2 The pressure lowering effect of laser cyclophotocoagulation is variable but values of 15 to 30 mm Hg might be achieved, and results overtime remain quite stable. Nd:YAG and diode laser cycloablations are relatively safe and effective at controlling IOP in eyes with advanced refractory glaucoma in the short and medium term.4 Glaucoma medications are generally also reduced after one or more laser sessions. Repeated treatments are nevertheless required in some patients when the intended lowering effect is not reached at the first session.
Laser Treatment in Glaucomas
63
LASER TREATMENTS AFTER FILTERING SURGERY After classical filtering surgery that has been performed without complications, it may happen that filtration progressively decreases. The IOP rises again to values measured before surgery. The main cause for such failure is an overscarring of the filtration bleb. The trabeculectomy technique requires a good closure of the scleral flap to prevent excessive aqueous outflow resulting in hypotony and shallow anterior chamber. But a too tight closure of the scleral flap may result in excessive elevation in IOP in the postoperative period. To prevent prolonged elevation in the IOP, it is possible to selectively cut some sutures to release the tension of the scleral flap.7,9 Scleral flap sutures are made of nylon or polypropylene sutures that are either black or deep blue. The thermal effect of argon laser is efficient in lysis of such material through the conjunctiva. Technically, the procedure is performed with a contact glass applied to the conjunctiva, using the Hoskins or the Ritch lens. 4,11 This allows a better visualization of the suture by flattening the Tenon and conjunctiva layers. It is better not to perform ocular massage immediately before the laser lysis, as the massage brings some subconjunctival fluid that will scatter laser light and reduce visibility and accessibility to the suture. The laser setting is 50 μm for the spot size, with a duration of 0.1 sec and power of 300 to 500 mW. The laser beam is focused on the suture and shots are applied until the suture is being cut. Intraocular pressure is then measured to ascertain the degree of efficiency reached. Gentle massage of the globe might also be performed to promote the outflow. Caution should be exercised not to excessively treat by cutting too many sutures resulting in hypotony, shallow anterior chamber, choroidal effusion, optic disk
64
Step by Step Minimally Invasive Glaucoma Surgery
and macular edema.1 The ideal time to perform suture lysis is 1 to 2 weeks after surgery in case of elevated IOP. After this period, the result is less prone to be efficient, probably because of scarring of the scleral flap.3 Other causes of elevated pressure like iris incarceration into the internal sclerostomy or malignant glaucoma, should be investigated and eliminated accordingly. Overfiltration on the other hand is a troublesome complication that requires efficient treatment. Overfiltrating bleb can be brought to a less effective size by enhancing the fibrosis. Invasive techniques like autologous blood injection in the bleb have been reported to be efficient. Noninvasive methods using laser techniques can also be developed to prevent persistent hypotony and create some local subconjunctival bleeding. By applying gentle laser spots onto the conjunctiva with a Nd:YAG laser, the conjunctival vessels are disrupted and bleeding occurs.2 The idea is to create adhesion scars between the conjunctival bleb and the Tenon shield that reduce the size and efficiency of the bleb. It is also possible to physically promote scarring of the subconjunctival space and Tenons and mechanically tighten the two layers. To achieve this goal, several burns are made at the edge of the bleb by using the Hoskins or the Ritch lens to depress the conjunctiva. The spot size is set between 50 and 100 μm, with a duration of 0.1 sec, a power of 200 to 400 mW. The beam is focused on the Tenon or slightly deeper to avoid perforation of the conjunctiva, and the spots are evenly spaced all around the bleb. Power should not be excessive as this will result in conjunctival buttonhole or formation of subconjunctival bubbles that will increase the bleb size instead of helping scar formation.6 Laser treatment in the postoperative period can also be used in conjunction with other surgical techniques used
Laser Treatment in Glaucomas
65
to treat refractory glaucoma. In this case, drainage devices are being used to create an effective outflow from the anterior chamber to the subconjunctival and sub-Tenon’s space. But this technique requires an adequate control of the outflow that can be achieved by placing a stent suture around the tube. In the postoperative period, the IOP is monitored and the suture may be released should the pressure be elevated.8 It may also happen that the tube opening in the anterior chamber becomes blocked by fibrin clots and this results in failure of the shunt technique. Nd:YAG laser membranectomy will clean the tube and thus restore a patent drainage to the external plate.12 In the new non-perforating techniques, like deep sclerectomy with collagen implants or viscocanalostomy, the trabecular meshwork remains untouched and only the inner wall of Schlemm’s canal and the juxtacanalicular meshwork are removed. 5,13 A very thin membrane prevents the anterior chamber to collapse during the filtering surgery. But after a few weeks or months, the trabeculodescemetic membrane may become fibrotic because of elevated IOP and should be open to allow better outflow. This procedure is called goniopuncture, and can easily be done with a Nd:YAG laser. The goal of this technique is to perforate the remaining trabecular meshwork at the surgery site by performing an internal trabeculotomy or descemetomy. A gonioscopic contact glass is set on the eye of the patient after topical anesthesia to gain access to the anterior chamber angle. The trabecular meshwork at the surgery site appears as a thin less pigmented membrane, some light from the sclerectomy being transmitted through the wall (Fig. 5.6). The laser beam is pointed to this membrane and several impacts are shot. The power level is set at 5 mJ. Some air-bubbles may be generated during the treatment. It is sometimes difficult
66
Step by Step Minimally Invasive Glaucoma Surgery
to ascertain the patency of the trabeculotomy, as the perforation diameter is very small, being less than 70 μm and the edge barely distinguishable from the surrounding poorly pigmented trabecular tissue. In such case, it is best advisable to measure the pressure a few days later and perform a second session if necessary. The postoperative treatment consists of topical corticosteroids 3 times a day, tapered in a few days. The hypotensive medication if required before goniopuncture, should be continued or stopped after laser treatment according to the IOP lowering effect achieved.10 SCLEROSTOMIES The technical approach of glaucoma surgery is based on the creation of a fistula that drains into a filtering bleb.
Fig. 5.6: Gonioscopic view of the anterior chamber, and inner aspect of the trabeculodescemetic membrane after Nd:YAG goniopuncture. Note the black suture used to secure the collagen implant
Laser Treatment in Glaucomas
67
Mechanical techniques that involve the use of cutting blades, blunt dissection, tissue removal and titrated sutures promote inflammatory responses that will modulate the healing and scarring processes. Overacting fistulas or inefficient filtering blebs result from variation of standard procedure and lead to the need of complementary surgery or adjunctive treatment. Laser, by its physical property, is a very useful tool that can provide calibrated beams at various energy levels. By developing adequate delivery systems to the trabecular meshwork, it is possible to perform a direct fistula through the tissue, a so-called sclerostomy.7 The advantages of such techniques are that the fistula diameter can be better predicted, tissue trauma could be less extended, especially regarding the development of the filtering bleb.3 Three methods have been developed to achieve this goal. All are based on the kind of delivery system being used to apply laser energy to create a channel through the sclera and trabecular meshwork. Basically there are two approaches possible, from outside the eye, the ab-externo procedure, or from inside, the ab-interno procedure. The latter can further be divided into two categories, invasive or non-invasive procedure. To perform a non-invasive ab-interno sclerostomy, a modification of the current laser technique has to be made before completion of the treatment. A pulse-dye laser is used to get a beam for the non-contact delivery system connected to the slit-lamp. A gonioscopy lens is applied on the eye to allow good visualization of the angle structures. The laser produces a beam at 660 nm, set at 200 μm spot size, 10 μsec duration and 200 to 400 mJ energy level. In order to get the most effects from the beam at that wavelength, the site of sclerostomy must be dyed with methylene blue dye with an iontophoresis marker.14 The
68
Step by Step Minimally Invasive Glaucoma Surgery
beam is then directed to the blue patch that is visible in the gonioscopic lens. Shots are given repetitively until the whole sclera has been drilled and the anterior chamber shallows and the conjunctival bleb develops.8 The invasive ab-interno sclerostomy consists of introducing an endolaser probe in the anterior chamber to deliver laser beam directly to the trabecular meshwork.11 The main advantage consists of leaving the conjunctiva untouched avoiding scar formation. Disadvantages of this technique are those related to any intraocular approach; the infectious risks, trauma to the endothelium, the iris structures and the lens. Thermal damages due to accumulation of heat at the impact site are also related to this technique. To introduce the endolaser probe, a paracentesis is performed on the cornea and the anterior chamber is filled with a viscoelastic agent. The fiberoptic probe is introduced and the tip is brought into perpendicular contact with the corneoscleral tissue, taking care to avoid the posterior trabecular meshwork. Laser beam is actuated and tissue ablation begins. The probe is moved forward as ablation removes tissue leaving space for further ablation. The end of the procedure is determined when the tip is seen through the conjunctiva, and the aqueous humor and viscoelastic agent flow into the bleb.1 The ab-externo sclerostomy consists in creating a channel through the sclera to the anterior chamber.12,13 A contact probe is placed at the limbus to guide the laser beam. The conjunctiva is cut 15 mm away from the intended treatment site to allow the probe to be placed correctly thus allowing an adequate contact with the sclera. A holmium:YAG laser is used to produce the energy required to ablate the tissue. The energy level is set at 100 mJ/pulse. The beam is applied to the sclera and can be seen through the cornea into the anterior chamber. Progression of creation of the channel can therefore be
Laser Treatment in Glaucomas
69
monitored until completion. At that stage, aqueous humor flows through the fistula into the subconjunctival space.10 After removal of the probe, the conjunctival incision is closed with a single suture and topical antiinflammatory medication given.2,5,6,9 REFERENCES Laser Principle and Introduction 1.
Birngruber R. Thermal modeling in biological tissues. In Hillenkamp F, Praetesi R, Sacchi CA (Eds): Laser in Biology and Medicine Plenum: New York, 1980. 2. Dietlein TS, Jacobi PC, Krieglstein GK. Ab-interno infrared laser trabecular ablation: Preliminary short-term results in patients with open-angle glaucoma. Graef’s Arch Clin Exp Ophthalmol 1997;235(6):349-53. 3. Dietlein TS, Jacobi PC, Krieglstein GK. Erbium: YAG laser trabecular ablation (LTA) in the surgical treatment of glaucoma. Lasers Surg Med 1998;23(2):104-10. 4. Hillenkamp F. Interaction between laser radiation and biological systems. In Hillenkamp F, Praetesi R, Sacchi CA (Eds): Laser in Biology and Medicine. Plenum: New York, 1980. 5. L’Esperance FA Jr. Ophthalmic Laser: Photocoagulation, Photoradiation and Surgery (3rd edn): Mosby: St. Louis 1989. 6. Loertscher H, Shi WQ, Grundfest WS. Tissue ablation through water with erbium: YAG lasers. IEEE Trans Biomed Eng 1992;39:86-88. 7. Mainster MA, Sliney DH, Blecher CD, et al. Laser photodisruptors: Damage mechanisms, instrument design and safety. Ophthalmology 1983;90:973-91. 8. Mainster MA, Ho PC, Mainster KJ. Argon and krypton laser photocoagulators. Ophthalmology 1983;90: 48-54. 9. Ready JF. Industrial applications of lasers. Academic Press: New York, 1978.
70
Step by Step Minimally Invasive Glaucoma Surgery
10.
Schuman JS, et al. Experimental use of semiconductor diode laser in contact transscleral photocoagulator in rabbits. Arch Ophthalmol 1990;108:1152-57. 11. Schuman JS, et al. Energy levels and probe placement in contact transscleral semiconductor diode laser cyclophotocoagulation in human cadaver eyes. Arch Ophthalmol 1991;109:1534-38. 12. Sliney DH, Mainster MA. Potential laser hazards to the clinician during photocoagulation. Am J Ophthalmol 1987;103:758-60. 13. Wetzel W, Brinkmann R, Koop N, et al. Photofragmentation of lens nuclei using the Er: YAG laser: Preliminary report of an in vitro study. Ger J Ophthalmol 1996;5(5): 281-84. 14. Wieder M, Pomerantzeff O, Schnieder J. Retinal vessel photocoagulation: A quantitative comparison of argon and krypton laser effects. Invest Ophthalmol Vis Sci 1981;20:418-24.
Laser Iridotomy 1.
Anderson DR, Forster RK, Lewis ML. Laser iridotomy for aphakic pupillary block. Arch Ophthalmol 1975;93:343-46. 2. Breingan PJ, Esaki K, Ishikawa H, et al. Iridolenticular contact decreases following laser iridotomy for pigment dispersion syndrome. Arch Ophthalmol 1999;117(3):32528. 3. Brooks AMV, Harper CA, Gillies W. Occurrence of malignant glaucoma after iridotomy. Br J Ophthalmol 1989;73:617-20. 4. Carassa RG, Bettin P, Fiori M, et al. Nd:YAG laser iridotomy in pigment dispersion syndrome: An ultrasound biomicroscopic study. Br J Ophthalmol 1998;82(2):150-53. 5. Fleck BW, Wright E, Fairley EA. A randomised prospective comparison of operative peripheral iridectomy and Nd:YAG laser iridotomy treatment of acute angle closure glaucoma: 3-year-visual acuity and intraocular pressure control outcome. Br J Ophthalmol 1997;81(10):884-88.
Laser Treatment in Glaucomas
6. 7. 8.
9. 10. 11. 12. 13.
14. 15. 16. 17.
71
Forman JS, et al. Pupillary block following posterior chamber lens implantation. Ophthalmic Laser Ther 1987;2:85-88. Gandolfi SA, Vecchi M. Effect of a YAG laser iridotomy on intraocular pressure in pigment dispersion syndrome. Ophthalmology 1996;103(10):1693-95. Janiec S, Rzendkowski M, Bolek S, et al. The effect of Nd:YAG laser iridotomy on irido-corneal angle width assessed with ultrasound biomicroscopy in patients with primary open-angle glaucoma. Klin Oczna 1998;100(1):1518. Kim YY, Jung HR. Dilated, miotic-resistant pupil and laser iridotomy in primary angle-closure glaucoma. Ophthalmologica 1977;211(4):205-08. Kraemer C, Gramer E. Posterior synechiae after Nd:YAG laser iridotomy. A clinical study. Ophthalmologe 1998;95(9):625-32. Kublin J, Simmons RJ. Use of tinted soft contact lenses to eliminate monocular diplopia secondary to laser iridectomies. Ophthalmic Laser Ther 1987;2:111-13. Lagreze WD, Mathieu M, Funk J. The role of YAG-laser iridotomy in pigment dispersion syndrome. Ger J Ophthalmol 1996;5(6): 435-38. Lim L, Seah SK, Lim AS. Comparison of argon laser iridotomy and sequential argon laser and Nd:YAG laser iridotomy in dark irides. Ophthalmic Surg Lasers 1996;27(4):285-88. Masket S. Piggyback intraocular lens implantation. J Cataract Refract Surg 1998;24(4):569-70. Meyer KT, Pettit TH, Straatsma BR. Corneal endothelium damage with neodymium: YAG laser. Ophthalmology 1984;91:1022-28. Murphy PH, Trope GE. Monocular blurring: a complication of YAG laser iridotomy. Ophthalmology 1991;98:1539-42. Panek WC, Lee DA, Christensen RE. The effects of Nd: YAG laser iridotomy on the corneal endothelium. Am J Ophthalmol 1991;111:505-07.
72 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28.
29. 30. 31.
Step by Step Minimally Invasive Glaucoma Surgery
Pavlin CJ, Foster FS. Plateau iris syndrome: Changes in angle opening associated with dark, light, and pilocarpine administration. Am J Ophthalmol 1999;128(3):288-91. Pavlin CJ, Macken P, Trope GE, et al. Accommodation and iridotomy in the pigment dispersion syndrome. Ophthalmic Surg Lasers 1996;27(2):113-20. Pesando PM, Ghiringhello MP, Tagliavacche P. Posterior chamber collamer phakic intraocular lens for myopia and hyperopia. J Refract Surg 1999;15(4):415-23. Pollack IP. Use of argon laser energy to produce iridotomies. Ophthalmic Surg 1980;11:506-15. Potash SD, et al. Ultrasound biomicroscopy in pigment dispersion syndrome. Ophthalmology 1994;101:332-39. Power WJ, Collum LMT. Electron microscopic appearances of human corneal endothelium following Nd:YAG laser iridotomy. Ophthalmic Surg 1992;23:347-50. Quigley HA. Long-term follow-up of laser iridotomy. Ophthalmology 1981;88:218-24. Ritch R, Podos SM. Argon laser treatment of angle-closure glaucoma. Perspect Ophthalmol 1980;4:129-34. Ritch R, Solomon IS. Glaucoma surgery. In L’Esperance FA (Ed): Ophthalmic Lasers (3rd edn): Mosby: St Louis, 1989. Robin AL. Intraocular pressure rise after iridotomy (letter). Arch Ophthalmol 1986;104:1117. Robin AL, Pollack IP, DeFaller JM. Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on intraocular pressure rise following argon laser iridotomy. Arch Ophthalmol 1987;105:1208-11. Rubin L, Arnett J, Ritch R. Delayed hyphema after argon laser iridectomy. Ophthalmic Surg 1984;15:852-53. Samples J, et al. Pupillary block with posterior chamber intraocular lenses. Am J Ophthalmol 1987;105:335-37. Schwartz LW, et al. Argon laser iridotomy in the treatment of patients with primary angle-closure or pupillary block glaucoma: A clinicopathologic study. Ophthalmology 1978;85:294-309.
Laser Treatment in Glaucomas
32. 33. 34.
73
Wollensak G, Eberwein P, Funk J. Perforation rosette of the lens after Nd:YAG laser iridotomy. Am J Ophthalmol 1997;123(4):555-57. Zadok D, Chayet A. Lens opacity after neodymium: YAG laser iridectomy for phakic intraocular lens implantation. J Cataract Refract Surg 1999;25(4):592-93. Zaldivar R, Davidorf JM, Oscherow S. Posterior chamber phakic intraocular lens for myopia of ~8 to ~19 diopters. J Refract Surg 1998;14(3):294-305.
Laser Trabeculoplasty 1. 2.
3.
4. 5. 6. 7. 8.
Barnebey HS, et al. The efficacy of brimonidine in decreasing elevation in intraocular pressure after laser trabeculoplasty. Ophthalmol 1993;100:1083-88. Barnes SD, Campagna JA, Dirks MS, et al. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2 percent to apraclonidine 1.0 percent. Ophthalmology 1999;106(10): 2033-37. Bergea B, Bodin L, Svedbergh B. Primary argon laser trabeculoplasty vs pilocarpine. IV Long-term effects on optic nerve head. Acta Ophthalmol Scand 1995;73(3):21621. Brown RH, et al. ALO 2145 reduces the IOP elevation after anterior segment surgery. Ophthalmol 1988;95:378-84. Brubaker RF. Liesegang TJ. Effect on trabecular photocoagulation on the aqueous humor dynamics of the human eye. Am J Ophthalmol 1983;96:139-47. Chen TC, Wilensky JT, Viana MA. Long-term follow-up of initially successful trabeculectomy. Ophthalmology 1997;104(7):1120-25. Damji KF, et al. Selective laser trabeculoplasty vs argon laser trabeculoplasty: A prospective randomised clinical trial. Br J Ophthalmol 1999;83(6):718-22. Gaasterland D, Kupfer C. Experimental glaucoma in rhesus monkey. IOVS 1974;13:455-57.
74 9.
10.
11.
12.
13. 14.
15. 16.
17. 18.
Step by Step Minimally Invasive Glaucoma Surgery
Guzey M, et al. Effects of frequency-doubled Nd:YAG laser trabeculoplasty on diurnal intraocular pressure variations in primary open-angle glaucoma. Ophthalmologica. 1999;213(4):214-18. Jacobi PC, Dietlein TS, Krieglstein GK. Primary trabeculectomy in young adults: Long-term clinical results and factors influencing the outcome. Ophthalmic Surg Lasers 1999;30(8):637-46. Jampel HD. Initial treatment for open-angle glaucomamedical, laser, or surgical? Laser trabeculoplasty is the treatment of choice for chronic open-angle glaucoma. Arch Ophthalmol 1998;116(2): 240-41. Koller T, Sturmer J, Reme C, et al. Membrane formation in the chamber angle after failure of argon laser trabeculoplasty: Analysis of risk factors. Br J Ophthalmol 2000;84(1):48-53. Lustgarten J, et al. Laser trabeculoplasty: A prospective study of treatment parameters. Arch Ophthalmol 1984;102:517-19. Mermoud A, Herbort CP, Schnyder CC, et al. Comparison of the effects of trabeculoplasty using the Nd-YAG laser and the argon laser. Klin Monatsbl Augenheilkd 1992; 200(5):404-06. Mermoud A, Pittet N, Herbort CP. Inflammation patterns after laser trabeculoplasty measured with the laser flare meter. Arch Ophthalmol 1992;110:368-70. Odberg T, Sandvik L. The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma. Acta Ophthalmol Scand 1999;77(2):176-81. Robin AL. Argon laser trabeculoplasty medical therapy to prevent the intraocular pressure rise associated with argon laser trabeculoplasty. Ophthalmic Surg 1991;22:31-37. Shingelton BJ, et al. Long-term efficacy of argon laser trabeculoplasty. Ophthalmol 1987;94:1513-19.
Laser Treatment in Glaucomas
19. 20. 21. 22. 23.
24. 25. 26. 27. 28. 29. 30. 31.
75
Schwartz AL, Love DC, Schwartz MA. Long-term followup of argon laser trabeculoplasty for uncontrolled openangle glaucoma. Arch Ophthalmol 1985;103:1482-84. Schwartz LW, et al. Variation of techniques on the results of argon laser trabeculoplasty. Ophthalmol 1983;90:78184. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Sevenyear-results. Ophthalmology 1998;105(7):1146-64. Ticho U, Nesher R. Laser trabeculoplasty in glaucoma. Tenyear-evaluation. Arch Ophthalmol 1989;107(6):844-46. Traverso CE, Greenidge KC, Spaeth GL. Formation of peripheral anterior synechiae following argon laser trabeculoplasty: A prospective study to determine relationship to position of laser burns. Arch Ophthalmol 1984;102:861-63. Varma R. Trabeculoplasty, trabeculectomy, and race: Is there a difference in response to treatment between blacks and whites? Ophthalmology 1998;105(7):1135-36. Weinreb RN, et al. Immediate intraocular pressure response to argon laser trabeculoplasty. Am J Ophthalmol 1983;95:279-86. Weinreb RN, et al. Influence of the number of laser burns administered on the early results of argon laser trabeculoplasty. Am J Ophthalmol 1983;95:287-92. Wickham MG, Worthen DM, Binder PS. Physiologic effects of laser trabeculectomy in rhesus monkey eyes. IOVS 1977;16:624-28. Wilensky JT, Jampol L. Laser therapy for open-angle glaucoma. Ophthalmol 1981;88:213-17. Wise JB. Ten-year-results of laser trabeculoplasty. Does the laser avoid glaucoma surgery or merely defer it? Eye 1987;1(Pt 1):45-50. Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma: A pilot study. Arch Ophthalmol 1979;97:31922. Wise JB. Status of laser treatment of open-angle glaucoma. Ann Ophthalmol 1981;13:149-50.
76
Step by Step Minimally Invasive Glaucoma Surgery
Laser Peripheral Iridoplasty 1. 2.
3. 4.
5.
6. 7. 8. 9. 10. 11.
Fourman S. “Malignant” glaucoma post laser iridotomy. Ophthalmology 1992;99(12):1751-52. Karjalainen K, Laatikainen L, Raitta C. Bilateral nonrhegmatogenous retinal detachment following neodymium-YAG laser iridotomies. Arch Ophthalmol 1986;104:1134. Karmon G, Savir H. Retinal damage after argon laser iridotomy. Am J Ophthalmol 1986;101:554-60. Lai JS, Tham CC, Lam DS. Limited argon laser peripheral iridoplasty as immediate treatment for an acute attack of primary angle closure glaucoma: A preliminary study. Eye 1999;13(Pt 1):26-30. Lam DS, Lai JS, Tham CC. Immediate argon laser peripheral iridoplasty as treatment for acute attack of primary angle-closure glaucoma: A preliminary study. Ophthalmology 1998;105(12):2231-36. Ritch R, Liebmann JM. Argon laser peripheral iridoplasty. Ophthalmic Surg Lasers 1996;27(4):289-300. Ritch R. Plateau iris is caused by abnormal positioned ciliary processes. J Glaucoma 1992;1:23-27. Sassani JW, et al. Histopathology of argon laser peripheral iridoplasty. Ophthalmic Surg 1993;24:740-45. Shapiro A, Tso MO, Goldberg MF. Argon laser-induced cataract. Arch Ophthalmol 1984;102:579-83. Verma N, Fromberg G. Combined argon laser iridoplasty and trabeculoplasty in the management of open angle glaucomas. Indian J Ophthalmol 1986;34:221-23. York K, Ritch R, Szmyd LJ. Argon laser peripheral iridoplasty: Indications, techniques and results. IOVS 1984;25(Suppl): 94.
Cyclocoagulation with YAG and Diode Laser 1.
Albaugh CH, Dunphy EB. Cyclodiathermy. Arch Ophthalmol 1942;27:543.
Laser Treatment in Glaucomas
2. 3. 4.
5. 6. 7. 8. 9. 10. 11. 12. 13. 14.
77
Azuara-Blanco A, Dua HS. Malignant glaucoma after diode laser cyclophotocoagulation. Am J Ophthalmol 1999;127(4): 467-69. Bietti G. Surgical intervention on the ciliary body: New trends for the relief of glaucoma. JAMA 1950;142:889. Bloom PA, Tsai JC, Sharma K, et al. “Cyclodiode”. Transscleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma. Ophthalmology 1997; 104(9):1508-19. Brindley G, Shields MB. Value and limitation of cyclocryotherapy. Graefe’s Arch Clin Exp Ophthalmol 1986;224: 545-48. Chen J, Cohn RA, Lin SC, et al. Endoscopic photocoagulation of the ciliary body for treatment of refractory glaucomas. Am J Ophthalmol 1997;124(6):787-96. Detry-Morel M, Gilon B. Treatment of refractory glaucoma with trans-scleral cyclophotocoagulation using a diode laser. Bull Soc Belge Ophthalmol 1999;272: 45-52. Hennis HL, Stewart WC. Transcleral cyclophotocoagulation using a semiconductor diode laser in cadaver eyes. Ophthalmic Surg 1991;22:274-78. Kida K, et al. Non-contact transscleral semi-conductor diode laser cyclophotocoagulation for refractory glaucoma. IOVS 1992;33 (Suppl): 1267. Linsen MC, Mannes C, Zeyen T. Diode laser cyclophotocoagulation in refractory glaucoma. Bull Soc Belge Ophthalmol 1998;270:69-73. Mora JS, et al. Endoscopic diode laser cyclophotocoagulation with a limbal approach. Ophthalmic Surg Lasers 1997;28(2):118-23. Nassise MP, et al. Inflammatory effects of continuous-wave Nd:YAG laser cyclocoagulation. IOVS 1992;33:2216. Oguri A, Takahashi E, Tomita G, et al. Trans-scleral cyclophotocoagulation with the diode laser for neovascular glaucoma. Ophthalmic Surg Lasers 1998;29(9):722-27. Plager DA. et al. Intermediate-term results of endoscopic diode laser cyclophotocoagulation for pediatric glaucoma. J AAPOS 1999;3(3):131-37.
78 15. 16. 17.
18. 19.
20. 21. 22.
Step by Step Minimally Invasive Glaucoma Surgery
Schlote T, Kreutzer B, Kriegerowski M, et al. Diode laser cyclophotocoagulation in treatment of therapy refractory glaucoma. Klin Monatsbl Augenheilkd 1997;211(4):250-56. Schubert HD, Agarwal A. Quantitative CW Nd:YAG pars plana trans-scleral photocoagulation in postmortem eyes. Ophthalmic Surg 1990;21:835-39. Schuman JS, et al. Energy levels and probe placement in contact trans-scleral semiconductor diode laser cyclophotocoagulation in human cadaver eyes. Arch Ophthalmol 1991;109:1534-38. Stocker FW. Response of chronic simple glaucoma to treatment with cyclodiathermy puncture. Arch Ophthalmol 1945;34:181. Vogt A Versuche zur intraokularen Druckherabsetzung mittels Diathermieschadigung des corpus ciliare (Zyklodiatermiestichelung) Klin Monatsbl Augenheilkd 1936;97:672. Weekers R, et al. Effects of photocoagulation of ciliary body upon ocular tension. Am J Ophthalmol 1961;52:156. Weve H. Die Zyklodiatermie das corpus ciliare bei Glaukom Zentralbl Ophthalmol 1933;29:256. Wong EY, Chew PT, Chee CK, et al. Diode laser contact trans-scleral cyclophotocoagulation for refractory glaucoma in Asian patients. Am J Ophthalmol 1997;124(6): 797-804.
Laser Treatments After Filtering Surgery 1.
Bardak Y, Cuypers MH, Tilanus MA, et al. Ocular hypotony after laser suture lysis following trabeculectomy with mitomycin C. Int Ophthalmol 1997-98;21(6):325-30. 2. Bettin P, Carassa RG, Fiori M, et al. Treatment of hyperfiltering blebs with Nd:YAG laser-induced subconjunctival bleeding. J Glaucoma 1999;8(6):380-83. 3. Chopra H, et al. Early postoperative titration of bleb function: Argon laser lysis and removable sutures in trabeculectomy. J Glaucoma 1992;1:54.
Laser Treatment in Glaucomas
4. 5. 6. 7. 8. 9. 10. 11. 12. 13.
79
Hoskins HD Jr, Migliazzo C. Management of failing filtering blebs with the argon laser. Ophthalmic Surg 1984;15:731. Karlen ME, Sanchez E, Schnyder CC, et al. Deep sclerectomy with collagen implant: Medium term results. Br J Ophthalmol 1999;83(1):6-11. Lanzl IM, Katz LJ, Shindler RL, et al. Surgical management of the symptomatic overhanging filtering bleb. J Glaucoma 1999;8(4):247-49. Lieberman MF. Suture lysis by laser and goniolens. Am J Ophthalmol 1983;95:257. Liebmann J, Ritch R. Intraocular suture ligature to reduce hypotony following Molteno seton implantation. Ophthalmic Surg 1992;23:51. Macken P, Buys Y, Trope GE. Glaucoma laser suture lysis. Br J Ophthalmol 1996;80(5):398-401. Mermoud A, Karlen ME, Schnyder CC, et al. Nd:YAG goniopuncture after deep sclerectomy with collagen implant. Ophthalmic Surg Lasers 1999;30(2):120-25. Ritch R, Potash SD, Liebmann JM. A new lens for argon laser suture lysis. Ophthalmic Surg 1994;25:126. Singh K, Eid TE, Katz LJ, et al. Evaluation of Nd:YAG laser membranectomy in blocked tubes after glaucoma tubeshunt surgery. Am J Ophthalmol 1997;124(6):781-86. Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg 1999;25(3):316-22.
Sclerostomies 1. 2. 3.
Berlin MS, Rajacich G, Duffy M, et al. Excimer laser photoablation in glaucoma filtering surgery. Am J Ophthalmol 1984;103:713-14. Friedman DS, Katz LJ, Augsburger JJ, et al. Holmium laser sclerostomy in glaucomatous eyes with prior surgery: 24month results. Ophthalmic Surg Lasers 1998;29(1):17-22. Haring G, Behrendt S, Wetzel W. Evaluation of laser sclerostomy fistulas using ultrasound biomicroscopy. Int Ophthalmol 1997-98;21(5):261-64.
80 4. 5. 6. 7.
8. 9. 10. 11. 12. 13.
14.
Step by Step Minimally Invasive Glaucoma Surgery
Iwach AG, Hoskins HD Jr. Laser sclerostomy for the management of glaucoma. Curr Opin Ophthalmol 1993;4(2):85-92. Iwach AG, Hoskins HD Jr, Drake MV, et al. Subconjunctival THC:YAG (“Holmium”) laser thermal sclerostomy abexterno. A one year report. Ophthalmol 1993;100:356-65. Jacobi PC, Dietlein TS, Krieglstein GK. Prospective study of ab externo erbium: YAG laser sclerostomy in humans. Am J Ophthalmol 1997;123(4):478-86. Kendrick R, Kollarits CR, Khan N. The results of ab-interno laser thermal sclerostomy combined with cataract surgery versus trabeculectomy combined with cataract surgery 6 to 12 months postoperatively. Ophthalmic Surg Lasers 1996;27(7):583-86. Latina MA, Melamed S, March WF, et al. Gonioscopic abinterno laser sclerostomy: A pilot study in glaucoma patients. Ophthalmol 1992;99:1736-44. Luntz MH, Fliegler RD, Mastrobattista J. Subconjunctival THC:YAG laser sclerostomy under a partial thickness flap. Eur J Ophthalmol 1996;6(3):268-72. Mannino G, et al. Ultrasound biomicroscopy in the clinical evaluation of ab-externo holmium: YAG laser sclerostomies. Ophthalmic Surg Lasers 1998;29(2):157-61. Melamed S, Neumann D. Internal sclerostomy with laser: A new approach to glaucoma surgery. Lasers Surg Med 1991;11(5):440-44. Onda E, Ando H, Jikihara S, et al. Holmium YAG laser sclerostomy ab-externo for refractory glaucoma. Int Ophthalmol 1996-97;20(6):309-14. Spiegel D, Wetzel W, Birngruber R. Ab-externo erbium YAG laser sclerostomy versus conventional trabeculectomy. Treatment of glaucoma patients. Ophthalmologe 1998;95(8):537-41. Wang Y, Cohen RE, Schuman JS. Iontophoresis of indocyanine green and monastral blue B for gonioscopic diode laser sclerectomy. Ophthalmic Surg Lasers 1996; 27(6):484-87.
82
Step by Step Minimally Invasive Glaucoma Surgery
NEODYMIUM YAG LASER IRIDOLENTICULAR SYNECHIOLYSIS Presence of a bound down pupil in patients of granulomatous uveitis is a well known phenomenon. This can lead to an obstruction to aqueous and secondary glaucoma. A sizeable percentage, especially from the poorer socioeconomic strata where medical attention is neither sought nor easily available tends to have the bound down pupil or ring synechiae with the pupil bound down in the miosed position. Most of these cases also have a complicated cataract in the posterior subcapsular area resulting in a profound visual loss. Many authors have reported using the argon laser photomydriasis in such cases but Nd:YAG laser has seldom been used for sectioning of iridolenticular adhesions are very few (Fig. 6.1).
Fig. 6.1: Bound down pupil with iridolenticular adhesions
Miscellaneous Laser Applications
83
Pre-laser Workup All patients are initially given a trial of pupillary dilatation by 2 percent homatropine and 10 percent phenylephrine eye drops (rule out hypertension) after which additional dilatation is tried by tropicamide 1 percent eye drops. One percent Atropine eye ointment is used in twice daily dosage on a long-term basis in these patients. Informed consent must be obtained. Technique of Laser Therapy They are seated on a Q-switched Nd:YAG laser machine and an Abraham type of iridotomy lens is used. The synechiae are cut by 1mJ of power by focusing the laser towards the iris rather than the lens surface starting in the inferior quadrant so that the debris and hemorrhage are not dispersed in the anterior chamber, impeding further laser. If excess debris and hemorrhage are dispersed in the anterior chamber then the next sitting is tried after 30 minutes and if again visualization is inadequate then the procedure is carried out after 48 hours. Postoperatively IOP is recorded hourly for 4 hours, then at 12 hours and thereafter daily till 7 days. It is also recorded subsequently whenever patient visits the outpatient department. Dilatation is tried by putting 2 percent homatropine and 10 percent phenylephrine drops starting immediately after laser at every 5 minutes for 30 minutes (Fig. 6.2). Patients are continued on antiglaucoma medications of 0.25 percent timolol maleate BD along with 1 percent tropicamide eye drops four times daily for 2 weeks. Postoperatively pupillary diameter, change in visual acuity along with any lenticular damage is recorded.
84
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 6.2: Dilatation of pupil after YAG laser synechiolysis
Clinical Results A study was conducted at Dr RP Centre for Ophthalmic Sciences, New Delhi (unpublished data) to evaluate the above technique. Fifteen patients of chronic granulomatous uveitis with bound down pupil or presence of ring synechiae where dilatation was not possible by pharmacological means were chosen for the study. Shallow anterior chamber, hazy cornea, active anterior uveitis and secondary glaucoma formed the contraindications to such a laser therapy. Each patient also has an associated complicated cataract in the posterior subcapsular zone with pigment dispersal on lens and cornea contributing to the visual loss. Each patient had a full work up and was under constant medical supervision at our uvea clinic. Every patient was given a choice of surgery or laser but all the
Miscellaneous Laser Applications
85
first 15 cases opted for an initial laser procedure after having been explained the possible complications and risks involved with such a procedure. The mean age of 15 patients was 31.80 ± 9.52 years. The mean pre-laser IOP was 22.61 mm Hg while the average post-laser IOP was 17.33 ± 3.59 mm Hg at 4 weeks followup. The average pre-laser pupillary size was 3.6 ± 1.0 mm while the average post-laser pupillary size was 5.06 ± 1.50 mm (p<0.001). An average of 45.93 ± 14.31 shots were used. More than 2 line increase in visual acuity occurred in 6 eyes (40%), while no eye had a loss of best corrected acuity. The complications included hemorrhage (15/15), mild hyphema (7/15) and mild to moderate uveitis in all 15 patients. IOP spikes were less than 25 mmHg in all patients treated. Iridolenticular adhesions with totally pharmacologically non-dilating pupil are not an uncommon entity in ophthalmic practice. It may result in iris bombe formation with peripheral anterior synechiae, and is commonly associated with cataract. It may interfere with vision, fundus visualization and evaluation for glaucoma becomes difficult. In all such cases, sectioning of adhesions should provide relief. Laser surgery being an outpatient procedure is obviously preferable. Our main purpose for trying synechiolysis in these cases was trying for visual improvement by increasing the pupillary diameter which could bypass the obstruction posterior subcapsular cataractous changes. The obvious additional advantage is that a number of these cases in time would go in for cataract surgery and performing an anterior capsulotomy is much easier along with aspiration of cortex without having to mechanically dilate the iris which could result in unwanted excess pigment dispersal and fibrinoid reaction postoperatively.
86
Step by Step Minimally Invasive Glaucoma Surgery
The results clearly reveal that this procedure is no panacea as only 6 out of 15 cases achieved any gain in visual acuity along with dilatation of pupil. However, as most of these patients have chronic inflammation and cataract, surgery is also fraught with complications and any gain of visual acuity which can postpone surgery is very welcome to the patient. All cases had an associated micro hemorrhage along with pigment dispersal in anterior chamber. However, it was usually self limiting and one had to only apply some pressure with the contact lens to abolish the hemorrhage. Though hemorrhage and pigment may cause short-term deterioration of visualization, in none of our patients did it result in a long-term deterioration of vision. The elevation of intraocular pressure was definitely present but was easily controlled on single anti-glaucoma medication. Thus overall no case showed any significant complication or any obvious lenticular damage on biomicrosocpy. Considering the advantages and relative safety, we recommend this procedure for routine use but by an experienced laser microsurgeon. Long-term results of visual benefit by this procedure must be reviewed in terms of further complications related to primary disease which can lead to enhancement of cataract, uveitis, retinal and optic nerve damage. Modified Technique for Nd: YAG Laser Iridolenticular Synechiolysis This technique differs from the above-mentioned technique of synechiolysis in the fact that instead of direct photodisruption, it utilizes the shock waves generated in aqueous to release the synechia. The aiming beam is focused at the center of the broad base synechia towards the side of iris. This is followed by slight anterior defocusing
Miscellaneous Laser Applications
87
of the aiming beam. A power of 1-2 millijoules is used. Shock waves were generated in the aqueous and immediate lysis of the whole of the synechiae is observed, with mild pigment dispersion. Post-laser treatment regimen includes topical 1 percent prednisolone acetate eye drops four time daily, 0.5 percent timolol maleate eye drops twice daily for four days and 1 percent tropicamide eye drop four times daily for one week. In an initial technique (Nd:YAG iridolenticular synechiolysis) direct cutting of the synechiae with Nd:YAG laser, and the beam is directed at the synechia just at the junction of iris and lens was used. Though with Nd:YAG iridolenticular synechiolysis we did not observe any lens damage or clinically significant flare up of the inflammation but the theoretical possibility of lens damage does exist. Few cases where bleeding occurred, it was transient and could controlled easily and had no untoward effects. The new modified technique differs from the previous one in the fact that instead of direct photodisruption it utilizes the shock wave generated in aqueous to release the synechia. Thus this technique actually combines the virtues of YAG sweeping with lysis, therefore making lysis easier at points where a broad based synechiae are available. As the laser was aimed onto the iris at the center of the synechiae, possibility of lens damage is almost eliminated. Additionally, slight anterior defocusing of the aiming beam helps to eliminate the risk of iris damage. However, with misalignment and malfocusing of the laser, it may hit the crystalline lens. Accidental hitting of the lens with low-power Nd:YAG may not have an untoward effect, however, theoretically it may lead to lens damage and focal opacification of lens. This procedure also carries the theoretical risk of bleeding in presence of new vessels in the synechiae.
88
Step by Step Minimally Invasive Glaucoma Surgery
Thus, this method appears to be a relatively safe technique for iridolenticular synechiolysis. Larger studies with longer follow-up are required to establish the complete safety and efficacy of this technique. LASER SUTUROLYSIS During trabeculectomy nylon sutures are applied to secure the scleral flap and to regulate the aqueous flow through the bleb. To avoid immediate postoperative hypotony and its complication especially in eyes with advanced glaucoma, tight sutures are preferred. However, if the intraocular pressure (IOP) is too high and anterior chamber is deep, laser suturolysis may be required. Lens: The Hoskins lens is used for this purpose. However, in case this special lens is not available, then one can use the edge of a regular gonioscope or a four mirror gonioscope to press on the conjunctiva overlying the suture and thus helping in visualization. Laser: Argon laser or frequency doubled Nd:YAG laser (532 nm) are the commonly used lasers. Laser parameters: Spot size — 50 microns, power — 250 to 750 mW, duration — 0.1 second. Technique Patient is seated on the slit-lamp. Conjunctival sac is anesthetized with 0.5 percent proparacaine / 4 percent xylocaine. In case the conjunctiva is hyperemic and congested, it is a good option to decongest the same using the phenylepherine eye drops (10%), instilled two to three times at 10 minutes interval. Hoskins lens is applied over the bleb area. It helps to visualize the underlying suture and also protects the conjunctiva from thermal injury. Laser
Miscellaneous Laser Applications
89
spot is applied over the visible suture arm. If there is accompanying subconjunctival hemorrhage or pigmentation, krypton red laser (600 nm) may be used in order to avoid damage to the conjunctiva as melanin, hemoglobin and nylon suture have absorption spectrum near 532 nm. Following suturolysis mild bleb massage is given and immediate lowering of IOP with mild shallowing of anterior chamber and bleb formation is noted. Suturolysis is generally performed within 2 weeks of surgery but can be performed up to 4 weeks, if adjunctive anti-fibrotic agents have been used. This technique is not effective at a later stage when the fibrosis has already set in. LASER-ASSISTED BLEB REMODELING Large overhanging bleb is a well documented complication of trabeculectomy, especially if Mitomycin C has been used. It can be associated with complications like over-filtration, hypotony and extremely large blebs can result in foreign body sensation, discomfort, decreases in visual acuity due to astigmatism, and dellen formation. These blebs are also predisposed to late onset leaks, blebitis, and endophthalmitis. Various therapeutic modalities like surgical repair, injection of autologous blood, cryotherapy, have been employed for treating this problem. The presumed mechanism through which the laser treatment works is based on the fact laser generates thermal energy which results in tissue protein denaturation. This causes shrinkage of the collagen tissue, and as the laser beam selectively affects the inner surface of the bleb leading to inflammation and fibrosis without damaging the overlying conjunctiva, this results in remodeling or shrinkage of the bleb.
90
Step by Step Minimally Invasive Glaucoma Surgery
Laser: Argon laser, frequency doubled Nd:YAG laser. Laser parameters: 300-500 mW power, 500 microns size and 0.1 seconds duration. Technique The eye is anesthetized with one drop of 0.5 percent proparacaine, and the patient is seated in front of the slitlamp mounted with laser. Heat absorption by epithelial surface can be promoted by application of a dye. The bleb surface is painted with gentian violet using sterile cotton tipped applicator. Another option is to use vital dyes like rose bengal and methylene blue dye, which require light epithelial abrasion. 25-50 spots are applied on the surface of bleb in the area of maximum height. An immediate shrinkage in the elevation of bleb is noticed. At follow-up apart from IOP monitoring, the bleb area is examined for any evident leak. Repeat treatments may be performed if required. Complications include bleb failure due to over treatment and iatrogenic perforation leading to wound leak. Bleb leaks due to laser induced perforation occur with over treatment, especially with thin and transparent blebs. Nd:YAG GONIOPUNCTURE Goniopuncture of the trabeculo-Descemet’s membrane complex is performed in cases with operated nonpenetrating deep sclerectomy (NPDS), where postoperative bleb functioning is inefficient and the IOP remains high. The laser treatment is performed with Q-switched Nd:YAG laser to puncture the Descemet’s membrane and convert the NPDS into a penetrating procedure. This significantly enhances the success of NPDS.
Miscellaneous Laser Applications
91
Lens: Lasag 15 gonioscopy contact lens (CGA1). Laser settings: Energy 2 to 4 mJ. Studies have shown that goniopunctures decreases the mean IOP with an immediate success rate of 70-85 percent. Apart from the eyes with operated NPDS with insufficient IOP control. Nd:YAG goniopuncture may also be performed as primary procedure along with deep sclerectomy in eyes with Sturge-Weber syndrome. This is a two staged technique described by Hara et al. In Stage 1, under conjunctival and thin scleral flaps, the deep (4 × 2 mm) scleral block containing the outer wall of Schlemm’s canal is removed. Stage 2, the puncturing of the remaining trabeculum with Q-switched Nd:YAG laser, is performed the next day. This helps to avoid hemorrhagic choroidal detachment which frequently occur in these eyes following a penetrating filtering surgery. Complications Iris synechia is a potential complication that may cause elevated IOP after laser goniopuncture in patients having NPDS. Occasionally a spontaneous iris prolapse may also occur leading to IOP elevation. ERBIUM-YAG LASER-ASSISTED DEEP SCLERECTOMY Lasers have been increasingly used for scleral ablation during NPDS. Laser decreases the mechanical or thermal damage resulting in decreased scarring. Both excimer laser and Erbium:YAG laser have been used for this purpose. Theoretically speaking Erbium:YAG laser (2940 nm/11 mJ, 7 Hz) provides extra safety by eliminating the possibility of ultraviolet light related cyto-toxicity and retinal toxicity.
92
Step by Step Minimally Invasive Glaucoma Surgery
Laser parameters: Energy of 40-100 mJ, Frequency of 1-10 Hz, spot size 500 microm and 1 mm (divergent beam). Technique After creating a superficial scleral flap (4.0 × 4.0 mm); a deep scleral ablation (3.0 × 3.0 mm) is performed with the pulsed Er:YAG laser to remove 220±40 microns thick deep scleral tissue. Schlemm’s canal is removed, and the cornea is dissected to Descemet’s membrane until aqueous humor percolates. This is followed by a water tight closure of scleral flap and conjunctiva. Study by Verges C et al showed a decrease in mean IOP from 28.3± 6.1 mmHg preoperatively to 16.3±4.2 mm Hg at 3 months, and 15.3±2.7 mm Hg at 15 months post-operatively. There were no significant complications. The success rate (IOP < or =18 mm Hg without medication) was 93.47 percent at 1 month and 84.78 percent at 15 months. Deep sclerectomy using the Er:YAG laser may be considered as a safe and effective in eyes with POAG, with significantly lower complications compared to trabeculectomy. Studies with a larger sample size and longer follow-up are needed to establish its efficacy. ANTERIOR HYALOIDOTOMY In eyes with aphakic and pseudophakic malignant glaucoma, Nd:YAG laser rupture of the anterior hyaloid phase directly, brings a dramatic cure due to release of the trapped aqueous. This procedure results in immediate deepening of the anterior chamber and relieves acute pain and provides sudden symptomatic relief to the patient. This procedure requires careful handling and should be done by experience laser surgeons only. The trick is to go deep and try and break the vitreous phase from behind
Miscellaneous Laser Applications
93
forward using 1-2mj of energy since chamber is very shallow therefore, chances of corneal damage are very high. However, even if the endothelium gets damaged at one place, we should try it at other place since this is much more convenient then going in for a vitrectomy which is a more difficult affair. LYSIS OF VITREOUS STRAND IN THE CATARACT WOUND It is well known that any strand of vitreous incarcerated in the wound can result in complications. The strand forms a route from where infection can travel into the eye. Also when a person goes from bright light to dim light the pupil size changes and this causes a pull on the strand. This can result in a retinal detachment. Lysis of such a strand can easily be carried out using the energy of 1-1.5 mJ of Nd:YAG spot focused directly on the strand to lyse it (Fig. 6.3).
Fig. 6.3: Vitreous strand going to the wound site which can be cut with YAG laser
94
Step by Step Minimally Invasive Glaucoma Surgery
BIBLIOGRAPHY Neodymium YAG Laser Iridolenticular Synechiolysis 1. 2. 3. 4. 5.
Fankhauser F, Kwasniewska S, et al. Neodymium Q-Switched YAG laser lysis of irisens synechiae. Ophthalmology 1985;92:790-92. James WA Jr, Roeth Jr, et al. Argon Laser Photomydriasis. Am J Ophthalmol 1976;81:6270. Kumar H, Sony P. A new technique for Nd:YAG iridolenticular synechiolysis (In press) Ophthalmic Surgery Lasers and imaging. L’Esperance FA Jr, James WA Jr. Argon Laser Photocoagulation of iris abnormalities. Trans Am Acad Ophthalmol Otolaryngol 1975;79:321-39. Obstbaum SA, Barasch KR, Galin MA, et al. Laser Photomydriasis in pseudophakic pupillary block. Am Intraocul Implant Soc J 1981;7:28-30.
Laser Suturolysis 1.
2. 3. 4. 5.
Akova YA, Dursun D, Aydin P, Akbatur H, Duman S. Management of hypotony maculopathy and a large filtering bleb after trabeculectomy with mitomycin C: Success with argon laser therapy. Ophthalmic Surg Lasers 2000;31:491-94. Day S, Uveal Tract, Taylor D (Eds): Paediatric Ophthalmology, Boston, Blackwell Scientific Publications. 1990; 276-98. Hara T, Hara T. Deep sclerectomy with Nd:YAG laser trabeculotomy ab-interno: Two-stage procedure. Ophthalmic Surg 1988;19:101-06. Liebmann MF. Doide laser suturolysis following trabeculectomy with mitomycin C. Arch Ophthalmol 1996;114:364. Liu Y, Yang W, Li S. Neodymium: YAG laser therapy in aphakic pupillary block glaucoma and aphakic malignant
Miscellaneous Laser Applications
6. 7.
8.
9. 10.
95
(ciliovitreal block) glaucoma. Yan Ke Xue Bao 1990;6(1-2): 11-6. Melamed S, Ashkenazi I, Glovinski J, Blumenthal M. Tight scleral flap trabeculectomy with postoperative laser suture lysis. Am J Ophthalmol 1990 15;109:303-09. Mermoud A, Karlen ME, Schnyder CC, Sickenberg M, Chiou AG, Hediguer SE, Sanchez E. Nd:Yag goniopuncture after deep sclerectomy with collagen implant. Ophthalmic Surg Lasers 1999;30:120-25. Pallikaris IG, Kozobolis VP, Christodoulakis EV. Erbium: YAG laser deep sclerectomy: An alternative approach to glaucoma surgery. Ophthalmic Surg Lasers Imaging 2003;34:375-80. Sony P, Kumar H, Pushker N. Treatment of overhanging bleb with frequency doubled Nd:YAG laser. Ophthalmic Surg Lasers Imaging. 2004;35:430-32. Verges C, Llevat E, Bardavio J. Laser-assisted deep sclerectomy. J Cataract Refract Surg 2002;28:758-65.
98
Step by Step Minimally Invasive Glaucoma Surgery
INTRODUCTION Open-angle glaucoma is the second leading cause of blindness in the world.1,2 Glaucomatous optic neuropathy (GON) is characterized by a loss of retinal ganglion cells and their axons, associated by a tissue remodeling both of the optic nerve head (ONH) and the retina leading to the characteristic ONH cupping. Many glaucoma patients present with elevated intraocular pressure (IOP), most often caused by reduced outflow capacity of aqueous humor. The outflow resistance is localized at the level of the trabecular meshwork, or, more precisely, at the juxtacanalicular meshwork and the inner wall of Schlemm’s canal. Data from several major studies available on this topic, such as the OHTS,3 EGPS,4 CIGTS,5 EMGT6 and the AGIS7 suggest that both development and progression of glaucomatous damage can be mitigated by lowering IOP. Moreover, the NTGS has clearly demonstrated that lowering of the IOP can slow down the progression of the disease even in patients with normal-tension glaucoma (NTG).8 Topical IOP-lowering medication is often the first-line therapy for glaucoma, even though it harbors potential disadvantages such as local and systemic side effects, tachyphylaxis, and, probably most important, compliance problems. Friedman and co-workers recently examined a cohort of 1712 glaucoma suspects and 3623 diagnosed glaucoma patients and found that a large proportion of individuals requiring treatment are falling out of care and are being monitored at rates lower than expected from recommendations of published guidelines because they do not come for follow-up visits and do not ask for a refill of their prescribed glaucoma medication.9 Apart from this disappointing information, it has to be added that local
Trabecular Meshwork Ablation
99
medication is also not always sufficient if a very low individual target IOP is required. The CNTGS has shown that a 30 percent reduction in IOP is often only reached by surgical intervention. Another point is that the costs of medical control over a lifetime might also be prohibitive for some glaucoma patients. Glaucoma surgery includes nowadays a number of potential therapies all aiming either to increase the outflow of aqueous humor or to decrease its production. Argon laser trabeculoplasty (ALT), for example, increases the conventional outflow through the trabecular meshwork and is easy to perform. The procedure has, however, a limited efficacy and duration of effect, as ALT produces thermal effects with coagulation of the trabecular meshwork. A successfully performed trabeculectomy shows a much better efficacy, however, a number of potential complications such as hypotony, suprachoroidal hemorrhage, and bleb failure exist. Patients often find the conjunctival bleb uncomfortable, moreover it can become thin and avascular, thus increasing the risk of bleb leaks, blebitis and endophthalmitis. In case of surgery failure, repeated operations can become necessary, however, the chances for success decrease as both sclera and conjunctiva are subjected to repeated surgical insults. Glaucoma drainage devices (tube shunts) have a relatively high success rate in experienced hands, however the patients are at greater risk for complications. In 1996, Vogel and co-workers reported a new IOPlowering operation technique: Using an excimer laser, they managed to ablate trabecular meshwork tissue with minimal thermal effects and necrosis, thus resulting in only minimal scar formation. The authors assumed that it should be possible to create an open connection between the anterior chamber and Schlemm’s canal. The group treated
100
Step by Step Minimally Invasive Glaucoma Surgery
6 patients with open-angle glaucoma. In 4 cases intraocular pressure was reduced by 11 mmHg over a follow-up time of 5 months. In 2 cases IOP rose by 2 mmHg in spite of medication.10 ERBIUM-YAG GONIOTOMY Also in 1996, an endoscopic erbium-YAG laser system allowing effects on trabecular tissue comparable to those produced by a 308 nm excimer laser became available. In the following years we could demonstrate a reduction in IOP with this laser system that was comparable to the excimer laser.11 We performed combined cataract surgery and erbium-YAG goniotomy in 24 eyes and compared the IOP results to a control group that underwent cataract surgery. In the combined surgery group, mean IOP dropped from 21.8 to 15.5 mmHg. IOP regulation was successful in 88 percent of these cases. In eyes that underwent only cataract surgery, the IOP reduction was less pronounced (mean IOP preoperative 20.0, postoperative 17.4, success rate 35%). The follow-up in this preliminary study was 4 months (mean 6.5 months, max. 12 months).12 In another non-randominized clinical trial with a 3 years follow-up, we treated 20 eyes of 20 patients suffering from both glaucoma and cataract with combined phacoemulsification and erbium-YAG goniotomy and compared them to a control group that underwent cataract surgery. Main outcome variables were IOP, visual acuity, and number of antiglaucomatous drugs 1 year after surgery. The mean IOP dropped by 30 percent (23.5 to 16.3 mmHg) after 12 months in the laser-treated group and by 9 percent (19.8 to 18.1 mmHg) in the control group. After 3 years, the mean IOP in the laser group was 15.0 mmHg. The mean
Trabecular Meshwork Ablation
101
number of antiglaucomatous drugs needed decreased significantly from 1.6 to 0.5 in the laser group and from 1.0 to 0.8 in the control group. Anterior chamber hemorrhage occurred in 12 eyes after laser treatment and resolved within 72 hours in all but 1 patient who was on warfarin sodium therapy. There were no cases of hypotony in either group.13 We also aimed to compare the efficacy of erbium:YAG goniotomy to trabeculectomy, with both methods as adjuncts to cataract surgery. Fifty-nine eyes of 59 glaucoma patients with coexistent cataract underwent combined phacoemulsification and erbium:YAG goniotomy. We compared this prospective treatment arm to a retrospective inclusion-matched control group treated by trabeculectomy and cataract surgery in a single procedure. Primary endpoints were IOP, number of antiglaucomatous drugs, postoperative complications, hospitalization time and visual acuity 1 year after surgery. In the laser-treated group, the mean IOP dropped by 30 percent from 23.4 to 16.3 mmHg after 12 months. Without reoperation, treatment was successful in 71 percent of these eyes. In the control group, the IOP decreased by 33.5 percent from 22.7 to 15.1 mmHg. The success rate without reoperation was 46 percent. The number of antiglaucomatous drugs needed decreased from 1.48 to 0.48 in the laser-treated group and from 2.0 to 0.39 in the controls. Postoperative complications were more frequent in the control group, and postoperative visual acuity was as well. Hospitalization time was shorter in the laser group. It can be concluded from these data that the IOP-lowering effect of combined erbium:YAG goniotomy and cataract surgery is comparable to that of combined trabeculectomy and cataract surgery. Moreover, due to fewer postoperative complications, erbium:YAG goniotomy seems to be superior to standard fistulation
102
Step by Step Minimally Invasive Glaucoma Surgery
surgery as the primary approach.14 To date, 3 years followup data of a small pilot group that underwent combined erbium:YAG goniotomy and cataract surgery are available; and the IOP-lowering effect has not diminished over this follow-up period.15 EXCIMER-LASER-TRABECULOTOMY (ELT) Background In the meantime, the CE-certified AIDA excimer laser (TuiLaser AG, Germering, Germany) has become commercially available (Fig. 7.1). We therefore switched from the erbium:YAG system prototype to the certified laser, assuming that it should have a comparable effect. Like the erbium:YAG laser, the AIDA excimer laser reestablishes the outflow of aqueous humor through conventional drainage pathways. By excising a defined
Fig. 7.1: The AIDA excimer laser (TuiLaser AG, Germering, Germany)
Trabecular Meshwork Ablation
103
area of trabecular meshwork, juxtacanalicular tissue, and the inner wall of Schlemm’s canal via a fiberoptic probe delivering 308 nm XeCL excimer laser energy, aqueous outflow is re-established.16 The creation of the openings through the trabecular meshwork and the inner wall of Schlemm’s canal is accomplished by using the fiberoptic delivery system LAGO 200 or LAGO 200 ENDO. In detail, the fiberoptic system is positioned across the anterior chamber to contact the trabecular meshwork. Laser pulses remove tissue to create a fistula into Schlemm’s canal. Direct viewing for positioning of the fiber is performed with either a goniolens or an endoscope. The small size of the delivery system (external diameter 0.5 mm for the LAGO 200, 1.3 × 0.95 mm for the LAGO 200 ENDO, coaxial endoscope) ensures access through a self sealing clear cornea incision (Figs 7.2 and 7.3). Twenty laser pulses are adequate to create a permanent opening into Schlemm’s canal. Once the corneal incision is prepared, the actual
Fig. 7.2: Photomontage of the fiberoptic system contacting the opposite trabecular meshwork
104
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 7.3: Operative setting: The ELT probe has been inserted via a clear cornea incision and approaches the opposite trabecular meshwork
procedure requires about three minutes. The procedure can easily be combined with cataract surgery. The wavelength of the AIDA laser - 308 nm has been found to ablate the trabecular meshwork without inducing thermal damage, thereby minimizing fibrous tissue healing reactions17-19 (Fig. 7.4). Surgical Procedure ELT can easily be performed through a clear cornea tunnel incision as used for cataract surgery. We constrict the pupil with topical pilocarpine 2 percent or intracameral injection of acetyline chloride (i.e. Miochol ® ), then inject a viscoelastic gel (i.e. Healon) into the anterior chamber and insert the laser probe. We then advance the probe to the
Trabecular Meshwork Ablation
105
Fig. 7.4: Histology demonstrated that the wavelength of the AIDA laser ablates the trabecular meshwork without inducing thermal damage, thereby minimizing fibrous tissue healing reactions
opposing chamber angle under gonioscopic or endoscopic visualization. The application of the laser pulses can be controlled when the probe tip is in contact with the trabecular meshwork (Figs 7.5 and 7.6). The probe tip is then repositioned such that ten trabecular meshwork perforations are created to the inferior 180°. Following removal of the probe (and endoscope), the viscoelastic is exchanged by BSS. Postoperatively, all eyes are treated with topical steroids 4x/d tapered over 3 weeks. In case of a persistent fibrin reaction, atropine 1 percent eye drops 2x/d can be added. In case of combined cataract + ELT procedure, we first perform cataract surgery followed by the ELT procedure, which takes about three minutes longer than cataract surgery alone.
106
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 7.5: ELT: Endoscopic view showing the fiberoptic delivery approaching the trabecular meshwork
Fig. 7.6: ELT: Two trabeculotomies are already created. Note: The retrograde bleeding from Schlemm’s canal which we take as a sign of successful perforation
Trabecular Meshwork Ablation
107
Study Results Pooled data from a number of study groups have demonstrated that ELT is a safe and sufficient IOP-lowering procedure that can easily be combined with cataract surgery.20 In our own clinic, we have retrospectively studied a group of 135 patients with open-angle glaucoma (n = 128) and ocular hypertension (n = 7) that were divided into two groups: (a) ELT as a stand-alone procedure (n=75), (b) combined cataract and ELT procedure (n= 60). Both groups were further divided into 2 subgroups: (1) Preoperative IOP > 22 mmHg, (2) Preoperative IOP • 22 mmHg. KaplanMeier survival curves were calculated. Success criterion was 20 percent decrease of IOP in combinaton with IOP • 21 mmHg and postoperative IOP-lowering medication • preoperative IOP-lowering medication. Follow-up time was 1 year. For group a) ELT, 1. Preoperative IOP > 22 mmHg, 2. Preoperative IOP • 22 mmHg: Kaplan-Meier survival curves showed a success rate of 57 percent in subgroup 1 and of 41 percent in subgroup 2 (Figs 7.7 and 7.8) For group b) Combined cataract and ELT procedure, 1. Preoperative IOP > 22 mmHg, 2. Preoperative IOP • 22 mmHg: Success rate was 91 percent in subgroup 1 and 52 percent in subgroup 2 (Figs 7.9 and 7.10). Side effects of the ELT were rare: In two cases, an iris adhesion at the tunnel occurred, in 3 cases there was a fibroid reaction that responded very well to topical steroids. One patient developed an occlusion of the central retinal vein 5 months after surgery. IOP however was wellcontrolled at that time, indicating that there was no connection between the CRVO and the ELT procedure. Our data indicate that ELT is not only a safe and efficient IOP-lowering procedure, but also that it is most effective
108
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 7.7: ELT: Kaplan-Meier-survival curve, preoperative IOP > 22 mmHg
Fig. 7.8: ELT: Kaplan-Meier-survival curve, preoperative IOP • 22 mmHg
Trabecular Meshwork Ablation
Fig. 7.9: ELT+Phako: Kaplan-Meier-survival curve, preoperative > 22 mmHg
Fig. 7.10: ELT+Phako: Kaplan-Meier-survival curve, preoperative • 22 mmHg
109
110
Step by Step Minimally Invasive Glaucoma Surgery
in patients with a high preoperative IOP. The 2-year-followup data are now available for many patients, and it seems obvious that the IOP-lowering effect of ELT is conserved also after this longer period of time. We have a prospective multicenter study ongoing in this field and are looking forward to its result. Due to its sufficient IOP-lowering effect and the minimal invasiveness of the procedure, ELT has become the therapy of choice for patients who suffer from cataract and glaucoma. We recommend the combined procedure in all cataract patients with an IOP of more than 22 mmHg without therapy. ELT as a stand-alone procedure is performed in patients whose IOP is above 22 mmHg despite maximally tolerated therapy. In patients with low preoperative IOP, such as patients with normal-tension glaucoma, ELT has proven to be less powerful. We assume that in such cases, the episcleral venous pressure limits the chances of success and prefer a trabeculectomy instead. CONCLUSION Excimer-Laser-Trabeculotomy is a promising IOPlowering technique both as a stand-alone procedure and in combination with cataract surgery. It is especially suitable for patients with high preoperative IOP levels and can easily be combined with cataract surgery. REFERENCES 1.
2.
Quigley HA. Proportion of those with open-angle glaucoma who become blind. Number of people with glaucoma worldwide. Ophthalmology 1999;106(11):203941. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80(5):389-93.
Trabecular Meshwork Ablation
3.
4. 5. 6.
7.
8.
9.
10. 11. 12.
111
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120(6):701-13; discussion 829-30. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112(3):366-75. Feiner L, Piltz-Seymour JR. Collaborative Initial Glaucoma Treatment Study: A summary of results to date. Curr Opin Ophthalmol 2003;14(2):106-11. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120(10):1268-79. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol 2000;130(4):429-40. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126(4):487-97. Friedman DS, Nordstrom B, Mozaffari E, Quigley HA. Glaucoma Management among Individuals Enrolled in a Single Comprehensive Insurance Plan. Ophthalmology 2005. Vogel M, Lauritzen K, Quentin CD. Punktuelle Ablation des Trabekelwerks mit dem Excimer-Laser beim primären Offenwinkelglaukom. Ophthalmologe 1996;93(5):565-68. Funk J, Schlunck G. Endoskopisch kontrollierte ErbiumYAG-Laser-Goniotomie. Erste präklinische Versuche. Ophthalmologe 1998;95(1):33-36. Funk J, Feltgen N, Asbeck D. Augendrucksenkung durch endoskopisch kontrollierte Erbium: YAG-Goniotomie. Ophthalmologe 2000;97(7):473-77.
112 13. 14.
15.
16.
17. 18. 19. 20.
Step by Step Minimally Invasive Glaucoma Surgery
Feltgen N, Mueller H, Ott B, Frenz M, Funk J. Combined endoscopic erbium:YAG laser goniopuncture and cataract surgery. J Cataract Refract Surg 2003;29(11):2155-62. Feltgen N, Mueller H, Ott B, Frenz M, Funk J. Endoscopically controlled erbium:YAG goniopuncture versus trabeculectomy: Effect on intraocular pressure in combination with cataract surgery. Graefes Arch Clin Exp Ophthalmol 2003;241(2):94-100. Philippin H, Wilmsmeyer S, Feltgen N, Ness T, Funk J. Combined cataract and glaucoma surgery: Endoscopecontrolled erbium:YAG-laser goniotomy versus trabeculectomy. Graefes Arch Clin Exp Ophthalmol 2005. Walker R, Specht H. Theoretical and physical aspects of excimer laser trabeculotomy (ELT) ab-interno with the AIDA laser operating at 308 nm. Biomedizinische Technik 2002;47(5):106-10. Berlin MS. Perspectives on new laser techniques in managing glaucoma. Ophthalmology Clinics of North America 1995;8(2):341-63. Berlin MS. We need a trabecular meshwork procedure that works. American Glaucoma Society Annual Meeting, San Jose 2002. Berlin MS. ELT Eximer Laser Trabeculostomy: Update 2003. ASCRS 2003. Berlin MS, Funk J, Pache M, Wilmsmeyer S, Giers U, Kleineberg L, et al. Excimer Laser Trabeculostomy. A new, minimally invasive surgical procedure for the treatment of open-angle glaucoma. Glaucoma Today 2004;2-6.
114
Step by Step Minimally Invasive Glaucoma Surgery
INTRODUCTION The ongoing devote on recent developments in glaucoma surgery reflects that an ideal solution is not available which would promise long-term IOP reduction and eliminate the necessity of supplementary pressurereducing medication at low complication rates. Trabeculectomy, first described in the sixties, 3,9,30 is probably the most widespread approach in glaucoma surgery presently. The intention of trabeculectomy is to bypass the resistance of trabecular meshwork by channelling aqueous humor directly to the Schlemm’s canal. In literature the success rate of trabeculectomy ranges between 32-96 percent.1,4,9,12,14,16-18,21-23,30,32-35 On the other hand, postoperative complications like hypotony and choroidal detachment are reported up to 24 percent.6 Variation of success rates may be explained by different criteria of surgical indications, selection of cases, various diagnoses, the various degrees of surgical experience and variations in postoperative medical treatment. Failure of pressure regulations is associated with the assence of a filtering bleb and depends on the duration of follow-up involved. It has become evident that successful reduction in IOP following trabeculectomy is clearly related to the presence of a filtering bleb.26 The more recent method of non-penetrating deep sclerectomy, was first described by Fjodorov in the eighties.8 This techniques tries to achieves an improved uveoscleral outflow and therefore is not depending on the presence of a filtering bleb. Koslov13 expanded this method by introducing a collagen implant. Literature on nonpenetrating deep sclerectomy indicates a success rate of 58 to 74 percent without collagen implant and 74 to 90 percent with collagen implantation.5,24
Sclerothalamotomy ab Interno a Minimally Invasive
115
In 1976, Benedikt2 described that the exposure of the ciliary body (i.e. a form of penetrating sclerectomy) was leading to successful long-term IOP regulation in 27 of 38 cases involving hemorrhagic, aphakic and irreversible angle-closure glaucoma after initially failed filtering surgery. This technique was the basis for later development of perforating deep sclerectomy, a method which has been used since 1985 was described previously 20 as “sclerothalamectomy”). Bypassing of the trabecular meshwork is an alternative for aqueous humour outflow from the anterior chamber to the Schlemm canal. It is the principal mechanism for non-penetrating glaucoma surgery, in particular, for deep sclerectomy and viscocanalostomy. These surgical procedures provide effective IOP reduction as well as the elimination of typical filtration bleb complications.7,15,31 So far clinical application of these procedures has been limited by technical difficulties to perform this kind of surgery and a poor predictability of pressure reduction. The concept of trabecular meshwork bypass as a surgical principle for glaucoma treatment evolved from the discovery that pathologic outflow resistance is caused primarily by the juxtacanicular conjunctive tissue of the trabecular meshwork and, in particular, by the inner wall of the Schlemm canal.10,11 A further publication in this area indicates that 35 percent of the outflow resistance arises distally to the inner wall of the Schlemm canal.25 Spiegel et al29 have described a new surgical technique involving the use of an implanted tube, the so-called trabecular meshwork bypass tube shunt, which should provide a direct connection between Schlemm canal and the anterior chamber. This surgical technique avoids technical difficulties of non-penetrating deep sclerectomy, especially the delicate microperforation of the trabecular
116
Step by Step Minimally Invasive Glaucoma Surgery
meshwork in order to ensure the permeability of the descemet membrane. Furthermore, these techniques avoid the disadvantages of filtration blebs. All surgical procedures for glaucoma involving the creation of external access may be complicated by the risk of fibroblast proliferation and failure of filtration. The novel procedure published offers a chance to avoid some of the above-mentioned disadvantages. We refer to this technique as sclerothalamotomy ab interno.19 PATIENTS AND METHODS Before beginning the clinical study phase, the tips used for the STT ab interno procedure were developed using a large number of pigs’ eyes. The high-frequency diathermic technique was already very well known in the application for capsulorhexis in cataract surgery. It was important to create a design for optimal application of the STT probe in the iridocorneal angle and to evaluate the characteristic of the achieved deep sclerotomy. By virtue of this results the STT ab interno probe development as describe below. 53 sclerothalamotomies ab interno in 53 patients were carried out in primary open-angle glaucoma between 1 April 2002 and 31 July 2002. Main inclusion criterion into this study was an insufficient response to medical treatment of IOP. Data was documented according to a prospective study protocol. Mean age of patients was 72.3±12.3 years (range: 15-92 years) (Fig. 8.1). 17 patients (32%) were female, 36 patients (68%) male. In 25 cases (47.4%) the right eye in 28 cases (52.6%) the left eye was treated. There was no patient who received bilateral surgery. Snellen visual acuity was 0.7±0.3 (range 0.1 to 1.0) preoperatively. In 5 cases a moderate cataract was observed which didn’t have influence on the visual acuity.
Sclerothalamotomy ab Interno a Minimally Invasive
117
Fig. 8.1: Mean age
A complete ophthalmologic status check was carried out in each patient prior to surgery including: uncorrected and best corrected visual acuity, IOP applanation tonometry, biomicroscopy of anterior segment, funduscopy (in particular, stereoscopic evaluation of the optic nerve head) and computerized visual field testing (Octopus 101, program G2). Complete ophthalmologic follow-up examinations were carried out postoperatively at day 1, 2, 3 and 4, after 1, 2 and 4 weeks, and 2, 3, 6, 12, 15, 18, 21, 24, 27, 30, 33 and 36 months. In a pilot study with at least of 24 months follow-up, 5 patients with therapy-resistant juvenile glaucoma were treated.
118
Step by Step Minimally Invasive Glaucoma Surgery
HIGH-FREQUENCY DIATHERMIC PROBE The high-frequency diathermic probe consists of an inner platinum electrode which is isolated from the outer coaxial electrode. The platinum probe tip is 1 mm in length, 0.3 mm high and 0.6 mm width and is bent posteriorly at an angle of 15° (Figs 8.2A and B). The external diameter of
Figs 8.2A and B: STT Glaucoma Tip (Oertli Reference VE 201750)
Sclerothalamotomy ab Interno a Minimally Invasive
119
the probe measures 0.9 mm. Modulated 500 kHz current generates a temperature of approximate 130°C at the tip of the probe. The set-up provides high frequency power dissipation in close vicinity of the tip. As a result, heating of tissue is locally very limited and is applied as a rotationed ellipsoid. SURGICAL PROCEDURE A clear cornea incision (1.2 mm wide) was placed in the temporal upper quadrant using a diamond knife. A second corneal incision was performed 120° apart from the first followed by injection of Healon GV. The high-frequency diathermic probe (Oertli) was inserted through the temporal corneal insertion (Fig. 8.3). Visual inspection of
Fig. 8.3: Insertion of the high-frequency diathermic probe (Oertli) through the temporal corneal insertion
120
Step by Step Minimally Invasive Glaucoma Surgery
the target zone (opposite iridocorneal angle) was observed by a 4-mirror gonioscopic lens (Fig. 8.4). The high frequency tip penetrates up to 1mm nasal into the sclera through the trabecular meshwork and Schlemm canal, forming a deep sclerotomy (i.e. “thalami”) of 0.3 mm high and 0.6 mm width (Figs 8.5 and 8.6). This procedure was repeated 4 times within one quadrant. Healon GV was evacuated from the anterior chamber with bimanual irrigation/aspiration (Fig. 8.7). Tobramycin/Dexamethason eye drops were then applied 3x daily for 1 month and Pilocarpin 2 percent eye drops 3x daily for 10 days. EVALUATION OF THE RESULTS Statistical evaluation of results was calculated with SPSS Program Version 10. Two-tailed Student t-test was used
Fig. 8.4: Visual inspection of the target zone (opposite iridocorneal angle) by a 4-mirror gonioscopic lens
Sclerothalamotomy ab Interno a Minimally Invasive
121
Fig. 8.5: Penetration of the high frequency tip
Fig. 8.6: Penetration up to 1mm nasal into the sclera through the trabecular meshwork and Schlemm canal
122
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 8.7: Healon GV was evacuated from the anterior chamber with bimanual irrigation/aspiration
for statistical evaluation of parametric data. The unit of significance was set at a critical p value of <0.05, including Bonferroni correlation for repetitive use of data sets. Results Mean preoperative IOP in the study population of 53 patients with primary open-angle glaucoma was 25.6 ± 2.3 mmHg (range18 to 48 mmHg). Average IOP was 17.6 ± 2.7 mmHg (range 2 to 36 mmHg) after a follow-up period of 1 day, 14.9 ± 2.4 mmHg (range 2 to 30 mmHg) after 2 days, 15.7 ± 2.4 mmHg (range 4 to 28 mmHg) after 3 days, 16.0 ± 2.6 mmHg (range 4 to 36 mmHg) after 4 days, 19.0 ± 2.6 mmHg (range 12 to 39 mmHg) after 7 days, 16.9 ± 2.5 mmHg (range 9 to 44 mmHg) after 1 month, 15.1 ± 1.8
Sclerothalamotomy ab Interno a Minimally Invasive
123
mmHg (range 11 to 20 mmHg) after 3 months, 14.7 ± 1.7 mmHg (range 11 to 20 mmHg) after 6 months, 14.8 ± 1.7 mmHg (range 10 to 20 mmHg) after 9 months, 14.7 ± 1.7 mmHg (range 10 to 20 mmHg) after 12 months, 15.5 ± 1.7 mmHg (range 11 to 20 mmHg) after 15 months, 14.1 ± 1.6 mmHg (range 11 to 20 mmHg) after 18 months, 16.5 ± 1.7 mmHg (range 12 to 22 mmHg) after 21 months, 15.0 ± 1.6 mmHg (range 11 to 20 mmHg) after 24 months, 14.7 ± 1.7 mmHg (range 11 to 20 mmHg) after 27 months, 14.7 ± 1.7 mmHg (range 10 to 20 mmHg) after 30 months, 15.5 ± 1.7 mmHg (range 11 to 20 mmHg) after 33 months and 14.6 ± 1.7 mmHg (range 10 to 20 mmHg) after 36 months a result which, at p<0.005, is statistically highly significant (Fig. 8.8). Pressure reduction at any time of standardised follow up was statistically significant compared to preoperative data at a level of α<0.03 (Bonferroni corrected). For all patients the follow-up was 36 months.
Fig. 8.8: Average level of intraocular pressure (IOP) after sclerothalamotomy (STT) ab interno surgery for all 53 cases at the time of scheduled examination
124
Step by Step Minimally Invasive Glaucoma Surgery
At month 36, 54.7 percent of patients had an IOP<15 mmHg, 77.4 percent had an IOP<18 mmHg and 83 percent had an IOP<21 mmHg (Fig. 8.9). After 36 months, 86.8 percent achieved >20 percent reduction in IOPs and 77 percent of treated patients achieved >30 percent reductions of the IOP. The complete success rate, defined as an IOP lower than 21 mmHg without medication, was 83 percent at 36 month. Qualified success rate, defined as an IOP lower than 21 mmHg with medication, was 100 percent at 36 month (Fig. 8.10). The average preoperative administration of pressurereducing eye agents was 2.6 ± 1.0. Following surgery, this value was decreased to 0.45 ± 0.72 after 1 month, 0.38 ± 0.60 after 3 months 0.38 ± 0.69 after 6 months, 0.19 ± 0.52 after 12 months, 0.21 ± 0.53 after 24 months and 0.50 ± 0.90 after 36 months (Fig. 8.11). After 36 months, it was necessary to administer IOP reducing medication in only 9 eyes, a figure which corresponds to 17 percent of all cases.
Fig. 8.9: Percentages of patients reaching specified intraocular pressure (IOP) levels
Sclerothalamotomy ab Interno a Minimally Invasive
125
Fig. 8.10: Preoperative and postoperative level of IOP 36 months of follow-up
Average visual acuity after treatment was 0.69 ± 0.31 (range 0.05 to 1.0). In 6 eyes (11.3%) moderate cataract development after surgery which was without influence of visual acuity. Another 3 eyes (5.7%) developed cataract with decreased visual acuity of one Snellen line. There is no significant difference regarding the cup/ disc ratio at baseline with 0.65±0.18 and at 36 months with 0.66±0.19 (p=0.11) (Figs 8.12A and B).
126
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 8.11: Administration of pressure-reducing eye agents during 36 months
Fig. 8.12A: Cup/disc ratio at baseline
Sclerothalamotomy ab Interno a Minimally Invasive
127
Fig. 8.12B: Cup/disc ratio at 36 months
There is no significant changes comparing the visual field at baseline with mean defect MD 9.45±2.32, loss variance LV 30.0±5.11 and at 36 months with MD 9.29±2.59, LV 31.4±5.66 (p=0.78 for MD, p=0.96 for LV) (Fig. 8.13). Temporary IOP elevation higher than 21 mmHg was observed in 12 of 53 eyes (22.6%). These patients responded well to pressure-reducing treatment with one agent and medication could gradually be withdrawn in all of these patients. A single case of hypotension (1.9%) that lasted for 3 days after surgery was observed. Hyphema was present in 6 cases (11.4%) which disappeared within the first 2 weeks after surgery. One eye (1.9%) exhibited transient fibrin formation at pupillary level. Fibrin was cleared within one day after frequent application of topical Dexamethason (Fig. 8.14).
128
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 8.13: Visual field analysis
Fig. 8.14: Complications after sclerothalamotomy (STT) ab interno surgery
Sclerothalamotomy ab Interno a Minimally Invasive
129
In a pilot study 5 patients with therapy-resistant juvenile glaucoma were treated. We observed an IOP reduction from 41 ± 6.4 mmHg prior to surgery to 12 ± 2.6 mmHg after surgery, a result that has remained stable without any additional pressure-reducing therapy for 24 months. DISCUSSION This study reports long-term results of a new surgical technique for treating open angle glaucoma. The STT ab interno method intends the creation of a direct channel between the anterior chamber and the Schlemm canal. Persistence of the sclerotomy can be investigated with a 3mirror Lens (Goldmann 903). The STT ab interno tip creates a deep sclerotomy with subsequent access of aqueous to the scleral layer. Both aspects may facilitate a bypass effect of aqueous outflow. In light of the fact that about 85 percent of the aqueous humour drains (in physiological terms) trans-trabecularly, we suspect an additional route for aqueous humour absorption in the case of elevated IOP. There is evidence in literature that such bypass effects may be present after surgical intervention which do not lead to the formation of filtering blebs. In a previous study,20 it was ascertained that eyes without filter bleb exhibited very stable long-term IOP regulation postoperatively. In addition to the bypassing of trabecular outflow resistance caused by STT ab interno treatment, outflow resistance may be further reduced by scleral thinning at the base of the thalamus. In addition to that aqueous humour could perhaps be absorbed by the ciliary body.20,27 After early postoperative reduction, the average IOP continued to decline gradually over a period of 6 months before reaching a relatively a constant level. It can be speculated that newly
130
Step by Step Minimally Invasive Glaucoma Surgery
formed blood vessel and lymph vessel close to the surgical site, may contribute to the decrease of IOP level during follow up.2 In literature the success rate range for trabeculectomy ranges between 57 and 96 percent,1,4,9,12,14-18,21- 23,30,32-35 for deep sclerectomy without collagen device between 57 and 74 percent, and for deep sclerectomy with collagen device between 58 and 90 percent.1,5,15,24 The STT ab interno technique with a complete success rate of 90.6 percent is comparable with other so far published surgery methods. Advantages of the STT ab interno method, compared with trabeculectomy and perforating and non-perforating deep sclerectomy seem to be a rate of postoperative complications and a constant level of reduced IOP. Hypotension, a frequent finding in trabeculectomy, perforating deep sclerectomy and non-perforating deep sclerectomy, is a relatively rare postoperative complication. The most frequent early complications in trabeculectomy are hyphema (24.6%), shallow anterior chamber (23.9%), hypotony (24.3%), wound leak (17.8%) and choroidale detachment (14.1%). The most frequent late complications are cataract (20.2%), visual loss (18.8%), iris incarceration (5.1%) and encapsulated bleb (3.4%). After STT ab interno cataract development was seen in 17 percent with only 5.7 percent loss of one line of visual acuity after 36 months. Compared with other techniques STT ab interno seems to be a relatively save surgical technique.1,5,6,7,15,16 Transient IOP elevation after STT ab interno may occur in the first 6 weeks and can be effectively brought under control with the use of a topical medication. In most cases, IOP-reducing therapy could be gradually withdrawn after 3 weeks post surgery. It was necessary to continue pressure-reducing therapy in 5 of 53 eyes, in all this cases medication was effective in controlling IOP.
Sclerothalamotomy ab Interno a Minimally Invasive
131
Problems of scarring to the Tenon’s capsule, fibroblast proliferation and secondary occlusion associated with trabeculectomy which are induced by the surgical procedure itself may the reason behind the practice of antimetabolites applications (Mitomycin C at concentration of 0.2-0.4 mg/ml for 1-5 minutes). Although this practice was conceived to modulate wound healing and thus to counteract scar formation, it often resulted in serious complications, such as scleral necrosis and an increased incidence of avascular filter bleb and their late complications.28 The surgical procedure applied in this study avoids stimulation of episcleral and conjunctival proliferations and may therefore be related with less secondary cell invasion at the filtrating bypass. Preliminary histological investigations of post mortem human eyes following STT ab interno did not indicate signs of indirect necrosis in cell layers adjacent to the thalamus formed by high-frequency diathermy. It is yet unknown, if the inner surface of the thalamus will be covered by endothelial cells of corneal or trabecular origin, and whether the thalamus and its function will remain intact on a much longer time scale. Avantages to STT ab interno include the comparative simplicity and quickness of the surgical procedure itself. This study point out, that the performance of 4 thalami has so far proved sufficient, what corresponds to a resorption surface area of 2.4 mm². The number of 4 thalami was defined empirical. Regarding the results of this study the creation of 4 thalami seems to provide a sufficient longterm decrease of IOP as a low rate of postoperative complications. For a further potentiality of IOP decreasing effect we recommend to perform up to 6 thalami. A randomized multicenter study will be conducted in the future to compare STT ab interno, trabeculectomy, and
132
Step by Step Minimally Invasive Glaucoma Surgery
deep sclerectomy for the surgical treatment of primary open angle glaucoma. REFERENCES 1. 2.
3.
4. 5.
6. 7.
8. 9.
10.
Akafo SK, Goulstine DB. Long-term post trabeculectomy intraocular pressure. Acta Ophthalmologica 1990;70:31216. Benedikt O, Hiti H. Die Ziliarkörperfreilegung. Eine neue Operationsmethode zur Behandlung des irreversiblen Winkelblockglaukoms und des Aphakieglaukoms. Klin Monatsbl Augenheilkd 1976;169:711-16. Burian HM. A case of Marfan’s syndrome with bilateral glaucoma. With a description of new type of operation for developmental glaucoma (trabeculotomy ab externo). Am J Ophthalmol 1960;50:1187-92. Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol 1968;66:673-79. Demailly P, Lavat P, Kretz G, et al. Non-penetrating deep sclerectomy with or without collagen device in primary open-angle glaucoma: middle-term retrospective study. Int Opthalmol 1997;20:131-40. Edmunds B, Thompson JR, Salmon JF, et al. The National Survey of Trabeculectomy. III. Early and late complications. Eye 2002;16:297-303. El Sayyad F, Helal M, El-Kholify H, et al. Nonpenetrating deep sclerectomy versus trabeculectomy in bilateral primary open-angle glaucoma. Ophthalmology 2000;107: 1671-74. Fjodorov SN, Loffe DI, Ronkina TI. Deep sclerotomy: technique and mechanism of new glaucomatous procedure. Glaucoma 1984;6:281-83. Fronimopoulos J, Lambrou N, Pelekis N, et al. Elliot’s trepanation with scleral cover (procedure for protecting the fistula in Elliot’s trepanation with a lamellar scleral cover). Klin Monatsbl Augenheilkd 1970; 156:1-8. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol 1963;69:738-801.
Sclerothalamotomy ab Interno a Minimally Invasive
11. 12. 13. 14. 15.
16. 17. 18. 19.
20.
21. 22.
133
Johnson DH, Johnson M. How does nonpenetrating glaucoma surgery work? Aqueous outflow resistance and glaucoma surgery. J Glaucoma 2001;10:55-67. Konstans AGP, Jay JL, Marshall GE, et al. Prevalence, diagnostic feature, and response to trabeculectomy in exfoliation glaucoma. Ophthalmology 1993;100:619-27. Kozlov VI, Bagrov SN, Anisimova SY, et al. Non penetrating deep sclerectomy with collagen. Ophthal Surg 1990;3:44-46. Mermoud A, Salmon JF, Barron A, et al. Surgical management of post-traumatic angle recession glaucoma. Ophthalmology 1993;100:634-42. Mermoud A, Schnyder CC, Sickenberg M, et al. Comparison of deep sclerotomy with collagen implanta and trabeculectomy in open-angle glaucoma. J Cataract Refract Surg 1999;25:323-31. Mills KB. Trabeculectomy: a retrospective long-term follow-up of 444 cases. Br J Ophthalmol 1981;65:790-95. Molteno ACB, Bosma NJ, Honours BSc, et al. Otago glaucoma surgery outcome study. Ophthalmology 1999;106:1742-50. Morell AJ, Searle AET, O’Neill EC. Trabeculectomy as an introduction to intraocular surgery in an ophthalmic training program. Ophthalmic Surg 1992;23:38-39. Pajic B, Pallas G, Gerding H, Böhnke M. A novel technique of ab interno glaucoma surgery: follow-up results after 24 months. Graefes Arch Clin Exp Ophthalmol 2005 Jul; 19: 1-6. Pallas G, Pajic B 1999. Die Sklerothalamektomie (STE): Stabile postoperative Augendruckregulierung beim Offenwinkel- und Kapselhäutchenglaukom. Klin Monatsbl Augenheilkd 2000;216:256-60. Popovic V, Sjöstrand J. Long-term outcome following trabeculectomy: Visual field survival. Acta Ophthalmologica 1991;69:305-09. Roth SM, Spaeth G, Starita RJ, et al. The effects of postoperative corticosteroids on trabeculotomy and the
134
23. 24. 25. 26. 27. 28. 29. 30. 31. 32.
33. 34. 35.
Step by Step Minimally Invasive Glaucoma Surgery
clinical course of glaucoma: Five-year follow-up study. Ophthalmic Surg 1991;22:724-29. Saiz A, Alcuaz A, Maquet JA, et al. Pressure-curve variations after trabeculectomy for chronic primary openangle glaucoma. Ophthalmic Surg 1990;21:799-801. Sanchez E, Schnyder CC, Sickenberg M, et al. Deep sclerectomy: Results with and without collagen implant. Int Ophthalmol 1997;20:157-62. Schuman JS, Chang W, Wang N, et al. Excimer laser effects on outflow facility and outflow pathway morphology. Invest Ophthalmol Vis Sci 1999;40:1676-80. Schwartz AL, Anderson DR. Trabecular surgery. Arch Ophthalmol 1974;92:134-38. Schwenn O, Dick B, Pfeiffer N. Trabekulotomie, tiefe Sklerektomie und Viskokanalostomie. Ophthalmologe 1998;95:835-43. Singh J, O’Brien C, Chawla HB. Success rate and complications of intraoperative 0.2 mg/ml mitomycin C in trabeculectomy surgery. Eye 1995;9:460-66. Spiegel D, Kobuch K. Trabecular meshwork bypass tube shunt: initial case series. Br J Ophthalmol 2002;86:1228-31. Starita RJ, Fellmann RL, Spaeth GL, et al. Short-and longterm effects of postoperative corticosteroids on trabeculectomy. Ophthalmology 1985;92:938-46. Sunaric-Megevand G, Leuenberger PM. Results of viscocanalostomy for primary open-angle glaucoma. Am J Ophthalmol 2001;132:221-28. Tanihara H. Surgical effects of trabeculectomy ab externo on adult eyes with primary open angle glaucoma and pseudoexfoliation syndrome. Arch Opthalmol 1993;111: 1653-61. Vernon SA, Spencer AF. Intraocular pressure control following microtrabeculectomy. Eye 1995;9:299-303. Watson PG, Barnett F. Effectiveness of trabeculectomy in glaucoma. Am J Ophthalmol 1975;74:831-45. Watson PG. When to operate an open angle glaucoma. Eye 1987;1:51-54.
136
Step by Step Minimally Invasive Glaucoma Surgery
INTRODUCTION There is an increasing interest in the use of the excimer laser in ophthalmology, particularly in refractive surgery. The argon fluoride excimer laser (193 nm) ablates tissue with a high precision and without any mechanical or thermal damage to surrounding structures. Within the fiveyear follow-up the intrastromal excimer laser ablation (ISELA) was smooth and regular and there was no evidence of inflammation or thermal damage. Our study demonstrates a beneficial effect of the excimer laser (193 nm) during the non-penetrating glaucoma surgery. BACKGROUND AND OBJECTIVE The initial application of excimer lasers has been oriented to the cornea and to refractive surgery.2,14 Today, different types of lasers have been used in the treatment of glaucoma (the Holmium laser, Erbium:YAG laser, Carbondioxide laser and Excimer lasers).3,8-10 All authors use well-known «traditional» methods of glaucoma treatment, but apply for this purpose the excimer laser with 193 nm wavelength: external trabeculoectomy, sclerostomy, trans-scleral sinusotomy, filtering sclerostomy, deep sclerectomy, NPDS, etc.1,4,5,17 The argon fluoride excimer laser ablates the tissue with a high precision (1 micron per pulse) and without mechanical or thermal damage to surrounding structures and also has a cytostatic effect (Figs 9.1 and 9.2).6,12,18 The current technology does not allow the 193 nm wavelength to transmit through the fiber optics, which limits the endo-ocular use of this laser. We designed a special excimer laser unit with 193 nm wavelength for glaucoma surgery in 1999. It is possible to use this device in the standard operating room under the
Laser Surgical Treatment of Glaucoma
137
Fig. 9.1: Light photomicrograph and scanning electron microscopy of the stroma of rabbit cornea after excimer laser
Fig. 9.2: Light photomicrograph and scanning electron microscopy of rabbit cornea after surgical incision
operating microscope. Portable in dimensions it has a special mobile manipulator to deliver the laser energy to the operating field. The laser beam works in “eraser mode” without the necessity of a special mask. The focal distance between the manipulator and the ocular tissues is about several millimeters, the beam area in the focal point is 0.5 × 1 mm (Fig. 9.3). This study was conducted to find out the effectiveness and longevity of non-penetrating glaucoma surgery (NPDS) 7 with the use of excimer laser with 193 nm wavelength.7,15,16 PATIENTS AND METHODS In a non randomized prospective study there were 160 eyes of 154 patients aged from 18 to 88 years, between March
138
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 9.3: A special mobile manipulator for a surgeon, that delivers the laser energy to the operating field of the eye
2000 and May 2005. The majority of patients had advanced and far-advanced stages of open-angle and narrow-angle glaucoma. Laser iridotomy was performed in 44 patients with narrow-angle glaucoma to enlarge the profile of the anterior chamber angle. Intraocular pressure (IOP) was
Laser Surgical Treatment of Glaucoma
139
recorded preoperatively and postoperatively at 1, 7, 14 days, at 1, 3, 6 and thereafter every 6 months. SURGICAL TECHNIQUE We describe a new technique of non-penetrating glaucoma surgery that uses the excimer laser to reduce the risk of perforation the trabeculo-descemet’s membrane. With this technique the ablation is precise and homogeneous. The procedure can be performed with topical anesthesia. Excimer laser surgery consists of: • fornix-based conjunctival flap 2.0-2.5 mm in the upper quadrant; • minimal episcleral cautery; • dissection of a superficial corneal groove; • dissection of a 2.5 × 2.5 mm rectangular in half thickness lamellar scleral flap; • excimer laser ablation; • closure of scleral flap and conjunctival closure with a running 8.0 silk suture. The deep layers of sclera were evaporated layer by layer with laser energy of a 150 mJ/cm2 density until vessels of ciliary body appeared (Fig. 9.4). Then the Schlemm’s canal was covered with a protector, and the deep layers of corneal stroma were removed by laser up to the Descemet’s membrane until the moment of the aqueous humor drop appearance (energy density 50 mJ/cm2) (Fig. 9.5). Postoperative treatment consisted of antibiotics and dexamethasone drops instilled four times a day during 2 weeks. RESULTS AND DISCUSSION As a result of intrastromal excimer laser ablation (ISELA) the ophthalmotonus normalization was achieved in all
140
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 9.4: The deep layers of sclera were evaporated by excimer laser until vessels of ciliary body appeared
Fig. 9.5: The deep layers of corneal stroma were removed by excimer laser up to the Descemet’s membrane until the moment of the aqueous humor drop appearance
Laser Surgical Treatment of Glaucoma
141
cases independently of disease stages. The IOP averaged 10±2 mm Hg in the early postoperative follow-up. There were observed no cases of hemorrhagic or other complications, and the postoperative period was notable for a favorable course. All patients did not note any painful sensations both intra- and post-operatively, in this connection this procedure may be transferred to the outpatient category. The B-scanning and ultrasound biomicroscopy were performed thoroughly in patients with hypotonia in order to reveal a choroidal detachment. As the rule, only edema and thickening of choroid by 50-100 μm took place in the first postoperative days that indirectly was evidence of aqueous humor resorption by vessels of ciliary body. The surgical technique supposes a creation of bypass between the Descemet’s membrane and vessels of ciliary body which absorbability is 50 times more than in ordinary capillaries (Fig. 9.6). In our opinion the normalization of intraocular pressure after the intrastromal excimer laser ablation is achieved owing to an improvement of uveal scleral outflow of aqueous humor, an elimination of Schlemm’s canal collapse and a recovery of its functionally maintained sites. As a result there are no sharp IOP fluctuations in the direction
Fig. 9.6: Basic outflow pathways of aqueous humor in ultrasound biomicroscopy: 1- into the intrascleral space and vessels of ciliary body; 2 - into the flat filtering bleb
142
Step by Step Minimally Invasive Glaucoma Surgery
of hypotonia that leads to proper complications (hyphema, choroidal detachment, cataract progression, etc.). Preoperatively the outflow facility index (C) did not exceed 0.04 mm3/min/mmHg while after the intervention this index (C) averaged 0.32 ± 0.02 mm3/min/mmHg, i.e. 7-9 times the increase. Moreover a tendency of the aqueous humor production (F) increase is revealed in a part of cases. In the majority of cases (about 70% of eyes) an improvement of visual acuity is noted on an average by 0.1-0.2 obviously due to a decompression of optic disk fibers and a reduction of peripapillary edema that needs a further study. In the long-term follow-up the outflow facility index (C) decreased slightly, but remained within the norm (mean 0.20±0.04 mm 3 /min/mmHg) that provided a compensation of ophthalmotonus on a level of 17.0 ± 2.5 mm Hg (Fig. 9.7). In the long-term follow-up in patients with initial and advanced stages of glaucoma the IOP was compensated in all cases. In the group of patients with the far-advanced stage of disease the YAG laser descemeto-goniopuncture (DGP)11,13 in the intervention area was required within periods from 4 to 6 months in 16 eyes (10% of cases). It
Fig. 9.7: IOP data after excimer laser treatment (ISELA) and NPDS
Laser Surgical Treatment of Glaucoma
143
allowed to restore aqueous humor outflow pathways and to normalize the IOP (Fig. 9.8). Within the follow-up of 1 year and more a development of cystic filtering bleb was observed in 2 eyes. A monotherapy with the 0.5 percent Betoptic solution instillation one or two times was administered in 12 patients with far-advanced glaucoma. CONCLUSION Thus, the creation of a domestic specialized excimer laser unit with 193 nm wavelength allowed to develop practically a new safe technology of glaucoma surgery that cannot be performed using traditional knife surgery. Small dimensions (portability), presence of manipulator for a surgeon, price of the unit differentiate it advantageously from other foreign excimer laser and also allow to adapt it in conditions of an ordinary operating room. A new technology of glaucoma surgery (ISELA) is developed that allows to restore natural aqueous humor outflow pathways without a destruction of the Schlemm’s canal, to return the greater part of aqueous humor to vessels
Fig. 9.8: The ultrasound biomicroscopy before and after the YAGlaser DGP (descemeto-goniopuncture) to create a microperforation in Descemet’s membrane behind Schwalbe’s line to improve filtration
144
Step by Step Minimally Invasive Glaucoma Surgery
of ciliary body. The procedure is especially efficient and safe in patients with initial and advanced stages of disease because allows to normalize ophthalmotonus and to maintain visual functions. REFERENCES 1. 2.
3. 4. 5. 6.
7.
8.
9.
Argento C, Sanseau AC, Basoza D, et al. Deep sclerectomy with a collagen implant using the excimer laser. J Cataract Refract Surg 2001;Apr.27(4):504-06. Aron-Rosa DS, Boutnoy JL, Carré F, et al. Excimer laser surgery of the cornea: qualitative and quantitative aspects of photoablation according to the energy density. J Cataract Refract Surg 1986;12:27-33. Beckman H, Fuller TA. Carbon dioxide laser scleral dissection and filtering procedure for glaucoma. Am J Ophthalmol 1979;88:73-77. Berlin MS, Martinez M, Papaioannou T, et al. Goniophotoablation: excimer laser glaucoma filtering surgery. Lasers Light Ophthalmol 1988;2:17-24. Brooks AM, Samuel M, Carroll N, et al. Excimer laser filtration surgery. Am J Ophthalmol 1995;119:40-47. Ereskin NN, Takhchidi KP, Vartapetov SK, et al. Advantages of a new excimer laser for glaucoma surgery. 4th International Glaucoma Symposium-I.G.S. Barcelona, Spain,19-22 March 2003;P-28. Fyodorov SN, Kozlov VI, Timoshkina NT, Sharova AB, Ereskin NN, Kozlova EE. Non-penetrating deep sclerectomy in open angle glaucoma. Ophthalmosurgery 1989;34:52-55. Iwach AG, Hoskins HD, Mora JS, et al. Update on the subconjunctival THC:YAG (holmium) laser sclerostomy Abexterno clinical trial: a 4-year report. Ophthalmic Surg Lasers 1996 Oct;27(10):823-31. Jacobi PC, Dietlein TS, Krieglstein GK. Prospective study of ab externo erbium: YAG laser sclerostomy in humans. Am J Ophthalmol 1997, Apr; 123(4):478-86.
Laser Surgical Treatment of Glaucoma
10. 11.
12. 13. 14. 15.
16.
17.
18.
145
Klink T, Lieb W, Grehn F. Erbium-YAG laser-assisted preparation of deep sclerectomy. Graefes Arch Clin Exp Ophthalmol 2000 Sep;238(9):792-96. Kozlov V, Magaramov D, Ereskin N. Laser surgery for open-angle glaucoma in eyes with intraocular pressure elevation after non-penetrating deep sclerectomy. Ophthalmosurgery 1990;4:62-66. Marshall J, Trokel S, Rothery S, et al. An ultrastructural study of corneal incisions induced by an excimer laser at 193 nm. Ophthalmol 1985;92:749-58. Mermoud A, Karlen ME, Schnyder CC, et al. Nd:YAG goniopuncture after deep sclerectomy with collagen implant. Ophthalmic Surg Lasers 1999 Feb; 30(2):120-25. Puliafito CA, Steinert RF, Deutsch TF, et al. Excimer laser ablation of the cornea and lens. Ophthalmol 1985;92(6): 741-48. Takhchidi KP, Ereskin NN. Surgical treatment of glaucoma by excimer laser with 193 nm wavelength. Intraocular Implant and Refractive Society, India. 2005 May;1(5):1113. Takhchidi KP, Ereskin NN, Doga AV, et al. A new microinvasive technology of glaucoma surgery by excimer laser. 5-th International Glaucoma Symposium-I.G.S. Cape Town, South Africa, 30 March-April 2,2005; P-A24. Traverso CE, Murialdo U, Dilorenzo G, et al. Photoablative filtration surgery with the excimer laser for primary openangle glaucoma: a pilot study. Int Ophthalmol 1992;16:45,363-5. Schuman JS, Chang W, Wang N, et al. Excimer laser effects on outflow facility and pathway morphology. Inves. Ophthalmol Vis Sci 1999;40:1676-80.
148
Step by Step Minimally Invasive Glaucoma Surgery
OBJECTIVE AND INTRODUCTION The arrival of glaucoma surgery into the framework of deep sclerectomy or cataract surgery using bimanual phacoemulsification, allows surgery to be performed on a closed anterior chamber. It was evident that these microinvasive techniques would use the same topical anesthesia technique. Topical anesthesia is used in ambulatory surgery where the patient must be able to return home immediately without any risk to health or from postoperative risks.5 Another advantage of using this anesthesia in glaucoma surgery, is that it becomes possible to position the eye on the exact axis to enable dissection of the scleral flap. This is easier for the surgeon than when using retrobulbar or peribulbar anesthesia. which paralyze the external muscles, or - worse - place the eye in an unsuitable position. In our experience, it appears that the length of hospitalization is about one hour:2 the amount of time needed to prepare and carry out the surgical operation. This is as long as the patient is kept calm and relaxed, which is simpler than it appears to be. When caring for the patient, we must ensure his optimum comfort and that the stress inherent in any operation is kept to the minimum.6 Topical anesthesia is not necessarily enough. It depends on the type of the operation and also the type of patient. This anesthesia, in the course of years, has been improved or, rather, completed by various surgeons and anesthetists. Glaucoma surgery is different from cataract surgery in that, at the beginning of the operation, an 12 mm incision is made in the conjunctiva with a perpendicular conjunctival cut. This dissection has to be made up to the tenon in order to find the sclera. It is sometimes necessary to use a cauter to coagulate the superficial vessels. For this
Topical Anesthetic and the Subconjunctival Bubble
149
reason, topical anesthesia is sometimes not sufficient, making a subconjunctival bubble during glaucoma surgery that allows mobility to be maintained. This is very convenient, as it allows the operated eye to be kept in the best position for microdissection of successive layers. HISTORICAL BACKGROUND At the beginning of the twentieth century, we see the appearance of topical anesthetics, among them, cocaine.19 In 1910, Julius Hirschberg presented a cataract operation using a 2 percent solution of cocaine as a topical anesthetic.14 In 1988, Robert Smith presented a anesthesia technique for cataract surgery in EEC, using 1 percent drops of amethocaine and a superior conjunctival injection of a bubble of 2 percent lidocaine.18 More recently, in 1991, R Fischman reported using tetracaine as drops for a phacoemulsification cataract operation. 17,10 C Williamson, in 1992, used lidocaine 4 percent in topical anesthesia, 4 drops before emulsification.25 In 1996, J P Gills improved the technique by introducing an introcamerular injection of lidocaine, diluted at 0.5 percent, which did away with the deep pains occurring with mobilization of the iris or the capsule.11,13 ANATOMICAL REVIEW OF CORNEAL INNERVATION The cornea is the most innervated tissue. This innervation is supplied mainly by the ciliary branches of the ophthalmic division of the trifacial nerve. It enters the cornea radially at the level of the stroma moyenne, forming a dense plexus under the Bowmann membrane. The central epithelium receives terminal axones from this plexus. There is a small sympathetic innervation which is probably at the origin of the cellular proliferation.23
150
Step by Step Minimally Invasive Glaucoma Surgery
Contrary to earlier theories, corneal innervation is made at the central level by the plexus which goes through the Bowmann membrane and, on the periphery, by a more superficial conjunctival tract. The innervation of the ciliary muscles and of the iris that generate during the deep pain occurring with mobilization of the globe. This comes from the plexus. This necessitates using a different anesthesia to get rid of the pains. The innervation of the tarsal and bulbar conjunctives also come from the trifacial nerve but by way of a different route to the cornea. PHARMACOLOGY The ideal topical anesthetic must have neither local nor systemic, nor a corneal toxicity. It must not bring about an epithelial edema. Whilst working fast without causing pain when introduced, it must work for an adequate period of time. There are several types of topical anesthetics. The most frequently used are cocaine, proparacaine, tetracaine and lidocaine. All topical anesthetic drops sting when they are put in. Cocaine and proparacaine have been abandoned because of significant bulbar and epithelial toxicity. Tetracaine is much less toxic but it doesn’t provide deep enough corneal anesthesia, and it becomes necessary to repeat the instillation of drops during the operation. This often causes an epithelial edema. 17 This group of anesthetics includes an ester, increasing their solubility in water and diminishing cellular penetration. Tetracaine has been preferred in the United States for a long time, because it was the only preservative free solution.15 Lidocaine belongs to the amide group. It is lipid soluble which allows greater tissue penetration and has a longer
Topical Anesthetic and the Subconjunctival Bubble
151
period of action. For corneal anesthesia, this anesthetic gives satisfactory anesthesia from 30 minutes to one hour, depending on the patient. At a concentration of 2 percent, it doesn’t present any toxicity problems and does not entail epithelial edema.21 Lidocaine given by intracamerula injection, at a dosage of not more than 0.5 percent, is not toxic for the human endothelium. This has been proved by multiple random prospective clinical studies.15 A study using rabbits has demonstrated that an injection of lidocaine can be toxic for the endothelium, but the dosage used and the conditions under which that study was done were far removed from those used in human microsurgery.16 DESCRIPTION OF TOPICAL ANESTHESIA TECHNIQUES Cataract Before disinfection, a drop of oxybuprocaine (Novésine) is put in. Five minutes before the operation, five drops of lidocaine 2 percent without preservative (Astra) is put in. Topical anesthesia is completed by an intracamerular injection of 1cc lidocaine 0.5 percent without preservative, done after the paracenteses and during hydrodeliniationhydrodissection. This gets rid of the deep pain during mobilization of the iris or the capsule.11,13 Glaucoma The initial stages of a glaucoma operation are similar to that of a cataract operation. Firstly, before disinfection, drops of oxybuprocaine are put in. Then, five minutes before the arrival of the patient in the operating theater, lidocaine 2 percent is put in. Then, instead of intracamerula
152
Step by Step Minimally Invasive Glaucoma Surgery
injection, using a swab, lidocaine 2 percent is put in on the conjunctiva. After this, 2 cc-3 cc of lidocaine 2 percent is injected under the conjunctiva with a 25G yellow needle to form a perfect bubble on the dissection surface of the scleral flap. This bubble must cover at least a quadrant of the eye. The anesthetic will take effect in about two minutes, after which the patient is asked to orientate his eye in the direction of the flap that is to be made. Usually, this presents no problem, and patient collaboration is excellent (Figs 10.1 and 10.2). Combined Cataract/Glaucoma Although the principle is the same in a combined glaucoma/cataract operation, the timing will vary, depending on how the surgery progresses. Firstly, five minutes before the arrival of the patient in the operating theater, drops of lidocaine 2 percent are put in. Then, the bubble is created by injecting lidocaine 2 percent under the conjunctiva. During the cataract operation an intracamerular injection of lidocaine at 0.2 percent dilution is made to reduce the deep pain. Generally, no additional topical anesthetic is needed to complete the second flap and the closure of the conjunctiva, but it can always be added, if needed. COMPLEMENTARY SEDATION USING INTRAVENOUS INJECTION It is always possible that sedation will need to be administered before or during the operation. The onset and rise of anxiety has always a contextual aspect. The role and the attitude of the surgeon and other participants cannot be underestimated in the onset and rise of patient anxiety. At the beginning of the operation and depending on the
Topical Anesthetic and the Subconjunctival Bubble
153
Fig. 10.1: Subconjunctival bubble of anesthesia lidocaine 2%
Fig. 10.2: Conjunctival dissection with wescoat under subconjunctival anesthesia lidocaine 2%
154
Step by Step Minimally Invasive Glaucoma Surgery
type of patient and their anxiety level, an intravenous dose of propofol can be administered at the same time as the subconjunctival injection is made. If the build up of patient anxiety cannot be controlled, a very slow and progressive intravenous injection of benzodiazepines (midazolamDormicum 0.5 to 1.5 mg) and/or opiates with a short halflife (alfentanil-Rapifen 50-100 mcg) can be made.3,7,8 PREPARATION OF THE PATIENT Preoperative Preparation The patient meets his surgeon and his anesthetist,9 and it is important, during this consultation, that all the patient’s questions are discussed. It is vital that the patient clearly understands the stages and procedures of the operation, so that trust is established and that he can follow his operation well. On the day of the operation, an assistant checks that the patient clearly recalls and understands all stages and procedures. It is imperative that the patient goes to the toilet before the operation to empty his bladder, thus allowing him not to be worried by external matters during the operation. Eye dilation is carried out by the patient at home. This reduces the waiting time before the operation begins – a time full of anxiety for the patient. Five minutes before going into the operating theater, the patient is given 5 drops of 2 percent lidocaine on the cornea. Great care must be taken at this point not to allow the cornea to dry out thorough small blinks of the eyelid. At this point, the anesthetist has an important role in verbally soothing the patient.21
Topical Anesthetic and the Subconjunctival Bubble
155
Preparation during the Operation Once the patient is settled comfortably in the operating theater, the operating field is rapidly applied. It is important to tell the patient what is going to happen before each action is carried out, so as to avoid undue alarm. The microscope light is very dazzling and it is experienced as painful by the patient.4 It is paramount, to accustom the patient, to start with a weak light and increase its strength progressively. Once the operating field is stuck on the face, the eyelid retractor is placed into position and then opened delicately, so that there is no eyelid akinesia. Once the eyelid retractor is in position, the surface of the conjunctiva is swabbed with 2 percent lidocaine, then a subconjunctival injection of lidocaine is made a little behind the site of the flap, so that the conjunctiva is not damaged and a high-quality anesthesia is achieved (Figs 10.3 and 10.4). After this, the operation proper can proceed as normal, always speaking to the patient so that he is not alarmed or surprised and does not move. Postoperative Care and Patient’s Home Return Once the operation is finished, there is in the patient an extreme sense of relief, and a natural relaxation, as patients always imagine that an eye operation will be much more painful than any other. Once the operation is finished, the patient must be taken care of by the nurse - especially in the case of an ambulatory patient who must not have a sense of being abandoned. The nurse offers him light refreshments, tea or coffee. The patient is discharged about thirty minutes after the end of the operation. The patient must go home with all
156
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 10.3: Positioning the globe to see the flap at the end of the operation
Fig. 10.4: Motility of the globe under topical and a conjunctival bubble of anesthesia
Topical Anesthetic and the Subconjunctival Bubble
157
the instructions he has to follow for his postoperative treatment and a follow-up appointment for the next day, to check the operation. He must be given a contact telephone number for the nurses and the surgeon, in case he is worried. CONCLUSION: ENVIRONMENT UNDER WHICH THE OPERATION TAKES PLACE Topical anesthesia in cataract operations has proved itself. In the case of glaucoma operations, subconjunctival anesthesia allows the mobility of extrinsic muscles to be kept intact and for the operating field to be placed exactly where the surgeon needs (Figs 10.3 and 10.4). For a successful topical anesthesia to be done, it is imperative that the surroundings should be familiar to the patient and that he does not feel suffocated. In ambulatory surgery, the patient must feel that he is in a caring, warm and professional environment.1,22 The team which takes charge of the patient must bond together well, be friendly but not familiar. Stress does not diminish the pain threshold! Since 1996, we have been practising this type of anesthesia regularly on all our patients, without any major complications. REFERENCES 1. 2. 3.
Bovet JJ. Minimal standard needs for out-patient surgery Abstract first ESOPES congress Vienna 1993. Bovet JJ, Molnar I, Baumgartner J-M, Bruckner J-C. Outpatient surgery comparing with In patient surgery round table Ascona symposium abstract April 1995. Bovet JJ, Baumgartner JM, Bruckner JC, Ilic V, Paccolat F, Maroni O, Bovet F. Chirurgie de la cataracte en topique intracamérulaire Abstract SSO-SOG. Sept 1997.
158 4. 5. 6. 7. 8. 9. 10. 11. 12.
13. 14. 15. 16. 17.
Step by Step Minimally Invasive Glaucoma Surgery
Bovet JJ, Lebuisson DA. Le microscope opératoire in Laroche L, Lebuisson DA, Montard M Chirurgie de la cataracte chap 7 pp81-8ed Masson 1996. Bruckner JC. Option zéro Abstract 2th ESOPES congress Genève 1994. Bruckner JC. Abstract 15e Asia-Pacific congress Honk kong mars 1995. Bruckner JC. Out-patient cataract surgery: yet another backseat role for the anesthetist? abstract 3th ESOPES congress postdam 1996. Esteve C, Lebuisson DA, Montin JF. Anesthésie topique dans la chirurgie de la cataracte par phakoémulsification de l’adulte Ophtalmologie 1997;11:246-8. Fraser SG, Siriwadena D, Jamieson H, Girault J, Bryan SJ. Indicators of patient suitability for topical anesthesia. J Cataract Surg 1997;23:781-3. Fischman, R ASCRS abstract, April 1992. JP Gills. Ocular surgery news abstract 1996. Gills JP, Cherchio M Raanan MG. The use of intraoperative unpreserved lidocaïne to control discomfort during IOL surgery under topical anesthesia. J Cataract Refract Surg 1997;23:527-35. Gills JP, Martin RG, Cherchio M. Topical anesthesia and intraocular lidocaïne in Cataract surgery the state of the art Gills JP chap 2 pp9-17 Slack inc 1998. Hirschberg J. History of ophtalmology 1910;284. Hustead RF, Hamilton RC. Pharmacology. In Gills JP, Hustead RF, Sanders DR. Ophthalmic Anesthesia chap 2 pp69-102 Slack inc ed 1993. Judge AJ, Najafi K, Lee DA, Kevin MM. Corneal endotheliale toxicity of topical anesthesia. Ophthalmology 1997;104:1373-9. Kershner RM. Cataract surgery technique using topical anesthesia In Fine I H, Fichman R A, Grabow H B. Clear Cornea Cataract Surgery and Topical Anesthesia. chap 11: pp141-153 Slack inc ed 1993.
Topical Anesthetic and the Subconjunctival Bubble
18. 19. 20.
21. 22.
23. 24. 25.
159
Klyve P, Nicolaissen B. Surgery of strabismus performed during topical anesthesia using adjustable suture. TidssrkNor-laegeferen 1992;112:774-5. Knapp H. On cocaïne and its use in ophthalmic and general surgery. Arch Ophthalmol 1884;13:402-3. Lebuisson DA, Bovet JJ. Le concept opératoire pour patients ophtalmologiques ambulants in Laroche L, Lebuisson DA, Montard M Chirurgie de la cataracte chap 6 pp61-74ed Masson 1996. Lebuisson DA, Chevaleraud E, Bovet JJ. Les anesthésies locales in Laroche L, Lebuisson DA, Montard M Chirurgie de la cataracte chap10 pp109-127ed Masson 1996. Lebuisson DA, Bovet JJ. Principle d’hygiène au bloc opératoire ophtalmolgique in Laroche L, Lebuisson DA, Montard M Chirurgie de la cataracte chap 5 pp39-58ed Masson 1996. Martin XY, Safran AB. Corneal hypoesthesia Survey Ophtal 1988;33:28-40. Smith R. Cataract extraction without retrobulbar injection Brit J Ophthalmol 1990;205-107. Williamson CH. Cataract keratotomy with topical anesthesia. Ocular Surgery News 1992;10:44.
162
Step by Step Minimally Invasive Glaucoma Surgery
INTRODUCTION Cyclodestructive procedures are generally used for refractory glaucomas. Previously it has been carried out by various methods like surgical excision of ciliary body,1 cyclodiathermy,2,3 cycloirradiation,4 cycloelectrolysis,5 cyclocryotherapy, 6-9 ultrasound, 10 microwave cyclodestruction,11 and currently by cyclophotocoagulation. Laser cyclophotocoagulation has now become the principal method of cyclodestructive procedures. Various laser has been used for this purpose which includes ruby, Nd:YAG, argon, krypton and diode laser, etc. Beckman and Sugar first popularized the use of transscleral cyclophotocoagulation (TSCPC) by ruby laser in early 1970s.12,13 Later they discovered that Nd:YAG laser was more effective in penetrating sclera and energy absorbed by ciliary body is also optimum.13 Secondary glaucomas like postpenetrating keratoplasty glaucomas, aphakic/pseudophakic glaucomas, neovascular glaucomas and glaucoma following trauma are examples where cyclodestructive procedures are favored due to a poor response to standard filtering procedures.14-16 INDICATIONS OF CYCLODESTRUCTIVE PROCEDURES 1. 2. 3. 4. 5.
Refractive primary ACG, OAG Neovascular glaucoma (NVG) Post-traumatic glaucoma Aphakic/pseudophakic glaucoma Severe congenital glaucoma with multiple failed surgeries 6. Postpenetrating keratoplasty glaucoma 7. Postretinal detachment surgery glaucoma
Cyclophotocoagulation
8. 9. 10. 11. 12. 13. 14.
163
Silicone oil-induced glaucoma Inflammatory glaucoma Glaucoma with severe conjunctival scarring. Failed trabeculectomy and drainage implants Medical condition precluding invasive surgery Patients’ refusal to undergo invasive surgery In emergent situation (i.e. acute onset NVG).
MECHANISM OF ACTION Various theories have been described regarding mechanism of cyclophotocoagulation. Decreased Aqueous Production • Destruction of the ciliary epithelium resulting in decreased aqueous production. • Destruction of ciliary blood vessels and coagulative necrosis also contributes in decreasing aqueous production.17 • Intraocular inflammation is also thought to be responsible for short-term hypotension.19 For both of these mechanisms presence of ciliary body pigment is important in absorbing laser energy.18 The diode laser (810 nm) has greater melanin absorption compared to the Nd:YAG laser (532 nm). Increased Aqueous Outflow • Nd:YAG laser also produces a neuroepithelial defect resulting in increase outflow which is related to the extent of treatment. In an in-vitro perfusion model, laser lesions placed 6 mm posterior to limbus had an equivalent effect on outflow to that of laser lesions directed towards ciliary process.20
164
Step by Step Minimally Invasive Glaucoma Surgery
Animal study 21 suggests that the decrease of the intraocular pressure after pars plicata cyclocoagulation resulted from the reduction of aqueous secretion, whereas that after pars plana cyclocoagulation resulted from enhancement of the uveoscleral outflow through the enlarged extracellular space from the anterior chamber into the suprachoroidal space. CYCLOPHOTOCOAGULATION Trans-scleral Cyclophotocoagulation with the Nd: YAG Laser In pulsed mode Nd:YAG laser focuses very intense laser energy into small area for a short period which produces mechanical photodisruption. But in continuous mode it creates 1000 folds greater energy than used for routine photodisruption. These high energy levels alter the ciliary body thermally and are used for trans-scleral cyclophotocoagulation.22 Trans-scleral cyclophotocoagulation with the Nd: YAG laser can be performed both as continuous and pulsed laser system. It may be a contact and non-contact procedure.23-25 Contact system uses hand-held probe, which is placed on conjunctiva to allow energy transmission directly to the ocular surface. Non-contact laser system transits the laser energy through air from a slit-lamp delivery system. Contact procedure requires a lesser energy than the non contact procedures. The commonly used settings in the thermal mode of Nd: YAG non-contact method employs 8 Joules for 20 msec, 32-40 spots over 360o. In comparison the contact technique requires 7 Watts for 0.7 seconds for each spot; 32-40 spots being applied over 360o (Table 11.1). In non-contact method laser applications have been placed 1 to 3 mm from limbus.
Cyclophotocoagulation
165
Whereas in case of contact method anterior edge of probe is placed 0.5 to 1 mm posterior to limbus. However, the YAG laser is bulky, expensive and requires careful maintenance. The success rate of Nd:YAG laser cyclophotocoagulation in various studies is listed in Table 11.2. Results of Clinical Trials In a large series of 500 patients by Shields MB et al26 suggests that noncontact trans-scleral Nd:YAG cyclophotocoagulation is the cyclodestructive procedure of choice. It Table 11.1: Treatment parameters for Nd:YAG laser cyclophotocoagulation
Energy Duration Number Circumference Spot size
Non-contact
Contact
4-8 J 10-20 msec 32 spots 360o Fixed, 70 um
4-9 watts 0.5-0.7 seconds 32 spots 360o Fixed, Quartz probe
Table 11.2: Success rates in various studies using Nd:YAG cyclophotocoagulation
Authors
No. Follow- Success Success Retreatof up Definition rate ments eyes (months) (mm Hg) (%) (eyes)
Phelan MJ et al28 Delgado MF et al29 Beiran I et al30 Schuman JS et al31 Schuman JS et al32 Miyazaki et al33 Hampton c et al34 Brancato et al35 Klapper et al36
10 115 52 116 140 26 106 23 30
15 27 12 12 6 10 6 8.6 6
21 22 21 22 5-22 22 7-20 25 22
50 65 70 65 59 77 51 66 86
7 33 — 31 16 12 29 13 7
166
Step by Step Minimally Invasive Glaucoma Surgery
offers a reasonable surgical option in patients with neovascular glaucoma, glaucomas with active uveitis, glaucomas in aphakia or pseudophakia, and other cases in which filtering surgery has failed or is felt to have a low chance for success. Satisfactory intraocular pressure reduction was achieved in 62 percent of the patients with one treatment session and with multiple treatments in 94 percent. However, visual loss remains a significant postoperative complication occurring in 39 percent of the study population. Patients with neovascular glaucoma had the greatest percentage of visual loss at 46 percent, compared with 34 and 38 percent for patients with glaucomas in pseudophakia and aphakia, respectively. But it is not known how many of these cases of visual loss were a direct result of the cyclophotocoagulation. A prospective study by Lin P et al27 of 68 eyes of 64 patients with advanced, uncontrolled glaucoma who received cyclophotocoagulation showed a significant reduction of IOP after surgery at 1, 5, and 10 years of followup; however, 51.5 percent of eyes failed by the end of 10 years, with most failures occurring within the first year (40%). Ten eyes of pediatric glaucoma was treated by Phelan MJ et al 28 with Nd:YAG contact trans-scleral laser cyclophotocoagulation. Five patients (50%) achieved IOP of less than 21 mm but Hg was in, retreatment was required in 7 of 10 eyes. Loss of vision was seen in four patients, and one case of phthisis bulbi was noted. Delgado MF et al 29 did noncontact trans-scleral Nd:YAG cyclophotocoagulation treatment for neovascular glaucoma in 115 eyes of 111 subjects treated. Success rate was 65.0 percent at 1 year, 49.8 percent at 3 years, and at 34.8 percent 6 years. Phthisis developed in 8.6 percent of the eyes.
Cyclophotocoagulation
167
Results of noncontact trans-scleral Nd:YAG cyclophotocoagulation in the treatment of postpenetrating keratoplasty refractory glaucoma is also promising. In Beiran’s series of fifty-two eyes, the mean post-treatment IOP was 15.8+/-9.7 mm Hg, pretreatment IOP being 38.7 +/-11.9 mm Hg. The probability of a graft remaining clear was 79 percent at 1 year and 56 percent at 5 years.30 But in another study out of 25 patients with clear grafts before cyclophotocoagulation, 11 (44%) had graft decompensation.77 Trans-scleral Cyclophotocoagulation with Semiconductor Diode Laser The ergonomics of the semiconductor Diode laser have made it a better alternative to the Nd:YAG laser.34,37 Moreover, the Diode laser at 830 nm has a better absorption by the pigmented tissue of the ciliary body, requiring lesser energy per spot. Histopathologic studies have shown the diode laser to produce most of its coagulative effect on the ciliary body stroma. It requires less energy than Nd:YAG laser (4.0 Jvs. 1.2 J).38 The procedure is performed in the outpatient clinic. Contact method is superior as it has the advantages of reduced scattering and increased scleral transmission. The response of ciliary body destruction is thought to be gauged by the ‘pop’ sound. Although there have been few comparisons between the Diode and YAG laser, but postlaser pain and chances of persistent hypotony are greater with the Nd:YAG laser. Settings used for contact mode in one of the largest studies by Bloom et al on 210 eyes were 1.5 watts for 1.5 seconds using 40 spots over 360o (Figs 11.1 and 11.2). The probe is to be placed with its edge at the limbus, but is actually centred 1.2 mm posterior to the limbus in the region of the ciliary body (Fig. 11.3). Other authors prefer to keep the power just below the level
168
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 11.1: DLCP machine (Nidek)
Fig. 11.2: DLCP probe (Nidek)
at which ‘pop’ sound is heard (Table 11.3). The contact method uses a G probe (Figs 11.4 to 11.6) which is designed to deliver energy 1.2 mm from the limbus and has a small protusion that indents the conjunctiva and sclera to optimize delivery.
Cyclophotocoagulation
169
Fig. 11.3: DLCP being done
Table 11.3: Treatnment parameters for diode laser cyclophotocoagulation
Non-contact Energy Duration Number Circumference
1.2 watts 990 msec 40 spots 360o
Contact 1.5 watts 1.5 seconds 25-30 spots 360o
Common complications following Diode laser cyclophotocoagulation are conjunctival burns, mild postoperative inflammation and atonic pupil. Uncommonly there may be severe uveitis, and loss of vision and rarely hyphema and vitreous hemorrhage. The success rate of Diode DLCP in various studies is listed in Table 11.4.
170
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 11.4: IRIS G-probe (side view)
Fig. 11.5: IRIS G-probe (end on view)
Cyclophotocoagulation
171
Fig. 11.6: DLCP being done with G-probe Table 11.4: Success rates in various studies using diode laser cyclophotocoagulation
Authors
No. Follow- Success of up definition eyes (months)
Kosoko et al49 Bloom et al50 Spencer et al51
27 12 210 10 58 19
Werner et al52
106 24
Pucci et al53 Noureddin et al54 Ocakoglu et al55 Agarwal et al56 Levinger E et al57 Lai JS et al40 Schlote T et al43 Mistlberger A et al58 Gupta V et al59
120 36 32 52 33 14 100 206 52
26 12 11.4 12 12 12 12 9 12
Success Retreatrate ments (eyes)
<23 mm Hg 72% <22 mm Hg 66% <22 mm Hg 81% <17mm Hg 59% <22 mm Hg/ 85% pain relief <22 mm Hg 54% <21 mm Hg 72% <22 mm Hg 56% <22 mm Hg 92% 22 mm Hg 73% 21 mm Hg 85.7% 5-21 mm Hg 74.2% 22 mm Hg 72.7% 22 mm Hg 92%
— 102 26 23 55 9 14 22 — 2 33 22
172
Step by Step Minimally Invasive Glaucoma Surgery
Results of Clinical Trials Agarwal HC et al39 evaluated contact and non-contact methods of diode laser delivery and found using an energy setting of 3 J per spot, both were equally effective in lowering IOP in eyes with refractory glaucoma. Lai JS et al40 evaluated the efficacy and safety of diode laser trans-scleral cyclophotocoagulation in the treatment of 14 patients of chronic angle-closure glaucoma. The total success rate defined as IOP < 21 mm Hg with or without medication(s) was 85.7 percent at 1 year of follow-up review. Two eyes required repeat treatment. Seven eyes (50%) had atonic pupil following the laser treatment. A retrospective analysis by Murphy CC et al41 of 263 eyes of 238 patients of refractory glaucoma who underwent trans-scleral diode laser cyclophotocoagulation at two centers showed 89 percent of patients achieved an IOP of less than 22 mm Hg or a greater than 30 percent drop in IOP after cyclodiode therapy. Hypotony occurred in 9.5 percent of patients, 76 percent of whom had neovascular glaucoma. Kramp K et al42 evaluated trans-scleral diode laser contact cyclophotocoagulation in the treatment of different glaucomas, also as primary surgery in 193 eyes. The IOP was successfully controlled (final IOP 10-22 mm Hg) in 76.4 percent of cases after a single or multiple TSCPC treatments. The best results were obtained among the patients with POAG, in the oldest age group and in those patients without any previous or subsequent glaucoma operations. The proportion of eyes requiring multiple treatments was 21.2 percent. There was a complication rate of 14.4 percent, mostly mild uveitis. Phthisis bulbi occurred in three eyes (1.6%).
Cyclophotocoagulation
173
In Schlote’s43 series of 100 eyes overall success rate was 74.2 percent. A high success rate was achieved in inflammatory glaucoma (75%), primary open-angle glaucoma (89.5%), and neovascular glaucoma (86.7%) whereas the results were relatively poor in traumatic glaucoma (57.1%), aphakic glaucoma (57.1%), and congenital or juvenile glaucoma (62.5%). Role of diode laser cyclophotocoagulation in the management of refractory pediatric glaucomas is also good. With repeated treatment, cyclodiode can provide effective control of IOP pediatric glaucomas though the success rate is lower than with adults. Younger eyes may recover from treatment more rapidly but it has a lower rate of severe adverse effects than surgical modalities and has roles as a temporizing measure, as an adjunct to surgery, or in managing selected patients in whom surgery is undesirable because of a high risk of surgical complications.44 Inflammatory glaucoma is still a diagnostic and therapeutic dilemma and surgical intervention is always associated with a high risk of failure. Schlote T et al45 showed a success rate of 77.3 percent (72.2% of those with uveitic glaucoma). DLCP may become the surgical procedure of choice in treating secondary glaucoma caused by chemical injury and also in scleritis associated glaucoma, using reduced parameters for application. Semchyshyn TM et al 46 assessed the outcome of supplemental trans-scleral diode laser cyclophotocoagulation in twenty-one eyes with uncontrolled IOP despite the presence of an aqueous tube shunt and maximally tolerated glaucoma medications and found that adjunctive trans-scleral diode cyclophotocoagulation treatment(s) is a viable option to lower IOP in these cases.
174
Step by Step Minimally Invasive Glaucoma Surgery
Patients with medically uncontrolled glaucoma persisting after intravitreal silicone oil removal can be treated with TSCP; however, the reduction of IOP is variable. The IOP usually falls after a mean of 2-3 sittings of DLCP.47 Patients with medically uncontrolled glaucoma secondary to intravitreal silicone oil injection can also be treated with TSCPC in spite of the retained intravitreal silicone oil.48 Krypton Laser Cyclophotocoagulation The layer absorbing greatest amount of energy is the pigmented epithelium of the ciliary body analogous to the role of retinal pigment epithelium, presumably, although there has been no experimental study on absorption of laser energy by the ciliary body. A large proportion of krypton laser energy is absorbed by the pigmented epithelium and then radiate to the non-pigmented epithelium of ciliary body. Though it has a poor scleral transmission its good absorption by the pigmented epithelium makes it a potentially useful method for cyclophotocoagulation. Settings used for 300 to 500 W energy for 10 seconds using 10 spots over 90o-360o (Table 11.5). Krypton produces comparable lesions at the ciliary body in an experimental study in rabbits with half the energy required by the Nd: Table 11.5: Treatment parameters for krypton laser cyclophotocoagulation
Trans-scleral Energy Duration Number Circumference
300 to 500 W 10 seconds 10 per quadrant 90-360o
Cyclophotocoagulation
175
YAG laser.60 An advantage of the method is that standard retinal krypton photocoagulators can be used for the procedure. Results of Clinical Trials Raivio VE et al61 evaluated krypton laser for trans-scleral contact cyclophotocoagulation (CPC) in the treatment of glaucoma in young patients. The treatment was delivered by means of a fiberoptic probe with compression of the sclera by the probe and followed up for 2 years. After one or more krypton CPCs, but no other glaucoma procedures, an IOP level of 8 to 21 mm Hg or a decrease in IOP of more than 30 percent was obtained in 14 of 22 (64%) eyes at the last follow-up. No permanent hypotonia, phthisis bulbi, or devastating CPC-related complications were noted. Raivio VE et al62 also evaluated the krypton laser for trans-scleral contact cyclophotocoagulation in the treatment of post-traumatic glaucoma. With one or more cyclophotocoagulation treatments, the IOP decreased from the baseline mean (+/- standard deviation) of 32.6 +/- 12.8 mm Hg to 21.8 +/- 7.5 mm Hg (n = 13) at 3 months, and to 19.6 +/- 10.5 mm Hg (n = 18) at the last control visit (mean, 19.4 months; range, 3 weeks to 73 months) after cyclophotocoagulation but no other glaucoma procedure. One (6%) case of phthisis occurred. Because of the refractory nature of the disease, repeated treatments may be needed. Di Staso S et al 63 studied the role of trans-scleral cyclophotocoagulation in neovascular glaucoma (NVG) treatment with krypton laser on 12 eyes of 12 patients. Six months after treatment, intraocular pressure was down enough for the pain to disappear.
176
Step by Step Minimally Invasive Glaucoma Surgery
Endoscopic Cyclophotocoagulation (ECP) ECP is a new technique to directly photocoagulate the ciliary body under endoscopic guidance. The ciliary body can be treated directly within the eye using argon laser light delivered through a 20-gauge fiberoptic probe placed through a pars plana port. A cotton-tipped applicator is used to indent the sclera and bring the ciliary processes into view through a dilated pupil.64-67 The end of the probe is placed about 3 mm from the ciliary body. This procedure is not commonly used because it is invasive. It may have some advantages in the management of post-penetrating keratoplasty glaucoma.67-69 Newer endoscopic systems that incorporate a viewing fiberoptic as well as a laser fiberoptic are available, which permits the ciliary body to be visualized on a television screen. Endoscopic laser endocyclophotocoagulation can be performed at the time of cataract extraction. The iris is lifted with a viscoelastic material, and the anterior portions of ciliary processes are treated. It can also be done at the time of vitrectomy, for example, in a diabetic patient with neovascular glaucoma and a vitreous hemorrhage. The two main approaches to reach the ciliary process are via a limbal or pars plana entry. In limbal approach cyclophotocoagulation is done through a temporal and nasal limbal entry for nasal 180 o and temporal 180o respectively. In pars plana approach after doing a limited three port anterior vitrectomy ECP probe is introduced through each superior port for opposite ciliary process treatment.67 It can be done with argon or diode laser (Table 11.6). The success rate of endoscopic cyclophotocoagulation in various studies is listed in Table 11.7.
Cyclophotocoagulation
177
Table 11.6: Treatment parameters for argon laser cyclophotocoagulation
Energy Duration Number Circumference Spot Size
Endoscopic
Transpupillary
500-1000 mW 0.1-0.2 sec 3-5 per ciliary process 180-360o Fixed 20 gauge probe
500-1000 mW 0.1-0.2 sec 3-5 per ciliary process Limited by view 50-200 um
Table 11.7: Success rates in various studies using endolaser cyclophotocoagulation
Authors
No. Follow- Success of up definition eyes (months)
Chen J et al68 68 Uram et al69 10 Gayton JL et al71 58
12.9 8.8 24
Success Retreatrate ments (%) (eyes)
21 mm Hg 90 21 mm Hg 90 19 mm Hg 65
5 0 4
Results of Clinical Trials Chen J performed endoscopic cyclophotocoagulation which encompassed 180 to 360 degrees of the ciliary body circumference in 68 eyes through a limbal incision. Ninety percent of eyes achieved an intraocular pressure < or = 21 mm Hg from a mean preoperative value of 27.7 +/- 10.3 mm Hg. Best-corrected visual acuity was stable or improved in 64 eyes (94%), with four (6%) losing 2 or more lines of Snellen acuity. No case of hypotony (intraocular pressure < 5 mm Hg) or phthisis was observed.68 Uram et al 69 treated 10 patients with intractable neovascular glaucoma by pars plana ECP to coagulate between 90 and 180 degrees of ciliary processes. With a mean follow-up of 8.8 months, the IOP was reduced from a mean preoperative level of 43.6 mm Hg to a mean of
178
Step by Step Minimally Invasive Glaucoma Surgery
15.3 mm Hg postoperatively. Nine of the 10 eyes (90%) were able to achieve an IOP < 21 mm Hg, with three of those eyes requiring glaucoma medication. The only major complication encountered was hypotony in two eyes, although both had chronic retinal detachments. Uram et al 70 also described 10 patients who had combined phacoemulsification, ECP, and intraocular lens (IOL) implantation. After phacoemulsification, 180 degrees of ciliary processes were treated before insertion of the posterior chamber IOL. After a mean follow-up of 19.2 months, the mean IOP was reduced to 13.5 mm Hg from a mean preoperative IOP of 31.4 mm Hg. There were no significant complications except a transient vitreous hemorrhage that was noted on the second postoperative day. Gayton JL et al71 conducted a randomized prospective study on 58 eyes of 58 patients comparing endoscopic laser cycloablation performed through a cataract incision at the time of cataract surgery with combined trabeculectomy and cataract surgery. At the final available visit of 2-year followup, 30 percent of endoscopic laser patients achieved intraocular pressure control (below 19 mm Hg) without medication and 65 percent with medication. Forty percent of trabeculectomy patients achieved control without medication and 52 percent with medication. Neely DE et al71 retrospectively review 51 endoscopic diode laser cyclophotocoagulation procedures performed on 36 eyes of 29 pediatric patients with glaucoma over a 6year period. Whereas baseline mean pretreatment IOP was 35.06 +/- 8.55 mm Hg final postoperative IOP was 23.63 +/- 11.07 mm Hg. Nine eyes (25%) were retreated at least once. Cumulative success rate after all procedures at last follow-up was 43 percent. Aphakic patients had an increased risk of postoperative complications including
Cyclophotocoagulation
179
retinal detachment in 2 patients, hypotony in 1 patient, and progression of vision loss from hand motion to no light perception in 1 patient. In postpenetrating keratoplasty glaucoma, ECP has also been shown to be an effective treatment and may have advantages over trans-scleral cyclophotocoagulation. In study by Lin SC et al 10 patients who had penetrating keratoplasties (PKPs) were treated by ECP to control their IOP.33 The IOP control rate (IOP < 22 mm Hg) was 80 percent at last follow up consisting of 30 months from the time of PKP. There were no corneal graft failures. In comparison, several studies evaluating TCP treatment of keratoplasty associated glaucoma have demonstrated a high rate of graft failure after laser.72, 73 Lima FE et al 74 compare endoscopic cyclophotocoagulation (ECP) and the Ahmed drainage implant in the treatment of refractory glaucoma. Their success rate at 24 months was 70.59 and 73.53 percent for the Ahmed and ECP groups, respectively and difference is not significant. The eyes that underwent Ahmed tube shunt implantation had more complications than those treated with ECP. One advantage of ECP is surgeon can ablate ciliary process under direct visualization which is particularly helpful in cases of severe congenital glaucoma. In congenital glaucoma because of enlargement of eyeball ciliary processes may be displaced resulting in failure of trans-scleral cyclophotocoagulation.75 Barkana Y et al76 reported a case of congenital glaucoma where IOP was effectively lowered with ECP while repeated trans-scleral DLCP failed. They showed both misplaced laser burn as well as viable ciliary process over correctly placed laser burn. The main disadvantage of ECP is that it is an intraocular procedure with the probable risks of penetrating surgeries.
180
Step by Step Minimally Invasive Glaucoma Surgery
Endophthalmitis, choroidal hemorrhage, and retinal detachment though rare, but remain potential complications.32 Hence, although ECP may be a preferable surgery in cases of refractory glaucoma with relatively intact vision, it is better to avoid in eyes with very poor vision, since it would unnecessarily expose them to such potential complications. It should be done in operation theater and not an office procedure. Transvitreal Cyclophotocoagulation This method of cyclophotocoagulation is performed in conjunction with vitrectomy. Procedure is performed after direct visualization through operating microscope of ciliary processes after scleral depression. It requires a clear media and aphakia or pseudophakia. After anterior vitrectomy, endolaser is inserted through same port used for vitrectomy. After doing limited pars plana anterior vitrectomy endolaser probe is inserted through same port for ciliary ablation while ciliary process is visualized through pupil by depressing sclera.67 Argon or diode laser can be used. 64,67,77 Patel A did vitrectomy and transvitreal endophotocoagulation of the ciliary processes to treat 18 eyes with severe glaucoma. Postoperative intraocular pressure was equal to or less than 20 mm Hg in 14 of 18 eyes, although nine of the 14 successful cases required postoperative medical therapy. Treatment of more than 180 degrees was necessary for sufficient lowering of the intraocular pressure. Complications included transient vitreous hemorrhage (2 eyes), transient choroidal detachment (2 eyes), and hypotony (1 eye).64 Zarbin MA et al67 in their study of 42 eyes with severe glaucoma that could not be managed successfully by
Cyclophotocoagulation
181
medical therapy and conventional glaucoma surgery did endolaser photocoagulation and followed up till 36 months (mean, 13 months). After one or two (7 eyes) treatment sessions, 11 eyes (26%) had an IOP less than 21 mm Hg without medications; 21 eyes (50%) had an IOP less than 21 mm Hg with medications; 5 eyes (12%) had an IOP of 21 to 25 mm Hg with or without medications; and 5 eyes (12%) had an IOP greater than 25 mm Hg. Twenty-three (72%) of 32 patients were able to discontinue carbonic anhydrase inhibitors. Transpupillary Cyclophotocoagulation In patients who have visible ciliary processes, it is sometimes possible to deliver argon laser energy directly to the anterior surface of the ciliary processes. Transpupillary cyclophotocoagulation is performed with a slitlamp delivery system through a Goldmann three-mirror lens.66, 78 This technique is most useful in patients with traumatic aniridia or with very large sector iridectomies. In patients with advanced neovascular glaucoma, the iris is sometimes pulled anteriorly and peripherally, allowing a view of the ciliary processes. Trans-pupillary CPC through peripheral iridectomy or widely dilated pupil can be effective in treating ciliary block glaucoma.79 The long-term pressure control achieved by treating the anterior ciliary processes is rather short. The treatment is usually performed using an argon laser with duration of 0.1 to 0.2 seconds, a spot size of 50 to 200 μm, and a starting power of about 500 mW; which is increased until a visible burn is observed. It takes three to four applications to coagulate all visible portion of a ciliary process. Results of transpupillary cyclophotocoagulation are variable. Merritt JC80 treated 7 eyes of 6 patients with
182
Step by Step Minimally Invasive Glaucoma Surgery
transpupillary photocoagulation. Only one patient showed a decrease in intraocular pressure to a normal level. This patient was the only one in this series in whom large numbers of ciliary processes could be coagulated. The limiting factor in effective transpupillary argon laser photocoagulation may, therefore, be the total number of ciliary processes visualized and treated. Results of Shields S et al81 is also not promising. Out of twenty-seven patients with glaucoma who underwent transpupillary argon laser cyclophotocoagulation only six patients (22.3%) had a successful outcome, and in many cases the postoperative course was complicated by an additional, sustained increase in intraocular pressure. Lee PF78,82 in their series did cyclophotocoagulation taking pit rather than whitening of the ciliary process as end point. Fifteen out of 22 patients showed 50 percent reduction in IOP. Kim DD et al 83 reported a patient with traumatic glaucoma who underwent transpupillary argon laser cyclophotocoagulation (TALC) for management of uncontrolled intraocular pressure (IOP) despite maximally tolerated medical therapy. Ten weeks after TALC, the patient’s IOP remained controlled with medications at 16 mmHg, and visual acuity had improved to 20/25 with an aphakic contact lens. So, in selected patients whose ciliary processes are visible with indirect gonioscopy due to the defect in the iris, TALC may be an effective alternative cyclodestructive procedure to lower IOP when conventional medical or laser treatments are not successful. Overall cyclophotocoagulation is a definitive advancement over previous modes of cilioablation. However, it is an unpredictable procedure with a narrow therapeutic window, and not reproducible. One should, thus, be careful while doing this procedure.
Cyclophotocoagulation
183
POSTOPERATIVE MANAGEMENT These procedures unlike cyclocryotherapy are less painful. • At the end of the procedure, subconjunctival corticosteroids are usually administered and patching done for approximately 6 hours. • The patient should be placed on topical cycloplegics, antibiotics and corticosteroids, which are tapered as the inflammation subsides. • Preoperative antiglaucoma medications, glaucoma medications are continued until the effect of the procedure can be determined. The cholinergic drugs are avoided. • Sometimes very strong analgesic is required and at times one may have to use narcotic analgesics. • Follow up at 1 hr., 1 day, 1 week, 1 month and then according to the response. • Additional therapy should be considered if needed after one month.84 Interventions include drainage device, trabeculectomy, cyclocryotherapy and enucleation. COMPLICATIONS 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12.
Marked pain Mild to severe iritis, synechiae and pupillary block Transient rise of IOP Hypotony Phthisis bulbi Conjunctival surface burn Lens and zonular damage Reduced accommodation Posterior capsule fibrosis in pseudophakia Pupillary distortion Corneal graft failure Scleral thinning and staphyloma
184
Step by Step Minimally Invasive Glaucoma Surgery
13. Malignant glaucoma 14. Macular edema 15. Retinal detachment 16. Serous and hemorrhagic choroidal detachment 17. Intraocular hemorrhage 18. Best corrected vision loss 19. Sympathetic ophthalmia 20. Endophthalmitis and panophthalmitis 21. Treatment failure Cyclodestructive procedures share similar risks, but they vary in degree of risk. The most troubling and common complication of these procedures is a decrease in visual acuity. This can result from a variety of causes, including hypotony, macular edema, and cataract. Due to risk of vision loss makes, cyclodesrtuctive procedures are a last resort in patients with good vision. Less intense laser therapy on a repeated basis rather than a single high dose treatment is suggested to minimize complications of treatment. Schuman et al3 in their study of 116 eyes treated by contact Nd:YAG TCP, had 19 eyes (16%) that progressed to NLP and 17 of 36 eyes (47%) having 20/200 or better vision lost 2 or more Snellen lines. In addition, nine out of 116 eyes (8%) developed hypotony (IOP of 3 mm Hg or less). Many of these hypotonous eyes were also considered to be phthisical. In Jennings’s85 series complications included anterior uveitis (42%), conjunctival injection (36%), pain (30%), and conjunctival hemorrhage (15%). Corneal edema, intraocular pressure spikes, and corneal epithelial defects were each noted in 9 percent of the eyes treated, whereas cataracts developed in 12 percent of the eyes. Two out of 33 eyes (6%) developed anterior segment ischemia with subsequent phthisis bulbi. Seven out of 33 eyes (21%) demonstrated no adverse reactions.
Cyclophotocoagulation
185
Destroying the correct amount of the ciliary body is not a precise procedure. In eyes with minimal aqueous outflow, a small change in aqueous production can cause marked changes in lOP. If too much ciliary function is destroyed, the patient can develop hypotony (and perhaps phthisis). The risk of hypotony varies among studies, but it appears to be higher with cyclocryotherapy than with laser procedures. The risk of phthisis increases with each procedure performed. The cyclodestructive procedures lead to increase in inflammation especially with cyclocryotherapy. Laser procedures generally cause less inflammation. Eyes will often experience chronic aqueous flare after these procedures because of a breakdown in the blood-aqueous barrier. Pain is a significant feature of cyclocryotherapy. A decrease in pain is the single most obvious advantage of laser procedures over cyclocryotherapy. Hyphema is also a common side effect in patients with neovascular glaucoma. Pressure spikes during and after cyclocryotherapy are also common. The postoperative rise in lOP peaks at about 6 hours. Surface burns occur with non-contact laser procedures and they can occur with contact lasers if debris is present on the end of the fiberoptic because the debris can absorb the laser energy and heat up. There have been several published reports of sympathetic ophthalmia (SO) following TSCPC.86-88 Lam et al reported that the incidence of SO at their institution was 5.8 percent (four of 69) and 0.67 percent (one of 150) after non-contact and contact Nd:YAG cyclophotocoagulation, respectively.87 Bechrakis et al have reported a case of sympathetic ophthalmia after 20 months of treatment with 3 sessions of contact Nd:YAG laser. Cyclophotocoagulation and 1 session of cyclocryotherapy
186
Step by Step Minimally Invasive Glaucoma Surgery
in a case of secondary glaucoma with Coat’s disease without any previous history of penetrating trauma or surgery, confirmed by classical histopathology of SO, thickening of choroid by lymphocytic infiltration with OKT3 positive mature T cells and Dalen-Fuchs nodules. Disintegration of uveal tissue seems to trigger a cellular immune response against uveal autoantigen possibly by release of high energy in a small spot, results in an explosion like reaction. Also postulated that these eyes being endstage glaucomatous may itself be a risk factor for developing SO.88 Malignant glaucoma has been reported both after diode laser TCP87,89 and after contact and noncontact Nd:YAG cyclophotocoagulation.90,91 A case of panophthalmitis has also been reported after contact diode laser cyclophotocoagulation in a patient with failed trabeculectomy and trabeculotomy for congenital glaucoma.92 About 3 to 5 percent of the power of laser reaches posterior pole as shown by a study by Jonathan et al. Noncontact Nd:YAG cyclophotocoagulation had significantly higher transmission compared to contact Nd:YAG and diode lasers. Exposure energies may approach or exceed ACGIH (American Conference of Governmental Industrial Hygienists) guidelines. Clinical significance of such exposure however is still not proven. It does not prove to be a source of visual loss in any patient. 93 Pupillary distortion has also been described after DLCP due to injury to peripheral iris caused by anterior displacement of laser spots. 94 Administration of 100 J with a Nd:YAG laser increases corneal touch threshold and causes a significant decrease in number, but not diameter, of major corneal nerve bundles. Nerve damage and corneal hypoesthesia are
Cyclophotocoagulation
187
etiologic factors in ulcerative keratitis following Nd:YAG cyclophotocoagulation.95 Results of the preliminary study by Raivio VE et al96 suggest that cyclophotocoagulation with the 670-nm diode laser does not impair corneal innervation. CONCLUSIONS The concept of cycloablation has been present for several decades, but the inability to titrate a predictable and reproducible response has been its drawback. However, Cyclodestructive procedures still plays an important role in our paradigm of glaucoma therapy, since it is the last resort treatments for intractable glaucomas in eyes with poor or no visual potential. Cyclocryotherapy was the most commonly used method previously but it has now been replaced by laser cyclophotocoagulation, which causes less pain and is associated with less inflammation, hypotony, and phthisis. This is because of their frequent complications and unpredictable degree of pressure lowering. Experience with Nd:YAG or diode endolaser cyclophotocoagulation holds promise for these and other patients because it appears to provide good results and lesser side effects. Trans-scleral diode cyclophotocoagulation with G-probe is the procedure of choice and most generally used laser procedure because it is noninvasive and does not require a clear cornea or widely dilated pupil. Additional experience will better define the indications and scope of these newer modalities of cycloablation. REFERENCES 1. 2.
Bietti G. Surgical intervention on the ciliary body; new trends for the relief of glaucoma. JAMA 1950;142:889-97. Meyer SJ. Diathermy cauterization of ciliary body for glaucoma. Am J Ophthalmol 1948;31:1504-7.
188 3. 4.
5. 6. 7. 8. 9. 10. 11. 12.
13. 14. 15. 16.
Step by Step Minimally Invasive Glaucoma Surgery
Walton DS, Grant WM. Penetrating cyclodiathermy for filtration. Arch Ophthalmol. 1970;83:47-8. Haik GM, Breffeilh LA, Barbar A. Bete irradiation as a possible therapeutic agent in glaucoma : an experimental study with report of a clinical case. Am J Ophthalmol. 1948;31:945. Berens C, Sheppard LB, Duel AB Jr. Cycloelectrolysis for glaucoma. Trans Am Ophthalmol Soc. 1949;47:364. DeRoeth A Jr. Cryosugery for the treatment of advanced simple glaucoma. Am J Ophthalmol 1968;66: 1034-41. Bellows AR, Grant WM. Cryotherapy in advanced inadequately controlled glaucoma. Am J Ophthalmol 1973;75:679-84. Caprioli J, Strang SL, Spaeth GL, et al. Cyclocryotherapy in treatment of advanced glaucoma. Ophthalmology 1985;92:947-53. Bellows AR, Grant WM. Cyclocryotherapy of chronic openangle glaucoma in aphakic eyes. Am J Ophthalmol 1978;85:615-21. Polack PJ, et al. Histologic effects of contact ultrasound for the treatment of glaucoma. Invest Ophthalmol Vis Sci. 1991;32:2136-42. Finger PT, et al. Trans-scleral microwave cyclodestruction. Invest Ophthalmol Vis Sci. 1990;31:2151-55. Beckman H, Kinoshita A, Rata An, et al. Transscleral ruby laser irradiation of the ciliary body in the treatment of intractable glaucoma. Trans Am Acad Ophthalmol Otol 1972;76:423-36. Beckman H, Sugar HS. Neodymium laser cyclocoagulation. Arch Ophthalmol 1973;90:27-8. Shields MB. Cyclodestructive surgery for glaucoma: past, present, and future. Trans Am Acad Ophthalmol Otolaryngol 1985;83:285-303. Mastrobattista JM, Luntz M. Ciliary body ablation: where are we and how did we get here? Surv Ophthalmol 1996;41:193-213. Caprioli J, et al. Cyclocryotherapy in the treatment of advanced glaucoma, Ophthalmology 1985;92:947-54.
Cyclophotocoagulation
17. 18. 19.
20.
21.
22. 23.
24. 25. 26.
27.
189
van der Zypen E, et al. The effects of trans-scleral laser cyclophotocoagulation on rabbit ciliary body vascularization. Graefes Arch Clin Exp Ophthalmol 1989;227:172. Cantor LB, et al. Neodymium-YAG trans-scleral cyclophotocoagulation/ The role of pigment. Invest Ophthalmol Vis Sci. 1989;30:1834-37. Schubert HD, Federman JL. A comparison of CW Nd:YAG contact transscleral cyclophotocoagulation with cyclocryopexy. Invest Ophthalmol Vis Sci. 1989 Mar;30(3): 536-42. Schubert HD, Agarwala A, Arbizo V. Changes in aqueous outflow after in vitro neodymium: yttrium aluminum garnet laser cyclophotocoagulation. Invest Ophthalmol Vis Sci. 1990 Sep;31(9):1834-8. Liu GJ, Mizukawa A, Okisaka S. Mechanism of intraocular pressure decrease after contact transscleral continuouswave Nd:YAG laser cyclophotocoagulation. Ophthalmic Res. 1994;26(2):65-79. Stewart WC. Clinical practice of glaucoma.1990, Slack. Alward WLM. Laser cyclophotocoagulation. In Weingeist TA, Sneed SR (Eds): Laser Surgery in Ophthalmology: Practical Applications. East Norwalk, Conn., Appleton and Lange, 1992. Schuman JS, et al. Contact transscleral continuous wave Nd:YAG laser cyclophotocoaguIation, Ophthalmology 1990;97:571-80. Wilensky JT, Welch D, Mirolovich M. Transscleral cyclophotocoagulation using a Nd:YAG laser, Ophthalmic Surg 1985;16:95-98. Shields MB, Shields SE. Noncontact transscleral Nd:YAG cyclophotocoagulation: a long-term follow-up of 500 patients. Trans Am Ophthalmol Soc. 1994;92:271-83; discussion 283-7. Lin P, Wollstein G, Glavas IP, et al. Contact transscleral neodymium:yttrium-aluminum-garnet laser cyclophotocoagulation Long-term outcome. Ophthalmology 2004 Nov;111(11):2137-43.
190 28.
29.
30.
31. 32.
33. 34.
35.
36.
37.
Step by Step Minimally Invasive Glaucoma Surgery
Phelan MJ, Higginbotham EJ. Contact transscleral Nd:YAG laser cyclophotocoagulation for the treatment of refractory pediatric glaucoma. Ophthalmic Surg Lasers 1995 SepOct;26(5):401-3. Delgado MF, Dickens CJ, Iwach AG, et al. Long-term results of noncontact neodymium:yttrium-aluminumgarnet cyclophotocoagulation in neovascular glaucoma. Ophthalmology 2003 May;110(5):895-9. Beiran I, Rootman DS, Trope GE, et al. Long-term results of transscleral Nd:YAG cyclophotocoagulation for refractory glaucoma postpenetrating keratoplasty. J Glaucoma. 2000 Jun;9(3):268-72. Schuman JS, Bellows AR, Shingleton BJ, et al. Contact transscleral Nd:YAG laser cyclophotocoagulation: midterm results. Ophthalmology 1992;99:1089–95. Schuman JS, Puliafito CA, Allingham RR, et al. Contact transscleral continuous wave neodymium:YAG laser cyclophotocoagulation. Ophthalmology 1990 May;97(5): 571-80. Miyazaki M, Hoya T. Effects of trans-scleral Nd:YAG laser cyclophotocoagulation: research for a new manner of treatment. Ophthalmologica 1994;208:122-30. Hampton C, Chields M B, Miller KN, et al. Evaluation of a protocol for trans-scleral neodymium :YAG cyclophotocoagulation in one hundred patients. Ophthalmology. 1990;97:910-17. Brancato R, Giovanni L, Trabucchi G, et al. Contact transscleral cyclophotocoagulation with Nd:YAG laser in uncontrolled glaucoma. Ophthalmic Surg 1989 Aug;20(8): 547-51. Klapper RM, Wandel T, Donnenfeld E, et al. Transscleral neodymium:YAG thermal cyclophotocoagulation in refractory glaucoma. A preliminary report. Ophthalmology 1988 Jun;95(6):719-22. Hennis HL, Stewart WC: Semiconductor diode laser transscleral cyclophotocoagulation in patients with glaucoma, Am J Ophthalmol 1992;13:81-85.
Cyclophotocoagulation
38. 39.
40.
41.
42.
43.
44. 45.
46.
47.
191
Barasch K, Galin MA, Baras I. Postcyclodialysis hypotony. Am J Ophthalmol 1967;68:644-48. Agarwal HC, Gupta V, Sihota R. Evaluation of contact versus non-contact diode laser cyclophotocoagulation for refractory glaucomas using similar energy settings. Clin Experiment Ophthalmol 2004 Feb;32(1):33-8. Lai JS, Tham CC, Chan JC, et al. Diode laser trans-scleral cyclophotocoagulation in the treatment of chronic angleclosure glaucoma: a preliminary study. J Glaucoma. 2003 Aug;12(4):360-4. Murphy CC, Burnett CA, Spry PG, et al. A two centre study of the dose-response relation for trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol 2003 Oct;87(10):1252-7. Kramp K, Vick HP, Guthoff R. Trans-scleral diode laser contact cyclophotocoagulation in the treatment of different glaucomas, also as primary surgery. Graefes Arch Clin Exp Ophthalmol 2002 Sep;240(9):698-703. Schlote T, Derse M, Rassmann K, et al. Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma. J Glaucoma 2001 Aug;10(4):294301. Kirwan JF, Shah P, Khaw PT. Diode laser cyclophotocoagulation: role in the management of refractory pediatric glaucomas. Ophthalmology 2002 Feb;109(2):316-23. Schlote T, Derse M, Zierhut M. Transscleral diode laser cyclophotocoagulation for the treatment of refractory glaucoma secondary to inflammatory eye diseases. Br J Ophthalmol 2000 Sep;84(9):999-1003. Semchyshyn TM, Tsai JC, Joos KM. Supplemental transscleral diode laser cyclophotocoagulation after aqueous shunt placement in refractory glaucoma. Ophthalmology 2002 Jun;109(6):1078-84. Kumar A, Dada T, Singh RP, et al. Diode laser trans-scleral cyclophotocoagulation for glaucoma following silicone oil removal. Clin Experiment Ophthalmol 2001 Aug;29(4): 2204.
192 48.
49.
50.
51. 52. 53. 54.
55.
56.
57.
Step by Step Minimally Invasive Glaucoma Surgery
Han SK, Park KH, Kim DM, et al. Effect of diode laser transscleral cyclophotocoagulation in the management of glaucoma after intravitreal silicone oil injection for complicated retinal detachments. Br J Ophthalmol 1999 Jun;83(6):713-7. Kosoko O, Gaasterland DE, Pollack IP, Enger CL. Longterm outcome of initial ciliary ablation with contact diode laser trans-scleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group. Ophthalmology 1996 Aug;103(8):1294-302. Bloom PA, Tsai JC, Sharma K, Miller MH, Rice NS, Hitchings RA, Khaw PT. “Cyclodiode”. Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma. Ophthalmology 1997 Sep;104(9): 1508-19. Spencer AF, Vernon SA. “Cyclodiode”: results of a standard protocol. Br J Ophthalmol 1999 Mar;83(3):311-6. Werner A, Vick HP, Guthoff R. [Cyclophotocoagulation with the diode laser. Study of long-term results] Ophthalmologe 1998 Mar;95(3):176-80. Pucci V, Tappainer F, Borin S, et al. Long-term follow-up after transscleral diode laser photocoagulation in refractory glaucoma. Ophthalmologica 2003 Jul-Aug;217(4):279-83. Noureddin BN, Zein W, Haddad C, Ma’luf R, Bashshur Z. Diode laser transcleral cyclophotocoagulation for refractory glaucoma: a 1-year follow-up of patients treated using an aggressive protocol. Eye 2005 Apr 29. Ocakoglu O, Arslan OS, Kayiran A. Diode laser transscleral cyclophotocoagulation for the treatment of refractory glaucoma after penetrating keratoplasty. Curr Eye Res 2005 Jul;30(7):569-74. Gupta V, Agarwal HC. Contact trans-scleral diode laser cyclophotocoagulation treatment for refractory glaucomas in the Indian population. Indian J Ophthalmol 2000 Dec;48(4):295-300. Levinger E, Segev E, Geyer O. Diode laser cyclophotocoagulation in refractory glaucoma. Harefuah 2003 Jul;142(7):500-2, 568, 567.
Cyclophotocoagulation
58. 59.
60.
61.
62.
63.
64. 65. 66. 67. 68.
193
Mistlberger A, Liebmann JM, Tschiderer H, et al. Diode laser transscleral cyclophotocoagulation for refractory glaucoma. J Glaucoma 2001 Aug;10(4):288-93. Gupta V, Agarwal HC. Contact trans-scleral diode laser cyclophotocoagulation treatment for refractory glaucomas in the Indian population. Indian J Ophthalmol 2000 Dec;48(4):295-300. Kivela T, Puska P, Raitta C, et al. Clinically successful contact transscleral krypton laser cyclophotocoagulation. Long-term histopathologic and immunohistochemical autopsy findings. Arch Ophthalmol 1995 Nov;113(11): 1447-53. Raivio VE, Immonen IJ, Puska PM. Transscleral contact krypton laser cyclophotocoagulation for treatment of glaucoma in children and young adults. Ophthalmology 2001 Oct;108(10):1801-7. Raivio VE, Immonen IJ, Laatikainen LT, et al. Transscleral contact krypton laser cyclophotocoagulation for treatment of posttraumatic glaucoma. J Glaucoma 2001 Apr;10(2):7784. Di Staso S, Genitti G, Verolino M, et al. Trans-scleral krypton laser cyclophotocoagulation: our experience of its use on patients with neovascular glaucoma. Acta Ophthalmol Scand Suppl. 1997;(224):37-8. Patel A, Thompson JT, Michels RG, et al. Endolaser treatment of the ciliary body for uncontrolled glaucoma, Ophthalmology 1986;93:825-30. Lin S. Endoscopic cyclophotocoagulation. Br J Ophthalmol. 2002 Dec;86(12):1434-8. Review. Holz HA, Lim MC. Glaucoma lasers: a review of the newer techniques. Curr Opin Ophthalmol 2005 Apr;16(2):89-93. Review. Zarbin MA, Michels RG, de Bustros S, et al. Endolaser treatment of the ciliary body for severe glaucoma. Ophthalmology 1988 Dec;95(12):1639-48. Chen J, Cohn RA, Lin SC, et al. Endoscopic photocoagulation of the ciliary body for treatment of refractory glaucomas. Am J Ophthalmol 1997 Dec;124(6):787-96.
194 69. 70.
71. 72.
73.
74.
75. 76. 77.
78.
Step by Step Minimally Invasive Glaucoma Surgery
Uram M. Ophthalmic laser microendoscope ciliary process ablation in the management of neovascular glaucoma. Ophthalmology 1992;99:1823–8. Uram M. Combined phacoemulsification, endoscopic ciliary process photocoagulation, and intraocular lens implantation in glaucoma management. Ophthalmic Surg 1995;26:346–52. Neely DE, Plager DA. Endocyclophotocoagulation for management of difficult pediatric glaucomas. J AAPOS. 2001 Aug;5(4):221-9. Cohen EJ, Schwartz LW, Luskind RD, et al. Neodymium: YAG laser transscleral cyclophotocoagulation for glaucoma after penetrating keratoplasty. Ophthalmic Surg 1989;20: 713–16. Threlkeld AB, Shields MB. Noncontact transscleral Nd:YAG cyclophotocoagulation for glaucoma after penetrating keratoplasty. Am J Ophthalmol 1995;120:569– 76. Lima FE, Magacho L, Carvalho DM, et al. A prospective, comparative study between endoscopic cyclophotocoagulation and the Ahmed drainage implant in refractory glaucoma. J Glaucoma 2004 Jun;13(3):233-7. Bechrakis NE, Müller-Stolzenurg NW, Helbig, et al. Sympathetic ophthalmia following laser cyclophotocoagulation. Arch Ophthalmol 1994;112:80–4. Mora JS, Iwach AG, Gaffney MM, et al. Endoscopic diode laser cyclophotocoagulation with a limbal approach. Ophthalmic Surg Lasers 1997 Feb;28(2):118-23. Lim JI, Lynn M, Capone A Jr, et al. Ciliary body endophotocoagulation during pars plana vitrectomy in eyes with vitreoretinal disorders and concomitant uncontrolled glaucoma. Ophthalmology 1996 Jul; 103(7): 1041-6. Lee P-F. Argon laser photocoagulation of the ciliary processes in cases of aphakic glaucoma, Arch Ophthalmol 1979;97:21352138.
Cyclophotocoagulation
79. 80. 81. 82. 83. 84. 85. 86. 87.
88. 89. 90. 91.
195
Herschler J. Laser shrinkage of the ciliary process. A treatment for malignant (ciliary block) glaucoma. Ophthalmology 1980;87:1155-9. Merritt JC. Transpupillary photocoagulation of the ciliary processes. Ann Ophthalmol 1976 Mar;8(3):325-8. Shields S, Stewart WC, Shields MB. Transpupillary argon laser cyclophotocoagulation in the treatment of glaucoma. Ophthalmic Surg 1988 Mar;19(3):171-5. Lee PF, Shihab Z, Eberle M. Partial ciliary process laser photocoagulation in the management of glaucoma. Lasers Surg Med 1980;1(1):85-92. Kim DD, Moster MR. Transpupillary argon laser cyclophotocoagulation in the treatment of traumatic glaucoma. J Glaucoma 1999 Oct;8(5):340-1. Schuman JS, Puliafito CA. Laser cyclophotocoagulation. Int Ophthalmol Clin 1990;30:111-9. Jennings BJ, Mathews DE. Complications of neodymium: YAG cyclophotocoagulation in the treatment of open-angle glaucoma. Optom Vis Sci. 1999 Oct;76(10):686-91. Edward DP, Brown SVL, Higginbothom E, et al. Sympathetic ophthalmia following neodymium:YAG cyclotherapy. Ophthalmic Surg 1989;20:544–6. Lam S. Tessler HH, Lam BL, et al. High incidence of sympathetic ophthalmia after contact and noncontact neodymium:YAG cyclotherapy. Ophthalmology 1992;99: 1818–22. Bechrakis NE, Müller-Stolzenurg NW, Helbig, et al. Sympathetic ophthalmia following laser cyclophotocoagulation. Arch Ophthalmol 1994;112:80–4. Azuara Blanco A, Dua HS. Malignant glaucoma after diode laser cyclophotocoagulation. Am J Ophthalmol 1999;127: 467-69. Harden DR, Brown JD. Malignant glaucoma after Nd:YAG cyclophotocoagulation. Am J Ophthalmol 1991;111:245-47. Wand M, Schuman JS, Pulinfito CA, et al. Malignant glaucoma after contact trans-scleral Nd:YAG laser cyclophotocoagulation. J Glaucoma 1993;2:110-111.
196 92.
93. 94. 95.
96.
Step by Step Minimally Invasive Glaucoma Surgery
Venkatesh P, Gogoi M, Sihota R, et al. Panophthalmitis following contact diode laser cyclophotocoagulation in a patient with failed trabeculectomy and trabeculotomy for congenital glaucoma. Br J Ophthalmol 2003;87(4):508. Jonathan S Myers, M G trevisani, N Imami, et al. Laser reaching posterior pole during Transscleral cyclophotocoagulation. Arch Ophthalmol 1998;116:488-91. Torsten schlote, M Derse, H J Thiel et al. Pupillary distortion after transscleral Diode laser cyclophotocoagulation. Br J Ophthalmol 2000;84:337-38. Weigt AK, Herring IP, Marfurt CF, et al. Effects of cyclophotocoagulation with a neodymium:yttriumaluminum-garnet laser on corneal sensitivity, intraocular pressure, aqueous tear production, and corneal nerve morphology in eyes of dogs. Am J Vet Res. 2002 Jun;63(6): 906-15. Raivio VE, Vesaluoma MH, Tervo TM, et al. Corneal innervation, corneal mechanical sensitivity, and tear fluid secretion after transscleral contact 670-nm diode laser cyclophotocoagulation. J Glaucoma 2002 Oct;11(5):446-53.
198
Step by Step Minimally Invasive Glaucoma Surgery
INTRODUCTION Trabeculectomy has been the operation of choice for glaucoma since its introduction in 1961 and as a fullthickness operation it had its complications. Guarded filtration procedures were developed to reduce these risks such as hypotony, and infections. 1-3 In the standard trabeculectomy, as reported by Cairns, the trabecular block is excised anterior to the scleral spur or alternatively from the posterior side as proposed by Watson.2 The success rate of trabeculectomy is influenced by several factors including patient’s characteristics, type of glaucoma and wound healing processes. Other important factors that might reduce the success of this surgery include tissue scarring, anterior segment neovascularization, active uveitis, aphakia, previous ocular surgery and chronic conjunctival inflammation.1-5 Over the past 10 years new modalities in glaucoma surgery have been introduced as possible alternatives to trabeculectomy. Krasnov and Zimmerman have identified those procedures into deep scleretomy and viscocanalostomy. 3 The non-penetrating glaucoma surgeries aim to allow drainage of the aqueous humor by slow percolation through the inner trabecular meshwork and/or Descemet membrane (trabeculo-descemetic membrane) rather than through a patent scleral opening, as in standard trabeculectomy. This avoids sudden reductions in IOP, hypotony and flat chambers. Performing such a non-penetrating glaucoma surgeries has great advantages are the absence of anterior chamber opening and iridectomy, the facts that limit the risk of cataract and infection.6-9 In the past 10 years new non-penetrating modalities in glaucoma surgery were introduced as
Milling Trabeculoplasty
199
possible alternatives to Trabeculectomy. Krasnov and Zimmerman have proposed these procedures as deep sclerotomy and viscocanalostomy.3 The non-penetrating glaucoma surgeries aim to allow drainage of the aqueous humor by slow percolation through the inner trabecular meshwork and/or trabeculo-descemetic membrane rather than a patent trabeculoscleral opening, as in standard trabeculectomy. This avoids sudden reductions in IOP, hypotony and flat chambers. Non-penetrating glaucoma procedures have important potential advantages mainly the absence of anterior chamber opening and iridectomy, the fact that limits the risk of cataract and infection.6-9 One of the important targets while performing trabeculectomy or non-penetrating glaucoma surgeries is to minimize the stimulation of fibroblast proliferation that might reduce the success rate of the procedure. The cutting, spreading, and tearing of tissue should be kept to a minimum. In addition, the surgeon should strive to keep the incisions linear, rather than multilaminate, to maintain as small and localized incisional scars as possible.9-11 Milling trabeculoplasty is considered a variation of deep sclerectomy with more refining. The technique of milling trabeculoplasty provides the opportunity to perform a nonpenetrating glaucoma surgery with greater attention for the dissection of the deep scleral flap or the deroofing of the Schlemm´s canal with the addition advantage that is being much faster.12 INDICATIONS Eyes with primary open angle glaucoma are the best candidates for the milling surgery. However, all indications of deep sclerectomy are cases of milling procedure.
200
Step by Step Minimally Invasive Glaucoma Surgery
PATIENT PREPARATION Preoperative Examination Before surgery, each patient had manifest refraction, slitlamp biomicroscopy with measurement of IOP by using Goldman tonometry, gonioscopy and computerized perimetry. Preoperative Medications Medications included Ciprofloxacin 0.3 percent eye drops 3 times/day for a week. The topical antiglaucoma therapy was stopped 3 days before the surgery. Anesthesia Peribulbar anesthesia in the form of combination of 8 ml of 0.75 percent Bupivacaine and 2 percent Lidocaine was injected. Intravenous sedation was used when necessary. A light compression with the Honnan balloon was applied 15 minutes prior to surgery for 5 minutes to insure diffusion of the anesthetic agent. MILLING SURGICAL PROCEDURE Instruments Milling drill (Katena Inc, Denville, NJ USA) is the main instrument necessary to perform this procedure. The mode of action of the drill is similar to that used to burr the nasal bone in dacryocystorhinostomy (DCR) surgery or that used to polish the bed after removing corneal foreign bodies. The drill used in our milling procedure is handheld 150 mg weight equipment and made of autoclaveble material (Fig. 12.1). Following the concept of refined tissue
Milling Trabeculoplasty
201
Fig. 12.1: Milling drill with the tips used in the surgery of milling
removal would decrease the rate of postoperative fibrosis, a high frequency and velocity motorized drill tip could be able to polish (no cutting method) the remaining scleral thickness with minimal tearing and smaller more localized scars at the end of the procedure. The high speed Milling drill (6000 RPM) allows easy (Fig. 12.2), quick and more controlled refining of the remaining scleral thickness by using sharp-metallic tip first to refine the sclera and later on as the tissue became thinner another notched hemispherical metallic tip was used to polish and not cut the remaining scleral thickness (Fig. 12.3). A new tip covered with diamond powder is also needed for more delicate maneuvers as removing debris making the technique ideal to have an extremely smooth bed (Fig. 12.4). In both groups, the procedure started as the initial steps of deep sclerotomy13 then the specific steps of milling surgery were continued. In Group II, the milling procedure is carried out until Schlemm’s canal is identified. Thereafter, phaco is performed (through a separate clear corneal incision) and after the IOL was implanted, the milling procedure was finished.
202
Step by Step Minimally Invasive Glaucoma Surgery
Fig. 12.2: The drill held with the tip unassembled just before the surgery
Fig. 12.3: Milling set of metallic tips. The set includes tips for cutting, other for refining
Milling Trabeculoplasty
203
Fig. 12.4: The notched hemispherical metallic tips to polish but not cut the remaining scleral thickness
Surgical Steps 1. The eyelids are sterilized with ophthalmic Betadine solution (Purdue Frederick, Norwalk, CT), and after the sterile drape was placed, a lid speculum was inserted. 2. An 8-mm fornix-based conjunctival flap is prepared superiorly and Tenon’s capsule was retracted. Bipolar cautery is then applied sparingly to cauterize individual limbal vessels one by one to achieve homeostasis preserving as much as possible the episcleral vessel. 3. A superficial scleral flap of 4 × 4 mm hinged at the limbus was designed using ultra sharp mini